Oncology-related protein and modified polynucleotide for producing peptide

JP2024123008A5Inactive Publication Date: 2024-11-15MODERNATX INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024087183
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2012-12-14
Filing Date
2024-05-29
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current cancer treatments, such as chemotherapy and radiotherapy, are non-specific and have undesirable side effects, while gene therapy for cancer management is not sufficiently targeted.

Method used

Development of modified mRNA (mmRNA) molecules encoding oncology-related polypeptides, designed to increase the level of specific polypeptides in subjects to treat and manage various cancers, using structural and chemical modifications to enhance delivery and reduce immune response.

Benefits of technology

The modified mRNA molecules effectively increase the level of oncology-related polypeptides, providing a targeted approach to reduce tumor growth and ameliorate cancer symptoms with reduced immune response and side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000052_0000
    Figure 00000052_0000
  • Figure 00000556_0000
    Figure 00000556_0000
  • Figure 00000583_0000
    Figure 00000583_0000
Patent Text Reader

Abstract

To provide an oncology-related polynucleotide, a primary construct, and a composition of a modified mRNA molecule (mmRNA), and a method, a process, a kit and a device for designing, preparing, manufacturing and / or formulating them.SOLUTION: A method for treating a disease, disorder and / or condition of a subject who needs treatment of the disease, disorder and / or condition by increasing the level of an objective oncology-related polypeptide is provided, the method including administering isolated polynucleotide encoding the oncology-related polypeptide to the subject.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Sequence Listing Reference This application has been filed in electronic format along with a Sequence Listing. The Sequence Listing file, entitled MNC2_20SQLST.txt, was created on March 9, 2013, and is 91,363,881 bytes in size. The information in this electronic format of the Sequence Listing is incorporated by reference in its entirety.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation of U.S. Provisional Patent Application No. 61 / 681,742, filed August 10, 2012, entitled "Modified Polynucleotides for the Production of Oncology-Related Proteins and Peptides," U.S. Provisional Patent Application No. 61 / 737,224, filed December 14, 2012, entitled "Terminally Optimized Modified RNAs," International Application No. PCT / US2012 / 069610, filed December 14, 2012, entitled "Modified Nucleoside, Nucleotide, and Nucleic Acid Compositions," U.S. Provisional Patent Application No. 61 / 618,862, filed April 2, 2012, entitled "Modified Polynucleotides for the Production of Biologics," and U.S. Provisional Patent Application No. 61 / 681,645, filed August 10, 2012, entitled "Modified Polynucleotides for the production of "Modified Polynucleotides for the Production of Biologics," U.S. Provisional Patent Application No. 61 / 737,130, filed December 14, 2012, entitled "Modified Polynucleotides for the Production of Biologics," U.S. Provisional Patent Application No. 61 / 618,866, filed April 2, 2012, entitled "Modified Polynucleotides for the Production of Antibodies," and U.S. Provisional Patent Application No. 61 / 681,647, filed August 10, 2012, entitled "Modified Polynucleotides for the Production of Antibodies," U.S. Provisional Patent Application No. 61 / 737,134, filed December 14, 2012, entitled "Modified Polynucleotides for the Production of Antibodies; U.S. Provisional Patent Application No. 61 / 618,868, filed April 2, 2012, entitled "Modified Polynucleotides for the Production of Vaccines; U.S. Provisional Patent Application No. 61 / 681,648, filed August 10, 2012, entitled "Modified Polynucleotides for the Production of Vaccines; U.S. Provisional Patent Application No. 61 / 737,135, filed December 14, 2012, entitled "Modified Polynucleotides for the Production of Vaccines; U.S. Provisional Patent Application No. 61 / 618,870, filed April 2, 2012, entitled "Modified Polynucleotides for the Production of Therapeutic Proteins and U.S. Provisional Patent Application No. 61 / 681,649, filed August 10, 2012, entitled "Modified Polynucleotides for the Production of Therapeutic Proteins and Peptides," U.S. Provisional Patent Application No. 61 / 737,139, filed December 14, 2012, entitled "Modified Polynucleotides for the Production of Therapeutic Proteins and Peptides," U.S. Provisional Patent Application No. 61 / 618,873, filed April 2, 2012, entitled "Modified Polynucleotides for the Production of Secreted Proteins," U.S. Provisional Patent Application No. 61 / 681,650, filed August 10, 2012, entitled "Modified Polynucleotides for the Production of Secreted Proteins," U.S. Provisional Patent Application No. 61 / 737,139, filed December 14, 2012, entitled "Modified Polynucleotides for the Production of Secreted Proteins,"Issue 147, titled "Modified Polynucleotides for the Production of Secreted U.S. Provisional Patent Application No. 61 / 618,878, filed April 2, 2012, entitled "Modified Polynucleotides for the Production of Plasma Membrane Proteins"; U.S. Provisional Patent Application No. 61 / 681,654, filed August 10, 2012, entitled "Modified Polynucleotides for the Production of Plasma Membrane Proteins"; U.S. Provisional Patent Application No. 61 / 737,152, filed December 14, 2012, entitled "Modified Polynucleotides for the Production of Plasma Membrane Proteins"; U.S. Provisional Patent Application No. 61 / 618,885, filed April 2, 2012, entitled "Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins" U.S. Provisional Patent Application No. 61 / 681,658, filed August 10, 2012, entitled "Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins," and U.S. Provisional Patent Application No. 61 / 737,155, filed December 14, 2012, entitled "Modified Polynucleotides for the Production of Cytoplasmic and "Modified Polynucleotides for the Production of Intracellular Membrane Bound Proteins," U.S. Provisional Patent Application No. 61 / 618,896, filed April 2, 2012, entitled "Modified Polynucleotides for the Production of Intracellular Membrane Bound Proteins," and U.S. Provisional Patent Application No. 61 / 668,157, filed July 5, 2012, entitled "Modified Polynucleotides for the Production of Intracellular Membrane Bound Proteins." U.S. Provisional Patent Application No. 61 / 681,661, filed August 10, 2012, entitled "Modified Polynucleotides for the Production of Intracellular Membrane Bound Proteins," U.S. Provisional Patent Application No. 61 / 737,160, filed December 14, 2012, entitled "Modified Polynucleotides for the Production of Intracellular Membrane Bound Proteins," and U.S. Provisional Patent Application No. 61 / 618,911, filed April 2, 2012, entitled "Modified Polynucleotides for the Production of Nuclear U.S. Provisional Patent Application No. 61 / 681,667, filed August 10, 2012, entitled "Modified Polynucleotides for the Production of Nuclear Proteins," U.S. Provisional Patent Application No. 61 / 737,168, filed December 14, 2012, entitled "Modified Polynucleotides for the Production of Nuclear Proteins," U.S. Provisional Patent Application No. 61 / 618,922, filed April 2, 2012, entitled "Modified Polynucleotides for the Production of Proteins," U.S. Provisional Patent Application No. 61 / 681,675, filed August 10, 2012, entitled "Modified Polynucleotides for the Production of Proteins," and U.S. Provisional Patent Application No. 61 / 737,174, filed December 14, 2012, entitled "Modified Polynucleotides for the Production of "Proteins," U.S. Provisional Patent Application No. 61 / 618,935, filed April 2, 2012, entitled "Modified Polynucleotides for the "Modified Polynucleotides for the Production of Proteins Associated with Human Disease," U.S. Provisional Patent Application No. 61 / 681,687, filed August 10, 2012, entitled "Modified Polynucleotides for the Production of Proteins Associated with Human Disease," U.S. Provisional Patent Application No. 61 / 737,184, filed December 14, 2012, entitled "Modified Polynucleotides for the Production of Proteins Associated with Human Disease," U.S. Provisional Patent Application No. 61 / 618,945, filed April 2, 2012, entitled "Modified Polynucleotides for the Production of Proteins Associated with Human Disease," and U.S. Provisional Patent Application No. 61 / 681,696, filed August 10, 2012, entitled "Modified Polynucleotides for the Production of Proteins Associated with Human Disease," No. 61 / 737,191, filed December 14, 2012, entitled "Modified Polynucleotides for the Production of Proteins Associated with Human Disease," U.S. Provisional Patent Application No. 61 / 618,953, filed April 2, 2012, entitled "Modified Polynucleotides for the Production of Proteins Associated with Human Disease," U.S. Provisional Patent Application No. 61 / 681,704, filed August 10, 2012, entitled "Modified Polynucleotides for the Production of Proteins Associated with Human Disease," U.S. Provisional Patent Application No. 61 / 737,No. 203, entitled "Modified Polynucleotides for the Production of Proteins Associated with Human Disease," and U.S. Provisional Patent Application No. 61 / 618,961, filed April 2, 2012, entitled "Dosing Methods for Modified mRNA," and U.S. Provisional Patent Application No. 61 / 648,286, filed May 17, 2012, entitled "Dosing Methods for Modified mRNA," the contents of each of which are incorporated herein by reference in their entireties.

[0003] This application is also related to International Publication No. PCT / US2012 / 58519, filed October 3, 2012, entitled "Modified Nucleosides, Nucleotides, and Nucleic Acids, and Uses Thereof," and International Publication No. PCT / US2012 / 69610, filed December 14, 2012, entitled "Modified Nucleoside, Nucleotide, and Nucleic Acid Compositions."

[0004] This application is also related to several co-pending applications, each of which was filed concurrently herewith on March 9, 2013, entitled "Modified Polynucleotides for the Production of Biologics and Proteins Associated with Human Disease," Attorney Docket No. M300.20 (PCT / US13 / XXXXX), entitled "Modified Polynucleotides," Attorney Docket No. M301.20 (PCT / US13 / XXXXX), entitled "Modified Polynucleotides for the Production of Secreted Proteins," Attorney Docket No. M304.20 (PCT / US13 / XXXXX), entitled "Modified Polynucleotides for the Production of Secreted Proteins," Attorney Docket No. M305.20 (PCT / US13 / XXXXX), entitled "Modified Polynucleotides for the Production of Secreted Proteins," Attorney Docket No. 304.20 (PCT / US13 / XXXXX) entitled "Modified Polynucleotides for the Production of Membrane Proteins," Attorney Docket No. M305.20 (PCT / US13 / XXXXX) entitled "Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins," Attorney Docket No. M306.20 (PCT / US13 / XXXXX) entitled "Modified Polynucleotides for the Production of Nuclear Proteins," Attorney Docket No. M308.20 (PCT / US13 / XXXXX) entitled "Modified Polynucleotides for the Production of Proteins," Attorney Docket No. M309.20 (PCT / US13 / XXXXX) entitled "Modified Polynucleotides for the Production of Proteins," with Human Disease,” Attorney Docket No. M310.20 (PCT / US13 / XXXXX), and Attorney Docket No. MNC1.20 (PCT / US13 / XXXXX) entitled “Modified Polynucleotides for the Production of Cosmetic Proteins and Peptides,” the contents of each of which are incorporated herein by reference in their entireties.

[0005] FIELD OF THE INVENTION The present invention relates to oncology-related polynucleotides, primary constructs, and compositions of modified mRNA molecules (mmRNA), methods, processes, kits, and devices for their design, preparation, manufacturing, and / or formulation. [Background technology]

[0006] Cancer is a disease characterized by uncontrolled cell division and growth in the body. In the United States, approximately one-third of all women and one-half of all men will experience cancer in their lifetime. Polypeptides are used to understand cancer cell biology (carcinogenesis, cell cycle inhibition, DNA repair, and angiogenesis), treatment (immunotherapy, hormone manipulation, enzyme inhibition), and the diagnosis of cancer types. Gene therapy for the manipulation of disease-associated peptides offers a more targeted approach to disease diagnosis, treatment, and management, in response to a host of undesirable consequences caused by standard treatments used today, such as chemotherapy and radiation therapy.

[0007] To this end, the inventors have shown that certain modified mRNA sequences have potential as therapeutic agents with benefits beyond simply evading, avoiding, or reducing immune responses. Such work is described in detail in published and co-pending applications, International Application Nos. PCT / US2011 / 046861, filed August 5, 2011, PCT / US2011 / 054636, filed October 3, 2011, and PCT / US2011 / 054617, filed October 3, 2011, the contents of which are incorporated herein by reference in their entireties.

[0008] The present invention addresses this need by providing nucleic acid-based compounds or polynucleotide-encoding nucleic acid-based compounds (e.g., modified mRNA or mmRNA) that encode oncology-related polypeptides of interest and have structural and / or chemical features that avoid one or more of the problems in the art.

[0009] Summary of the Invention Described herein are compositions of modified mRNA (mmRNA) molecules that encode at least one oncology-related polypeptide of interest, methods, processes, kits, and devices for the design, preparation, manufacturing, and / or formulation of modified mRNA (mmRNA) molecules that encode at least one oncology-related polypeptide of interest.

[0010] The present invention provides methods for treating diseases, disorders, and / or conditions in a subject in need thereof by increasing the level of an oncology-related polypeptide of interest, comprising administering to the subject an isolated polynucleotide encoding the oncology-related polypeptide. The diseases, disorders, and / or conditions include adrenocortical carcinoma, advanced cancer, anal cancer, aplastic anemia, cholangiocarcinoma, bladder cancer, bone cancer, bone metastasis, brain tumor, brain cancer, breast cancer, childhood cancer, cancer of unknown primary site, Castleman's disease, cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer, Ewing's tumor, eye cancer, gallbladder cancer, gastrointestinal carcinoid, gastrointestinal stromal tumor, gestational trophoblastic disease, Hodgkin's disease, Kaposi's sarcoma, renal cell carcinoma, laryngeal and hypopharyngeal cancer, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, lung carcinoma The cancer may include, but is not limited to, rhabdomyosarcoma, cutaneous lymphoma, malignant mesothelioma, multiple myeloma, myelodysplastic syndrome, cancer of the nasal cavity and paranasal sinuses, nasopharyngeal carcinoma, neuroblastoma, non-Hodgkin's lymphoma, oral and oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, penile cancer, pituitary tumor, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, adult soft tissue sarcoma, basal and squamous cell carcinoma, melanoma, small intestine cancer, gastric cancer, testicular cancer, pharyngeal cancer, thymic cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom's macroglobulinemia, Wilms' tumor, and secondary cancers resulting from cancer treatment.

[0011] The present invention provides a method for reducing, eliminating or preventing the growth of a tumor in a subject in need thereof by increasing the level of an oncology-related polypeptide of interest, the method comprising administering to the subject an isolated polynucleotide encoding the oncology-related polypeptide. Tumor growths include adrenocortical carcinoma, advanced cancer, anal cancer, aplastic anemia, bile duct cancer, bladder cancer, bone cancer, bone metastasis, brain tumor, brain cancer, breast cancer, childhood cancer, cancer of unknown primary, Castleman's disease, cervical cancer, colon / rectal cancer, endometrial cancer, esophageal cancer, Ewing's tumor, eye cancer, gallbladder cancer, gastrointestinal carcinoid, gastrointestinal stromal tumor, gestational trophoblastic disease, Hodgkin's disease, Kaposi's sarcoma, renal cell carcinoma, laryngeal and hypopharyngeal cancer, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, pulmonary carcinoid tumor, cutaneous lymphoma, malignant mesothelioma, and multiple myeloma. These include, but are not limited to, those associated with or caused by diseases, disorders, and / or conditions such as, but not limited to, myeloma, myelodysplastic syndromes, cancer of the nasal cavity and paranasal sinuses, nasopharyngeal carcinoma, neuroblastoma, non-Hodgkin's lymphoma, oral and oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, penile cancer, pituitary tumors, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary adenoma, adult soft tissue sarcoma, basal and squamous cell carcinoma, melanoma, small intestine cancer, gastric cancer, testicular cancer, pharyngeal cancer, thymic cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom's macroglobulinemia, Wilms' tumor, and secondary cancers resulting from cancer treatment.

[0012] The present invention provides a method for reducing and / or ameliorating at least one symptom of cancer in a subject in need thereof by increasing the level of an oncology-related polypeptide of interest, the method comprising administering to the subject an isolated polynucleotide encoding the oncology-related polypeptide.

[0013] The present invention provides an isolated polynucleotide comprising a first region of linked nucleosides. The first region encodes an oncology-related polypeptide of interest. A first flanking region located at the 5' end of the first region comprises a linked nucleoside sequence selected from the group consisting of the naturally occurring 5' untranslated region of any of SEQ ID NOS: 4704-9203, 1-4, and functional variants thereof. A second flanking region located at the 3' end of the first region comprises a linked nucleoside sequence selected from the group consisting of the naturally occurring 3' UTR of any of SEQ ID NOS: 4704-9203, 5-21, and functional variants thereof, and a 3' tail sequence of the linked nucleoside. Furthermore, the isolated polynucleotide may be substantially purified.

[0014] Furthermore, the first region of the isolated polynucleotide of the present invention may comprise two stop codons. In one embodiment, the first region further comprises a first stop codon "TGA" and a second stop codon selected from the group consisting of "TAA," "TGA," and "TAG."

[0015] The 3' tail sequence of the isolated polynucleotide of the present invention can further comprise, but is not limited to, a poly-A tail of about 130 nucleotides and linked nucleosides, such as a poly A-G quartet.

[0016] The first flanking region of the isolated polynucleotide may further comprise at least one 5' end cap such as, but not limited to, Cap0, Cap1, ARCA, inosine, N1-methyl-guanosine, 2'fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, and 2-azido-guanosine.

[0017] The nucleotides of the isolated polynucleotides of the present invention may contain at least two modifications and a translatable region. The modifications may be present on at least one nucleoside and / or the backbone of the nucleotide, or both the nucleoside and the backbone linkage, or the sugar of the nucleoside. The modifications may include replacing at least one phosphodiester bond with a phosphorothioate linkage. Modifications include pyridin-4-one ribonucleoside, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyluridine, 1-taurinomethyl-pseudouridine. , 5-taurinomethyl-2-thiouridine, 1-taurinomethyl-4-thiouridine, 5-methyluridine, 1-methylpseudouridine, 4-thio-1-methylpseudouridine, 2-thio-1-methylpseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine 2-Methoxyuridine, 2-Methoxy-4-thio-uridine, 4-Methoxy-pseudouridine, 4-Methoxy-2-thio-pseudouridine, 5-Aza-cytidine, Pseudoisocytidine, 3-Methylcytidine, N4-Acetylcytidine, 5-Formylcytidine, N4-Methylcytidine, 5-Hydroxymethylcytidine, 1-Methyl-pseudoisocytidine, Pyrrolo-cytidine, Pyrrolo-pseudoisocytidine, 2-Thio-cytidine, 2-Thio -5-methylcytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methylcytidine, 4-methoxy-pseudoisocytidine,4-Methoxy-1-methyl-pseudoisocytidine, 2-aminopurine, 2,6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyladenosine, N6-methyladeno adenosine, N6-isopentenyladenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine, N6-glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonylcarbamoyladenosine, N6,N6-dimethyladenosine, 7-methyl The amino acid sequence may include, but is not limited to, thioladenine, 2-methylthio-adenine, 2-methoxy-adenine, inosine, 1-methyl-inosine, wyosine, wybutosine, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, and N2,N2-dimethyl-6-thio-guanosine. The backbone bonds may be modified by substitution of one or more oxygen atoms. The modified nucleobases may be selected from, but are not limited to, cytosine, guanine, adenine, thymine, and uracil.

[0018] The isolated polynucleotides of the present invention can be formulated. The formulation can include lipids, including, but not limited to, DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, 98N12-5, C12-200, DLin-MC3-DMA, PLGA, PEG, PEG-DMG, pegylated lipids, and mixtures thereof.

[0019] The isolated polynucleotides of the present invention may be administered at a total daily dose of 0.001 μg to 150 μg. Administration may be by injection, topical administration, ocular administration, and intranasal administration. Injections may include, but are not limited to, intradermal, subcutaneous, and intramuscular administration. Topical administration may be, but is not limited to, creams, lotions, ointments, gels, sprays, solutions, and the like. Topical administration may further include penetration enhancers such as, but not limited to, surfactants, fatty acids, bile salts, chelating agents, non-chelating non-surfactants, polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether, fatty acids and / or salts containing bile acids and / or salts, sodium salts containing lauric acid, capric acid, and UDCA.

[0020] The isolated polynucleotide formulation may further comprise a pharmaceutically acceptable excipient such as, but not limited to, a solvent, aqueous solvent, non-aqueous solvent, dispersion medium, diluent, dispersant, suspending aid, surfactant, isotonic agent, thickener or emulsifier, preservative, lipid, lipidoid liposome, lipid nanoparticle, core-shell nanoparticle, polymer, lipoplex, peptide, protein, cell, hyaluronidase, and mixtures thereof.

[0021] The details of various embodiments of the invention are set forth in the following detailed description. Other features, objects, and advantages of the invention will be apparent from the detailed description and drawings, and from the claims.

[0022] The foregoing and other objects, features, and advantages will become apparent from the following description of specific embodiments of the invention, as illustrated in the accompanying drawings, in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating and illustrating the principles of various embodiments of the invention. [Brief explanation of the drawings]

[0023] [Figure 1] FIG. 1 is a schematic diagram of the oncology-related primary constructs of the present invention. [Figure 2] Figure 1 illustrates prior art lipid structures useful in the present invention. The structures of 98N12-5 (TETA5-LAP), DLin-DMA, DLin-K-DMA (2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane), DLin-KC2-DMA, DLin-MC3-DMA, and C12-200 are shown. [Figure 3]

[0049] Figure 1 is a representative plasmid useful in the IVT reactions taught herein. This plasmid contains insert 64818, designed by the inventors. [Figure 4] Gel profile of modified mRNA encapsulated in PLGA microspheres. DETAILED DESCRIPTION OF THE INVENTION

[0024] In the therapeutics, diagnostics, reagent fields, and biological assays, it is of great interest to be able to deliver nucleic acids, e.g., ribonucleic acid (RNA), into cells, whether in vitro, in vivo, in situ, or ex vivo, to, for example, cause intracellular translation of the nucleic acid and production of the encoded polypeptide of interest. The delivery and function of non-integrated polynucleotides is particularly important.

[0025] Described herein are compositions (including pharmaceutical compositions) of polynucleotides encoding one or more oncology-related polypeptides of interest, as well as methods for their design, preparation, manufacture, and / or formulation. Also provided are systems, processes, devices, and kits for selecting, designing, and / or utilizing polynucleotides encoding the oncology-related polypeptides of interest described herein.

[0026] According to the present invention, these oncology-related polynucleotides are preferably modified to avoid the defects of other polypeptide-encoding molecules in the art, and therefore these polynucleotides are referred to as modified mRNAs or mmRNAs.

[0027] The use of modified polynucleotides in the areas of antibodies, viruses, veterinary applications, and various in vivo environments has been investigated by the present inventors, and these investigations are described, for example, in co-pending and co-owned U.S. Provisional Patent Application Nos. 61 / 470,451, filed March 31, 2011, which teaches in vivo applications of mmRNA; 61 / 517,784, filed April 26, 2011, which teaches engineered nucleic acids for the production of antibody polypeptides; and 61 / 517,784, filed April 26, 2011, which teaches veterinary applications of mmRNA technology. US Patent No. 61 / 519,158, filed May 17, 2011, which teaches the application of mmRNA technology in antibacterial agents; US Patent No. 61 / 533,537, filed September 12, 2011, which teaches the application of mmRNA technology in viral applications; US Patent No. 61 / 533,554, filed September 12, 2011, which teaches various chemical modifications for use in mmRNA technology; US Patent No. 61 / 542,533, filed October 3, 2011, which teaches mobile devices for use in the production and use of mmRNA technology; No. 61 / 570,690, filed December 14, 2011, teaching the use of mmRNA in critical care settings; No. 61 / 570,708, filed December 14, 2011, teaching terminally modified structures of mmRNA; No. 61 / 576,651, filed December 16, 2011, teaching methods for delivering mmRNA using lipidoids; No. 61 / 576,705, filed December 21, 2011, teaching methods for increasing organ or tissue viability using mmRNA; No. 1 / 578,271, filed December 29, 2011, which teaches mmRNA encoding cell-penetrating peptides; No. 61 / 581,322, filed December 29, 2011, which teaches the incorporation of cytotoxic nucleosides into mmRNA; and No. 61 / 631,729, filed January 10, 2012, which teaches methods of using mmRNA to cross the blood-brain barrier, all of which are incorporated herein by reference in their entireties.

[0028] Provided in part herein are oncology-related polynucleotides, oncology-related primary constructs, and / or oncology-related mmRNA encoding oncology-related polypeptides of interest designed to improve one or more of: stability and / or clearance in tissues, receptor uptake and / or kinetics, cellular access by the composition, engagement with the translation machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency (if applicable), accessibility to blood circulation, protein half-life, and / or modulation of cellular state, function, and / or activity.

[0029] I. Compositions of the Invention (mmRNA) The present invention provides nucleic acid molecules, specifically oncology-related polynucleotides, oncology-related primary constructs, and / or oncology-related mmRNA, that encode one or more oncology-related polypeptides of interest. The term "nucleic acid," in its broadest sense, includes any compound and / or substance comprising a polymer of nucleotides. These polymers are often referred to as polynucleotides. Exemplary nucleic acids or polynucleotides of the present invention include, but are not limited to, ribonucleic acid (RNA), deoxyribonucleic acid (DNA), threose nucleic acid (TNA), glycol nucleic acid (GNA), peptide nucleic acid (PNA), locked nucleic acid (LNA, including LNA with a β-D-ribo configuration, α-LNA with an α-L-ribo configuration (a diastereomer of LNA), 2'-amino-LNA with a 2'-amino functionalization, and 2'-amino-α-LNA with a 2'-amino functionalization), or hybrids thereof.

[0030] In a preferred embodiment, the nucleic acid molecule is messenger RNA (mRNA). As used herein, the term "messenger RNA (mRNA)" refers to any oncology-related polynucleotide that encodes an oncology-related polypeptide of interest and that can be translated to produce the encoded oncology-related polypeptide of interest in vitro, in vivo, in situ, or ex vivo.

[0031] Traditionally, the major components of an mRNA molecule include at least a coding region, a 5' UTR, a 3' UTR, a 5' cap, and a polyA tail. Building on this wild-type modular structure, the present invention expands the scope of functionality of conventional mRNA molecules by providing oncology-related polynucleotides or oncology-related primary RNA constructs that maintain the modular organization but contain one or more structural and / or chemical modifications or alterations that confer useful properties to the polynucleotide, including, in some embodiments, a lack of substantial induction of a cellular innate immune response to the site where the oncology-related polynucleotide is introduced. Thus, the modified mRNA molecules of the present invention are referred to as "mmRNAs." As used herein, a "structural" feature or modification is one in which two or more linked nucleotides are inserted, deleted, duplicated, inverted, or randomized in an oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA without significant chemical modification to the nucleotides themselves. Because chemical bonds are necessarily broken and reformed to result in the structural modification, the structural modification is chemical in nature and is therefore a chemical modification. However, the structural modification results in a different nucleotide sequence. For example, the polynucleotide "ATCG" can be chemically modified to "AT-5meC-G." The same polynucleotide can be structurally modified from "ATCG" to "ATCCCG," where the dinucleotide "CC" is inserted, resulting in the structural modification to an oncology-related polynucleotide.

[0032] mmRNA structure The mmRNAs of the present invention are distinguished from wild-type mRNAs in their functional and / or structural design features that, as demonstrated herein, help to overcome existing problems in effective polypeptide production using nucleic acid-based therapeutics.

[0033] Figure 1 shows a representative polynucleotide primary construct 100 of the present invention. As used herein, the term "primary construct" or "primary mRNA construct" refers to an oncology-related polynucleotide transcript that encodes one or more oncology-related polypeptides of interest and that retains sufficient structural and / or chemical characteristics to allow the polypeptides of interest encoded therein to be translated. An oncology-related primary construct may be an oncology-related polynucleotide of the present invention. When structurally or chemically modified, an oncology-related primary construct may be referred to as an oncology-related mmRNA.

[0034] Referring to FIG. 1 , an oncology-related primary construct 100 contains a first region of binding nucleotides 102 flanked by a first flanking region 104 and a second flanking region 106. As used herein, the "first region" may be referred to as a "coding region" or "coding region," or simply as a "first region." This first region may include, but is not limited to, an encoded oncology-related polypeptide of interest. The oncology-related polypeptide of interest may include one or more signal sequences at its 5' end encoded by a signal sequence region 103. The flanking region 104 may include a region of binding nucleotides that includes one or more complete or incomplete 5' UTR sequences. The flanking region 104 may also include a 5' end cap 108. The second flanking region 106 may include a region of binding nucleotides that includes one or more complete or incomplete 3' UTRs. The flanking region 106 may also include a 3' tail sequence 110.

[0035] Bridging the 5' ends of the first region 102 and the first flanking region 104 is a first operational region 105. Conventionally, this operational region includes a start codon. Alternatively, this operational region can include any translation initiation sequence or signal that includes a start codon.

[0036] Bridging the 3' end of the first region 102 and the second flanking region 106 is a second operational region 107. Conventionally, this operational region includes a stop codon. Alternatively, this operational region may include any translation initiation sequence or signal that includes a stop codon. Multiple consecutive stop codons may also be used in accordance with the present invention. In one embodiment, an operational region of the present invention may include two stop codons. The first stop codon may be "TGA," and the second stop codon may be selected from the group consisting of "TAA," "TGA," and "TAG."

[0037] Generally, the minimum length of the first region of a primary construct of the present invention can be a length of nucleic acid sequence sufficient to encode a dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptide, nonapeptide, or decapeptide. In another embodiment, the length can be sufficient to encode a peptide of 2 to 30 amino acids, e.g., 5 to 30, 10 to 30, 2 to 25, 5 to 25, 10 to 25, or 10 to 20 amino acids. The length can be sufficient to encode a peptide of at least 11, 12, 13, 14, 15, 17, 20, 25, or 30 amino acids, or no longer than 40 amino acids, e.g., no longer than 35, 30, 25, 20, 17, 15, 14, 13, 12, 11, or 10 amino acids. Examples of dipeptides that the polynucleotide sequence can encode include, but are not limited to, carnosine and anserine.

[0038] Generally, the length of the first region encoding an oncology-related polypeptide of interest of the present invention is greater than about 30 nucleotides in length (e.g., at least about 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 2,600, 3,700, 4,800, 5,900, 6,100, 6,100, 7,100, 7,200, 7,300, 8,100, 8,100, 9,200, 10,100, 11,100, 12,100, 13,100, 14,100, 15,100, 16,100, 17,100, 18,110, 19,220, 19,230, 19,240, 19,250, 20,260, 2100, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, nucleotides in length (up to or exceeding 100,000). As used herein, a "first region" may be referred to as a "coding region" or "coding region," or simply as a "first region."

[0039] In some embodiments, the oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA is from about 30 to about 100,000 nucleotides (e.g., 30-50, 30-100, 30-250, 30-500, 30-1,000, 30-1,500, 30-3,000, 30-5,000, 30-7,000, 30-10,000, 30-25,000, 30-50,000, 30-70,000, 100~250, 100~500, 100~1,000, 100~1,500, 100~3,000, 100~5,000, 100~7,000, 100~10,000, 100~25,000, 100~50,000, 100~70,000, 100~100,000, 500~1,000, 500~1,500, 500~2,000, 500~3,000, 500~5,000, 500~7,000, 500~10,000 , 500~25,000, 500~50,000, 500~70,000, 500~100,000, 1,000~1,500, 1,000~2,000, 1,000~3,000, 1,000~5,000, 1,000~7,000, 1,000~10,000, 1,000~25,000, 1,000~50,000, 1,000~70,000, 1,000~100,000, 1,500~3,000, 1,500~5, 000, 1,500-7,000, 1,500-10,000, 1,500-25,000, 1,500-50,000, 1,500-70,000, 1,500-100,000, 2,000-3,000, 2,000-5,000, 2,000-7,000, 2,000-10,000, 2,000-25,000, 2,000-50,000, 2,000-70,000, and 2,000-100,000 pieces).

[0040] In accordance with the present invention, the first and second flanking regions can independently range from 15 to 1,000 nucleotides in length (e.g., greater than 30, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, and 900 nucleotides in length, or at least 30, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, and 1,000 nucleotides in length).

[0041] According to the present invention, the tail sequence can range from 0 to 500 nucleotides in length (e.g., at least 60, 70, 80, 90, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, or 500 nucleotides in length). When the tail region is a polyA tail, the length can be determined in units of, or as a function of, polyA binding protein binding. In this embodiment, the polyA tail is long enough to bind at least four monomers of polyA binding protein. A polyA binding protein monomer binds to a stretch of approximately 38 nucleotides. Thus, polyA tails of approximately 80 nucleotides and 160 nucleotides have been observed to be functional.

[0042] According to the present invention, the capping region can comprise a single cap or a series of nucleotides forming a cap. In this embodiment, the capping region can be 1 to 10, e.g., 2 to 9, 3 to 8, 4 to 7, 1 to 5, 5 to 10, or at least 2, or no more than 10 nucleotides in length. In some embodiments, the cap is absent.

[0043] In accordance with the present invention, the first and second operational regions may be 3 to 40, e.g., in the range of 5 to 30, 10 to 20, 15, or at least 4, or no more than 30 nucleotides in length, and may include one or more signal and / or restriction sequences in addition to a start codon and / or a stop codon.

[0044] Circular mmRNA According to the present invention, oncology-related primary constructs or oncology-related mmRNA can be circularized or concatemerized to generate translation-competent molecules and facilitate the interaction between polyA-binding proteins and 5'-end binding proteins. The mechanism of circularization or concatemerization can occur through at least three different pathways: 1) chemical pathway, 2) enzymatic pathway, and 3) ribozyme catalytic pathway. The newly formed 5' / 3' linkage can be intramolecular or intermolecular.

[0045] In the first pathway, the 5' and 3' ends of the nucleic acid may contain chemically reactive groups that, when brought into close proximity, form a new covalent bond between the 5' and 3' ends of the molecule. The 5' end may contain an NHS-ester reactive group, and the 3' end may contain a 3'-amino terminal nucleotide, such that in an organic solvent, the 3'-amino terminal nucleotide on the 3' end of the synthetic mRNA molecule undergoes nucleophilic attack on the 5'-NHS-ester moiety to form a new 5' / 3' amide bond.

[0046] In the second pathway, T4 RNA ligase can be used to enzymatically attach 5'-phosphorylated nucleic acid molecules to the 3'-hydroxyl group of a nucleic acid, forming a new phosphorodiester bond. In an example reaction, 1 μg of nucleic acid molecule is incubated with 1-10 units of T4 RNA ligase (New England Biolabs, Ipswich, MA) for 1 hour at 37°C according to the manufacturer's protocol. Ligation can occur in the presence of a split oligonucleotide that can base-pair side-by-side with both the 5' and 3' regions to support the enzymatic ligation reaction.

[0047] In the third pathway, either the 5' or 3' end of the cDNA template encodes a ligase ribozyme sequence, such that during in vitro transcription, the resulting nucleic acid molecule contains an active ribozyme sequence capable of ligating the 5' end of a nucleic acid molecule to the 3' end of a nucleic acid molecule. The ligase ribozyme can be derived from a group I intron, a group I intron, hepatitis delta virus, a hairpin ribozyme, or selected by SELEX (systematic evolution of ligands by exponential enrichment). The ribozyme ligase reaction can take 1 to 24 hours at temperatures between 0 and 37°C.

[0048] mmRNA multimers According to the present invention, multiple distinct oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNAs can be linked via their 3' ends using 3'-modified nucleotides. Chemical complexation can be used to control the stoichiometry of delivery to cells. For example, glyoxylate cycle enzymes, isocitrate lyase, and malate synthase can be supplied to HepG2 cells in a 1:1 ratio to alter cellular fatty acid metabolism. This ratio can be controlled by chemically linking oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNAs using 3'-azido-terminal nucleotides on one oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA species and C5-ethynyl- or alkynyl-containing nucleotides on the other oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA species. The modified nucleotides are added post-transcriptionally using terminal transferase (New England Biolabs, Ipswich, MA) according to the manufacturer's protocol. After addition of the 3'-terminal modified nucleotide, these two oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNA species can be combined in aqueous solution in the presence or absence of copper to form a new covalent bond via click chemistry mechanisms as described in the literature.

[0049] In another example, three or more oncology-related polynucleotides can be linked using a functionalized linker molecule. For example, a functionalized saccharide molecule can be chemically modified to contain multiple chemically reactive groups (SH-, NH2-, N3, etc.) to react with a cognate moiety (i.e., 3'-maleimide ester, 3'-NHS-ester, alkynyl) on a 3'-functionalized oncology-related mRNA molecule. The number of reactive groups on the modified saccharide can be controlled in a stoichiometric manner to directly control the stoichiometry of the conjugated oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNA.

[0050] mmRNA complexes and combinations To further enhance oncology-related protein production, the oncology-related primary constructs or oncology-related mmRNA of the present invention may be combined with other polynucleotides, oncology-related polypeptides, dyes, intercalating agents (e.g., acridine), crosslinking agents (e.g., psoralen, mitomycin C), porphyrins (TPPC4, texaphyrin, sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases (e.g., EDTA), alkylating agents, phosphate, amino, mercapto, PEG (e.g., PEG-40K), MPEG, [MPEG-40K], or other suitable nucleotides. ]2, polyamino, alkyl, substituted alkyl, radiolabeled markers, enzymes, haptens (e.g., biotin), transport / absorption enhancers (e.g., aspirin, vitamin E, folic acid), synthetic ribonucleases, proteins, e.g., glycoproteins, or peptides, e.g., molecules with specific affinity for co-ligands, or antibodies, e.g., antibodies that bind to particular cell types such as cancer cells, endothelial cells, or bone cells, hormones and hormone receptors, non-peptide species, e.g., lipids, lectins, carbohydrates, vitamins, cofactors, or drugs.

[0051] Complexation may result in increased stability and / or half-life and may be particularly useful when targeting an oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA to a specific site in a cell, tissue, or organism.

[0052] In accordance with the present invention, the oncology-related mmRNA or oncology-related primary construct may be administered together with or may further encode one or more of an RNAi agent, siRNA, shRNA, miRNA, miRNA binding site, antisense RNA, ribozyme, catalytic DNA, tRNA, RNA that induces triple helix formation, aptamer, or vector, etc.

[0053] Bifunctional mmRNA One embodiment of the present invention is a bifunctional oncology-related polynucleotide (e.g., a bifunctional oncology-related primary construct or a bifunctional oncology-related mmRNA). As the name suggests, a bifunctional oncology-related polynucleotide is a polynucleotide that has at least two functions or is capable of at least two functions. By convention, these molecules may also be referred to as multifunctional.

[0054] The multiple functions of a bifunctional oncology-related polynucleotide may be encoded by the RNA (the function may not be apparent until the encoded product is translated) or may be a property of the polynucleotide itself. This may be structural or chemical. A bifunctional oncology-related modified polynucleotide may contain functions covalently or electrostatically associated with the polynucleotide. Furthermore, these two functions may be provided in the context of a complex of mmRNA and another molecule.

[0055] Bifunctional oncology-related polynucleotides can encode antiproliferative oncology-related peptides. These peptides can be linear, cyclic, constrained, or random coil. They can function as aptamers, signaling molecules, ligands, or mimetics thereof. Antiproliferative peptides can be 3-50 amino acids long when translated. They can be 5-40, 10-30, or about 15 amino acids long. They can be single-, multi-, or branched chains, and can form complexes, aggregates, or any multi-unit structure when translated.

[0056] Non-coding oncology-related polynucleotides and primary constructs As described herein, oncology-related polynucleotides and oncology-related primary constructs are provided that have partially or substantially non-translatable sequences, e.g., non-coding regions. Such non-coding regions may be the "first region" of an oncology-related primary construct. Alternatively, the non-coding region may be a region other than the first region. Such molecules are not normally translated but may affect protein production by one or more of binding to and sequestration by one or more components of the translation machinery, such as ribosomal proteins or transfer RNAs (tRNAs), thereby effectively reducing protein expression in cells or regulating one or more pathways or cascades in cells, which then alter protein levels. The oncology-related polynucleotides and / or oncology-related primary constructs may contain or encode one or more long non-coding RNAs (lncRNAs or lincRNAs) or portions thereof, small nuclear RNAs (sno-RNAs), microRNAs (miRNAs), small interfering RNAs (siRNAs), or Piwi interfering RNAs (piRNAs).

[0057] Target polypeptide In accordance with the present invention, oncology-related primary constructs are designed to encode one or more oncology-related polypeptides of interest or fragments thereof. Oncology-related polypeptides of interest can include, but are not limited to, entire polypeptides, multiple polypeptides, or fragments of polypeptides, which may be independently encoded by one or more nucleic acids, multiple nucleic acids, fragments of nucleic acids, or variants of any of the foregoing. As used herein, the term "oncology-related polypeptide of interest" refers to any polypeptide selected and encoded in an oncology-related primary construct of the present invention. As used herein, "polypeptide" refers to a polymer of amino acid residues (natural or non-natural) linked, most often by peptide bonds. This term, as used herein, refers to proteins, polypeptides, and peptides of any size, structure, or function. In some instances, if the encoded polypeptide is smaller than about 50 amino acids, the polypeptide is referred to as a peptide. If the polypeptide is a peptide, it is at least about 2, 3, 4, or at least 5 amino acid residues in length. Thus, polypeptides include gene products, naturally occurring polypeptides, synthetic polypeptides, homologs, orthologs, paralogs, fragments of the foregoing, and other equivalents, variants, and analogs. Polypeptides can be single molecules or multimolecular complexes such as dimers, trimers, or tetramers. They can also include single-chain or multi-chain polypeptides, such as antibodies or insulin, which can be associated or linked. In most cases, disulfide bonds are found in multi-chain polypeptides. The term "polypeptide" can also apply to amino acid polymers in which one or more amino acid residues are artificial chemical analogs of the corresponding naturally occurring amino acids.

[0058] The term "polypeptide variant" refers to molecules whose amino acid sequence differs from a native or reference sequence. Amino acid sequence variants may have substitutions, deletions, and / or insertions at certain positions within the amino acid sequence compared to the native or reference sequence. Typically, variants will have at least about 50% identity (homology) with the native or reference sequence; preferably, they will be at least about 80%, and more preferably at least about 90% identical (homological) to the native or reference sequence.

[0059] In some embodiments, a "mutant mimic" is provided. As used herein, the term "mutant mimic" refers to a mimic containing one or more amino acids that mimic an activation sequence. For example, glutamate can act as a mimic of phosphoro-threonine and / or phosphoro-serine. Alternatively, a mutant mimic can result in the inactivation or inactivation of a product containing the mimic; for example, phenylalanine can act as an inactivating substitute for tyrosine, or alanine can act as an inactivating substitute for serine.

[0060] " Homology " when applied to amino acid sequences is defined as the percentage (%) of residues in a candidate amino acid sequence that are identical to the residues in the amino acid sequence of a second sequence, after aligning the sequences and introducing gaps as necessary to obtain the maximum homology percentage. Methods and computer programs for alignment are well known in the art. It is understood that homology depends on the calculation of percent identity, but values ​​may vary due to gaps and penalties introduced in the calculation.

[0061] "Homolog" when applied to a polypeptide sequence means a corresponding sequence in another species that has a significant degree of identity to a second sequence in the second species. "Analog" is intended to include polypeptide variants that differ by one or more amino acid modifications, e.g., substitution, addition, or deletion of an amino acid residue, that still retain one or more properties of the parent or starting polypeptide.

[0062] The present invention contemplates several types of polypeptide-based compositions, including variants and derivatives. These include substitution, insertion, deletion, and covalent variants and derivatives. The term "derivative" is used interchangeably with the term "variant," but generally refers to a molecule that has been modified and / or changed in any way relative to a reference or starting molecule.

[0063] Therefore, mmRNAs encoding oncology-related polypeptides containing substitutions, insertions and / or additions, deletions, and covalent modifications relative to the reference sequences, particularly the oncology-related polypeptide sequences disclosed herein, are encompassed within the scope of the present invention. For example, sequence tags or amino acids, such as one or more lysines, can be added to the peptide sequences of the present invention (e.g., at the N- or C-terminus). Sequence tags can be used for peptide purification or localization. Lysines can be used to increase peptide solubility or enable biotinylation. Alternatively, amino acid residues located in the carboxy- and amino-terminal regions of the amino acid sequence of a peptide or protein can be optionally deleted to provide a truncated sequence. Alternatively, certain amino acids (e.g., C- or N-terminal residues) can be deleted during expression of the sequence, for example, as part of a larger, more soluble sequence, or can be attached to a solid support, depending on the use of the sequence.

[0064] "Substitutional variants," when referring to polypeptides, are those in which at least one amino acid residue in a native or starting sequence has been removed and a different amino acid inserted in its place at the same position. These substitutions may be single, where only one amino acid in the molecule has been substituted, or they may be multiple, where more than one amino acid has been substituted in the same molecule.

[0065] As used herein, the term "conservative amino acid substitution" refers to the substitution of an amino acid normally present in a sequence with a different amino acid of similar size, charge, or polarity. Examples of conservative substitutions include the substitution of a non-polar (hydrophobic) residue such as isoleucine, valine, and leucine for another non-polar residue. Similarly, examples of conservative substitutions include the substitution of a polar (hydrophilic) residue such as arginine for lysine, glutamine for asparagine, and glycine for another. Furthermore, the substitution of a basic residue such as lysine, arginine, or histidine for another basic residue, or the substitution of an acidic residue such as aspartic acid or glutamic acid for another acidic residue, are further examples of conservative substitutions. Examples of non-conservative substitutions include the substitution of a non-polar (hydrophobic) amino acid residue such as isoleucine, valine, leucine, alanine, or methionine for a polar (hydrophilic) residue such as cysteine, glutamine, glutamic acid, or lysine, and / or the substitution of a polar residue for a non-polar residue.

[0066] An "insertion variant," when referring to a polypeptide, is one in which one or more amino acids have been inserted immediately adjacent to an amino acid at a particular position in a native or starting sequence. "Immediately adjacent to" an amino acid means linked to either the alpha-carboxy or alpha-amino functionality of the amino acid.

[0067] "Deletion variants," when referring to polypeptides, are those in which one or more amino acids in a native or starting amino acid sequence have been removed. Typically, deletion variants delete one or more amino acids in a particular region of the molecule.

[0068] "Covalent derivatives," when referring to polypeptides, include modification of the native or starting protein with an organic proteinaceous or non-proteinaceous derivatizing agent and / or post-translational modification. Covalent modifications are traditionally introduced by reacting targeted amino acid residues of the protein with an organic derivatizing agent capable of reacting with selected side chains or terminal residues, or by utilizing post-translational modification mechanisms operative in selected recombinant host cells. The resulting covalent derivatives are useful in programs aimed at identifying residues important for biological activity, immunological assays, or preparation of anti-protein antibodies for immunoaffinity purification of recombinant glycoproteins. Such modifications are within the skill of the art and are performed without undue experimentation.

[0069] Certain post-translational modifications are the result of the action of recombinant host cells on the expressed oncology-related polypeptides. Glutaminyl and asparaginyl residues are frequently post-translationally deamidated to the corresponding glutamyl and aspartyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Either form of these residues may be present in the oncology-related polypeptides produced according to the present invention.

[0070] Other post-translational modifications include hydroxylation of proline and lysine, phosphorylation of the hydroxyl group of seryl or threonyl residues, and methylation of the α-amino groups of lysine, arginine, and histidine side chains (TECreighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)).

[0071] A "feature," when referring to a polypeptide, is defined as a distinct amino acid sequence-based component of a molecule. Features of polypeptides encoded by the mmRNA of the present invention include surface appearance, local conformational shape, fold, loop, half-loop, domain, half-domain, site, terminus, or any combination thereof.

[0072] As used herein, when referring to a polypeptide, the term "surface expression" refers to the appearance of the polypeptide component of the protein on the outermost surface. As used herein, when referring to a polypeptide, the term "local conformational shape" refers to the appearance of a polypeptide-based structure of a protein located within a definable space of the protein.

[0073] As used herein, when referring to a polypeptide, the term "fold" refers to the resulting three-dimensional structure of an amino acid sequence upon energy minimization. Folding can occur at the secondary or tertiary level of the folding process. Examples of secondary level folds include beta sheets and alpha helices. Examples of tertiary level folds include domains and regions formed due to the aggregation or separation of energy forces. Regions formed in this manner include hydrophobic and hydrophilic pockets, etc.

[0074] As used herein, the term "turn," when referring to protein structure, means a bend that changes the orientation of the backbone of a peptide or polypeptide and may involve one, two, three or more amino acid residues.

[0075] As used herein, when referring to a polypeptide, the term "loop" refers to a structural feature of a polypeptide that can serve to reverse the orientation of the peptide or polypeptide backbone. When a loop is found in a polypeptide and only changes the orientation of the backbone, it can contain four or more amino acid residues. Oliva et al. identified at least five classes of protein loops (J. Mol Biol 266(4):814-830; 1997). Loops can be open or closed. Closed or "cyclic" loops can contain 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more amino acids between bridging moieties. Such bridging moieties can include cysteine-cysteine ​​bridges (Cys-Cys), which are typical in polypeptides with disulfide bridges, or alternatively, the bridging moieties can be non-proteinaceous, such as dibromozylyl agents, as used herein.

[0076] As used herein, when referring to a polypeptide, the term "half-loop" refers to a portion of a loop that has at least half of the amino acid residues identified as the loop from which it is derived. It is understood that a loop does not necessarily contain an even number of amino acid residues. Thus, when a loop contains or is identified as containing an odd number of amino acids, a half-loop of an odd-numbered loop includes an integral or next integral portion of the loop (number of amino acids in the loop / 2 + / - 0.5 amino acids). For example, a loop identified as a 7-amino acid loop can result in a half-loop of 3 or 4 amino acids (7 / 2 = 3.5 + / - 0.5, resulting in 3 or 4).

[0077] As used herein, when referring to a polypeptide, the term "domain" refers to a motif in a polypeptide having one or more identifiable structural or functional features or characteristics (e.g., binding ability, serving as a site of interaction between proteins).

[0078] As used herein, when referring to a polypeptide, the term "half-domain" refers to a portion of a domain having at least half of the amino acid residues identified as the domain from which it is derived. It is understood that a domain does not necessarily contain an even number of amino acid residues. Thus, if a domain contains or is identified as comprising an odd number of amino acids, a half-domain of an odd-numbered domain comprises an integral or next integral portion of the domain (number of amino acids in the domain / 2 + / - 0.5 amino acids). For example, a domain identified as a 7-amino acid domain may result in a half-domain of 3 or 4 amino acids (7 / 2 = 3.5 + / - 0.5, resulting in 3 or 4). It is also understood that subdomains may be identified within a domain or half-domain, and that these subdomains may have structural or functional properties that are less than all of the structural or functional properties identified in the domain or half-domain from which they are derived. It is also understood that the amino acids comprising any of the domain types herein need not be adjacent along the polypeptide backbone (i.e., non-adjacent amino acids may structurally fold to result in a domain, half-domain, or subdomain).

[0079] As used herein, when referring to polypeptides, the term "site" is used interchangeably with "amino acid residue" and "amino acid side chain" when referring to amino acid-based embodiments. Sites represent positions within a peptide or polypeptide that can be modified, manipulated, altered, derivatized, or changed within the polypeptide-based molecules of the invention.

[0080] As used herein, when referring to a polypeptide, the term "terminus" or "terminus" refers to the end of a peptide or polypeptide. Such terminus may not only be limited to the first or final portion of a peptide or polypeptide, but may also include additional amino acids in the terminal region. The polypeptide molecules of the present invention may be characterized as having both an N-terminus (terminated by an amino acid with a free amino group (NH)) and a C-terminus (terminated by an amino acid with a free carboxyl group (COOH)). In some cases, the proteins of the present invention may consist of multiple polypeptide chains linked by disulfide bonds or non-covalent forces (multimers, oligomers). These types of proteins have multiple N- and C-termini. Alternatively, the termini of polypeptides may be modified so that they begin or end with non-polypeptide moieties, such as organic complexes.

[0081] Once any of these features are identified or defined as the desired components of the polypeptide encoded by the oncology-related primary construct or oncology-related mmRNA of the present invention, any of the manipulations and / or modifications of these features can be performed by moving, exchanging, inverting, deleting, randomizing, or duplicating.Furthermore, it is understood that the manipulation of features will produce the same results as the modification of the molecules of the present invention.For example, manipulation involving the deletion of domains will result in a change in the length of the molecule, such as the modification of a nucleic acid that encodes less than the full-length molecule.

[0082] Modifications and manipulations can be accomplished by methods known in the art, such as, but not limited to, site-directed mutagenesis. The resulting modified molecules can then be tested for activity using in vitro or in vivo assays, such as those described herein, or any other suitable screening assay known in the art.

[0083] In accordance with the present invention, oncology-related polypeptides may comprise consensus sequences discovered through a series of experiments. As used herein, a "consensus" sequence is a single sequence that represents a collective population of sequences that allows for variability at one or more sites.

[0084] As will be recognized by those skilled in the art, protein fragments, functional protein domains, and homologous proteins are also considered to be within the scope of the oncology-related polypeptides of interest of the present invention. For example, any protein fragment (meaning an oncology-related polypeptide sequence that is at least one amino acid residue shorter than the reference oncology-related polypeptide sequence but is otherwise identical) of a reference protein that is 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or more than 100 amino acids in length is provided herein. In another example, any oncology-related protein that contains a stretch of about 20, 30, 40, 50, or 100 amino acids that is about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, or about 100% identical to any of the sequences described herein can be utilized in accordance with the present invention. In certain embodiments, a polypeptide utilized in accordance with the present invention comprises 2, 3, 4, 5, 6, 7, 8, 9, 10 or more mutations set forth in any of the sequences provided or referenced herein.

[0085] Encoded oncology-related polypeptides The oncology-related primary constructs or oncology-related mmRNA of the present invention may be designed to encode polypeptides of interest, such as oncology-related peptides and proteins.

[0086] In one embodiment, the oncology-related primary construct or oncology-related mmRNA can encode a variant polypeptide that has a certain identity with a reference oncology-related polypeptide sequence.As used herein, "reference oncology-related polypeptide sequence" refers to the starting oncology-related polypeptide sequence.The reference sequence can be a wild-type sequence or any sequence that is referenced in the design of another sequence. A "reference polypeptide sequence" can be, for example, any one of SEQ ID NOs: 4704-9203 disclosed herein, e.g., SEQ ID NOs: 4704, 4705, 4706, 4707, 4708, 4709, 4710, 4711, 4712, 4713, 4714, 4715, 4716, 4717, 4718, 4719, 4720, 4721, 4722, 4723, 4724, 4725, 4726, 4727, 4728, 4729, 4730, 4731, 4732, 4733 , 4734, 4735, 4736, 4737, 4738, 4739, 4740, 4741, 4742, 4743, 4744, 4745, 4746, 4747, 4748, 4749, 4750, 4751, 4752, 4753, 4754, 4755, 4756, 4757, 4758, 4759, 4760, 4761, 4762, 4763, 4764, 4765, 4766, 4767, 4768, 4769, 4770, 4771, 4772, 4773, 4774, 4 775, 4776, 4777, 4778, 4779, 4780, 4781, 4782, 4783, 4784, 4785, 4786, 4787, 4788, 4789, 4790, 4791, 4792, 4793, 4794, 4795, 4796, 4797, 4798, 4799, 4800, 4801, 4802, 4803, 4804, 4805, 4806, 4807, 4808, 4809, 4810, 4811, 4812, 4813, 4814, 4815, 481 6, 4817, 4818, 4819, 4820, 4821, 4822, 4823, 4824, 4825, 4826, 4827, 4828, 4829, 4830, 4831, 4832, 4833, 4834, 4835, 4836, 4837, 4838, 4839, 4840, 4841, 4842, 4843, 4844, 4845, 4846, 4847, 4848, 4849, 4850, 4851, 4852, 4853, 4854, 4855, 4856, 4857,4858、4859、4860、4861、4862、4863、4864、4865、4866、4867、4868、4869、4870、4871、4872、4873、4874、4875、4876、4877、4878、4879、4880、4881、4882、4883、4884、4885、4886、4887、4888、4889、4890、4891、4892、4893、4894、4895、4896、4897、4898、4899、4900、4901、4902、4903、4904、4905、4906、4907、4908、4909、4910、4911、4912、4913、4914、4915、4916、4917、4918、4919、4920、4921、4922、4923、4924、4925、4926、4927、4928、4929、4930、4931、4932、4933、4934、4935、4936、4937、4938、4939、4940、4941、4942、4943、4944、4945、4946、4947、4948、4949、4950、4951、4952、4953、4954、4955、4956、4957、4958、4959、4960、4961、4962、4963、4964、4965、4966、4967、4968、4969、4970、4971、4972、4973、4974、4975、4976、4977、4978、4979、4980、4981、4982、4983、4984、4985、4986、4987、4988、4989、4990、4991、4992、4993、4994、4995、4996、4997、4998、4999、5000、5001、5002、5003、5004、5005、5006、5007、5008、5009、5010、5011、5012、5013、5014、5015、5016、5017、5018、5019、5020、5021、5022、5023、5024、5025、5026、5027、5028、5029、5030、5031、5032、5033、5034、5035、5036、5037、5038、5039、5040、5041、5042、5043、5044、5045、5046、5047、5048、5049、5050、5051、5052、5053、5054、5055、5056、5057、5058、5059、5060、5061、5062、5063、5064、5065、5066、5067、5068、5069、5070、5071、5072、5073、5074、5075、5076、5077、5078、5079、5080、5081、5082、5083、5084、5085、5086、5087、5088、5089、5090、5091、5092、5093、5094、5095、5096、5097、5098、5099、5100、5101、5102、5103、5104、5105、5106、5107、5108、5109、5110、5111、5112、5113、5114、5115、5116、5117、5118、5119、5120、5121、5122、5123、5124、5125、5126、5127、5128、5129、5130、5131、5132、5133、5134、5135、5136、5137、5138、5139、5140、5141、5142、5143、5144、5145、5146、5147、5148、5149、5150、5151、5152、5153、5154、5155、5156、5157、5158、5159、5160、5161、5162、5163、5164、5165、5166、5167、5168、5169、5170、5171、5172、5173、5174、5175、5176、5177、5178、5179、5180、5181、5182、5183、5184、5185、5186、5187、5188、5189、5190、5191、5192、5193、5194、5195、5196、5197、5198、5199、5200、5201、5202、5203、5204、5205、5206、5207、5208、5209、5210、5211、5212、5213、5214、5215、5216、5217、5218、5219、5220、5221、5222、5223、5224、5225、5226、5227、5228、5229、5230、5231、5232、5233、5234、5235、5236、5237、5238、5239、5240、5241、5242、5243、5244、5245、5246、5247、5248、5249、5250、5251、5252、5253、5254、5255、5256、5257、5258、5259、5260、5261、5262、5263、5264、5265、5266、5267、5268、5269、5270、5271、5272、5273、5274、5275、5276、5277、5278、5279、5280、5281、5282、5283、5284、5285、5286、5287、5288、5289、5290、5291、5292、5293、5294、5295、5296、5297、5298、5299、5300、5301、5302、5303、5304、5305、5306、5307、5308、5309、5310、5311、5312、5313、5314、5315、5316、5317、5318、5319、5320、5321、5322、5323、5324、5325、5326、5327、5328、5329、5330、5331、5332、5333、5334、5335、5336、5337、5338、5339、5340、5341、5342、5343、5344、5345、5346、5347、5348、5349、5350、5351、5352、5353、5354、5355、5356、5357、5358、5359、5360、5361、5362、5363、5364、5365、5366、5367、5368、5369、5370、5371、5372、5373、5374、5375、5376、5377、5378、5379、5380、5381、5382、5383、5384、5385、5386、5387、5388、5389、5390、5391、5392、5393、5394、5395、5396、5397、5398、5399、5400、5401、5402、5403、5404、5405、5406、5407、5408、5409、5410、5411、5412、5413、5414、5415、5416、5417、5418、5419、5420、5421、5422、5423、5424、5425、5426、5427、5428、5429、5430、5431、5432、5433、5434、5435、5436、5437、5438、5439、5440、5441、5442、5443、5444、5445、5446、5447、5448、5449、5450、5451、5452、5453、5454、5455、5456、5457、5458、5459、5460、5461、5462、5463、5464、5465、5466、5467、5468、5469、5470、5471、5472、5473、5474、5475、5476、5477、5478、5479、5480、5481、5482、5483、5484、5485、5486、5487、5488、5489、5490、5491、5492、5493、5494、5495、5496、5497、5498、5499、5500、5501、5502、5503、5504、5505、5506、5507、5508、5509、5510、5511、5512、5513、5514、5515、5516、5517、5518、5519、5520、5521、5522、5523、5524、5525、5526、5527、5528、5529、5530、5531、5532、5533、5534、5535、5536、5537、5538、5539、5540、5541、5542、5543、5544、5545、5546、5547、5548、5549、5550、5551、5552、5553、5554、5555、5556、5557、5558、5559、5560、5561、5562、5563、5564、5565、5566、5567、5568、5569、5570、5571、5572、5573、5574、5575、5576、5577、5578、5579、5580、5581、5582、5583、5584、5585、5586、5587、5588、5589、5590、5591、5592、5593、5594、5595、5596、5597、5598、5599、5600、5601、5602、5603、5604、5605、5606、5607、5608、5609、5610、5611、5612、5613、5614、5615、5616、5617、5618、5619、5620、5621、5622、5623、5624、5625、5626、5627、5628、5629、5630、5631、5632、5633、5634、5635、5636、5637、5638、5639、5640、5641、5642、5643、5644、5645、5646、5647、5648、5649、5650、5651、5652、5653、5654、5655、5656、5657、5658、5659、5660、5661、5662、5663、5664、5665、5666、5667、5668、5669、5670、5671、5672、5673、5674、5675、5676、5677、5678、5679、5680、5681、5、 682、5683、5684、5685、5686、5687、5688、5689、5690、5691、5692、5693、5694、5695、5696、5697、5698、5699、5700、5701、5702、5703、5704、5705、5706、5707、5708、5709、5710、5711、5712、5713、5714、5715、5716、5717、5718、5719、5720、5721、5722、5723、5724、5725、5726、5727、5728、5729、5730、5731、5732、5733、5734、5735、5736、5737、5738、5739、5740、5741、5742、5743、5744、5745、5746、5747、5748、5749、5750、5751、5752、5753、5754、5755、5756、5757、5758、5759、5760、5761、5762、5763、5764、5765、5766、5767、5768、5769、5770、5771、5772、5773、5774、5775、5776、5777、5778、5779、5780、5781、5782、5783、5784、5785、5786、5787、5788、5789、5790、5791、5792、5793、5794、5795、5796、5797、5798、5799、5800、5801、5802、5803、5804、5805、5806、5807、5808、5809、5810、5811、5812、5813、5814、5815、5816、5817、5818、5819、5820、5821、5822、5823、5824、5825、5826、5827、5828、5829、5830、5831、5832、5833、5834、5835、5836、5837、5838、5839、5840、5841、5842、5843、5844、5845、5846、5847、5848、5849、5850、5851、5852、5853、5854、5855、5856、5857、5858、5859、5860、5861、5862、5863、5864、5865、5866、5867、5868、5869、5870、5871、5872、5873、5874、5875、5876、5877、5878、5879、5880、5881、5882、5883、5884、5885、5886、5887、5888、5889、5890、5891、5892、5893、5894、5895、5896、5897、5898、5899、5900、5901、5902、5903、5904、5905、5906、5907、5908、5909、5910、5911、5912、5913、5914、5915、5916、5917、5918、5919、5920、5921、5922、5923、5924、5925、5926、5927、5928、5929、5930、5931、5932、5933、5934、5935、5936、5937、5938、5939、5940、5941、5942、5943、5944、5945、5946、5947、5948、5949、5950、5951、5952、5953、5954、5955、5956、5957、5958、5959、5960、5961、5962、5963、5964、5965、5966、5967、5968、5969、5970、5971、5972、5973、5974、5975、5976、5977、5978、5979、5980、5981、5982、5983、5984、5985、5986、5987、5988、5989、5990、5991、5992、5993、5994、5995、5996、5997、5998、5999、6000、6001、6002、6003、6004、6005、6006、6007、6008、6009、6010、6011、6012、6013、6014、6015、6016、6017、6018、6019、6020、6021、6022、6023、6024、6025、6026、6027、6028、6029、6030、6031、6032、6033、6034、6035、6036、6037、6038、6039、6040、6041、6042、6043、6044、6045、6046、6047、6048、6049、6050、6051、6052、6053、6054、6055、6056、6057、6058、6059、6060、6061、6062、6063、6064、6065、6066、6067、6068、6069、6070、6071、6072、6073、6074、6075、6076、6077、6078、6079、6080、6081、6082、6083、6084、6085、6086、6087、6088、6089、6090、6091、6092、6093、6094、6095、6096、6097、6098、6099、6100、6101、6102、6103、6104、6105、6106、6107、6108、6109、6110、6111、6112、6113、6114、6115、6116、6117、6118、6119、6120、6121、6122、6123、6124、6125、6126、6127、6128、6129、6130、6131、6132、6133、6134、6135、6136、6137、6138、6139、6140、6141、6142、6143、6144、6145、6146、6147、6148、6149、6150、6151、6152、6153、6154、6155、6156、6157、6158、6159、6160、6161、6162、6163、6164、6165、6166、6167、6168、6169、6170、6171、6172、6173、6174、6175、6176、6177、6178、6179、6180、6181、6182、6183、6184、6185、6186、6187、6188、6189、6190、6191、6192、6193、6194、6195、6196、6197、6198、6199、6200、6201、6202、6203、6204、6205、6206、6207、6208、6209、6210、6211、6212、6213、6214、6215、6216、6217、6218、6219、6220、6221、6222、6223、6224、6225、6226、6227、6228、6229、6230、6231、6232、6233、6234、6235、6236、6237、6238、6239、6240、6241、6242、6243、6244、6245、6246、6247、6248、6249、6250、6251、6252、6253、6254、6255、6256、6257、6258、6259、6260、6261、6262、6263、6264、6265、6266、6267、6268、6269、6270、6271、6272、6273、6274、6275、6276、6277、6278、6279、6280、6281、6282、6283、6284、6285、6286、6287、6288、6289、6290、6291、6292、6293、6294、6295、6296、6297、6298、6299、6300、6301、6302、6303、6304、6305、6306、6307、6308、6309、6310、6311、6312、6313、6314、6315、6316、6317、6318、6319、6320、6321、6322、6323、6324、6325、6326、6327、6328、6329、6330、6331、6332、6333、6334、6335、6336、6337、6338、6339、6340、6341、6342、6343、6344、6345、6346、6347、6348、6349、6350、6351、6352、6353、6354、6355、6356、6357、6358、6359、6360、6361、6362、6363、6364、6365、6366、6367、6368、6369、6370、6371、6372、6373、6374、6375、6376、6377、6378、6379、6380、6381、6382、6383、6384、6385、6386、6387、6388、6389、6390、6391、6392、6393、6394、6395、6396、6397、6398、6399、6400、6401、6402、6403、6404、6405、6406、6407、6408、6409、6410、6411、6412、6413、6414、6415、6416、6417、6418、6419、6420、6421、6422、6423、6424、6425、6426、6427、6428、6429、6430、6431、6432、6433、6434、6435、6436、6437、6438、6439、6440、6441、6442、6443、6444、6445、6446、6447、6448、6449、6450、6451、6452、6453、6454、6455、6456、6457、6458、6459、6460、6461、6462、6463、6464、6465、6466、6467、6468、6469、6470、6471、6472、6473、6474、6475、6476、6477、6478、6479、6480、6481、6482、6483、6484、6485、6486、6487、6488、6489、6490、6491、6492、6493、6494、6495、6496、6497、6498、6499、6500、6501、6502、6503、6504、6505、6506、6507、6508、6509、6510、6511、6512、6513、6514、6515、6516、6517、6518、6519、6520、6521、6522、6523、6524、6525、6526、6527、6528、6529、6530、6531、6532、6533、6534、6535、6536、6537、6538、6539、6540、6541、6542、6543、6544、6545、6546、6547、6548、6549、6550、6551、6552、6553、6554、6555、6556、6557、6558、6559、6560、6561、6562、6563、6564、6565、6566、6567、6568、6569、6570、6571、6572、6573、6574、6575、6576、6577、6578、6579、6580、6581、6582、6583、6584、6585、6586、6587、6588、6589、6590、6591、6592、6593、6594、6595、6596、6597、6598、6599、6600、6601、6602、6603、6604、6605、6606、6607、6608、6609、6610、6611、6612、6613、6614、6615、6616、6617、6618、6619、6620、6621、6622、6623、6624、6625、6626、6627、6628、6629、6630、6631、6632、6633、6634、6635、6636、6637、6638、6639、6640、6641、6642、6643、6644、6645、6646、6647、6648、6649、6650、6651、6652、6653、6654、6655、6656、6657、6658、6659、6660、6661、6662、6663、6664、6665、6666、6667、6668、6669、6670、6671、6672、6673、6674、6675、6676、6677、6678、6679、6680、6681、6682、6683、6684、6685、6686、6687、6688、6689、6690、6691、6692、6693、6694、6695、6696、6697、6698、6699、6700、6701、6702、6703、6704、6705、67、 06、6707、6708、6709、6710、6711、6712、6713、6714、6715、6716、6717、6718、6719、6720、6721、6722、6723、6724、6725、6726、6727、6728、6729、6730、6731、6732、6733、6734、6735、6736、6737、6738、6739、6740、6741、6742、6743、6744、6745、6746、6747、6748、6749、6750、6751、6752、6753、6754、6755、6756、6757、6758、6759、6760、6761、6762、6763、6764、6765、6766、6767、6768、6769、6770、6771、6772、6773、6774、6775、6776、6777、6778、6779、6780、6781、6782、6783、6784、6785、6786、6787、6788、6789、6790、6791、6792、6793、6794、6795、6796、6797、6798、6799、6800、6801、6802、6803、6804、6805、6806、6807、6808、6809、6810、6811、6812、6813、6814、6815、6816、6817、6818、6819、6820、6821、6822、6823、6824、6825、6826、6827、6828、6829、6830、6831、6832、6833、6834、6835、6836、6837、6838、6839、6840、6841、6842、6843、6844、6845、6846、6847、6848、6849、6850、6851、6852、6853、6854、6855、6856、6857、6858、6859、6860、6861、6862、6863、6864、6865、6866、6867、6868、6869、6870、6871、6872、6873、6874、6875、6876、6877、6878、6879、6880、6881、6882、6883、6884、6885、6886、6887、6888、6889、6890、6891、6892、6893、6894、6895、6896、6897、6898、6899、6900、6901、6902、6903、6904、6905、6906、6907、6908、6909、6910、6911、6912、6913、6914、6915、6916、6917、6918、6919、6920、6921、6922、6923、6924、6925、6926、6927、6928、6929、6930、6931、6932、6933、6934、6935、6936、6937、6938、6939、6940、6941、6942、6943、6944、6945、6946、6947、6948、6949、6950、6951、6952、6953、6954、6955、6956、6957、6958、6959、6960、6961、6962、6963、6964、6965、6966、6967、6968、6969、6970、6971、6972、6973、6974、6975、6976、6977、6978、6979、6980、6981、6982、6983、6984、6985、6986、6987、6988、6989、6990、6991、6992、6993、6994、6995、6996、6997、6998、6999、7000、7001、7002、7003、7004、7005、7006、7007、7008、7009、7010、7011、7012、7013、7014、7015、7016、7017、7018、7019、7020、7021、7022、7023、7024、7025、7026、7027、7028、7029、7030、7031、7032、7033、7034、7035、7036、7037、7038、7039、7040、7041、7042、7043、7044、7045、7046、7047、7048、7049、7050、7051、7052、7053、7054、7055、7056、7057、7058、7059、7060、7061、7062、7063、7064、7065、7066、7067、7068、7069、7070、7071、7072、7073、7074、7075、7076、7077、7078、7079、7080、7081、7082、7083、7084、7085、7086、7087、7088、7089、7090、7091、7092、7093、7094、7095、7096、7097、7098、7099、7100、7101、7102、7103、7104、7105、7106、7107、7108、7109、7110、7111、7112、7113、7114、7115、7116、7117、7118、7119、7120、7121、7122、7123、7124、7125、7126、7127、7128、7129、7130、7131、7132、7133、7134、7135、7136、7137、7138、7139、7140、7141、7142、7143、7144、7145、7146、7147、7148、7149、7150、7151、7152、7153、7154、7155、7156、7157、7158、7159、7160、7161、7162、7163、7164、7165、7166、7167、7168、7169、7170、7171、7172、7173、7174、7175、7176、7177、7178、7179、7180、7181、7182、7183、7184、7185、7186、7187、7188、7189、7190、7191、7192、7193、7194、7195、7196、7197、7198、7199、7200、7201、7202、7203、7204、7205、7206、7207、7208、7209、7210、7211、7212、7213、7214、7215、7216、7217、7218、7219、7220、7221、7222、7223、7224、7225、7226、7227、7228、7229、7230、7231、7232、7233、7234、7235、7236、7237、7238、7239、7240、7241、7242、7243、7244、7245、7246、7247、7248、7249、7250、7251、7252、7253、7254、7255、7256、7257、7258、7259、7260、7261、7262、7263、7264、7265、7266、7267、7268、7269、7270、7271、7272、7273、7274、7275、7276、7277、7278、7279、7280、7281、7282、7283、7284、7285、7286、7287、7288、7289、7290、7291、7292、7293、7294、7295、7296、7297、7298、7299、7300、7301、7302、7303、7304、7305、7306、7307、7308、7309、7310、7311、7312、7313、7314、7315、7316、7317、7318、7319、7320、7321、7322、7323、7324、7325、7326、7327、7328、7329、7330、7331、7332、7333、7334、7335、7336、7337、7338、7339、7340、7341、7342、7343、7344、7345、7346、7347、7348、7349、7350、7351、7352、7353、7354、7355、7356、7357、7358、7359、7360、7361、7362、7363、7364、7365、7366、7367、7368、7369、7370、7371、7372、7373、7374、7375、7376、7377、7378、7379、7380、7381、7382、7383、7384、7385、7386、7387、7388、7389、7390、7391、7392、7393、7394、7395、7396、7397、7398、7399、7400、7401、7402、7403、7404、7405、7406、7407、7408、7409、7410、7411、7412、7413、7414、7415、7416、7417、7418、7419、7420、7421、7422、7423、7424、7425、7426、7427、7428、7429、7430、7431、7432、7433、7434、7435、7436、7437、7438、7439、7440、7441、7442、7443、7444、7445、7446、7447、7448、7449、7450、7451、7452、7453、7454、7455、7456、7457、7458、7459、7460、7461、7462、7463、7464、7465、7466、7467、7468、7469、7470、7471、7472、7473、7474、7475、7476、7477、7478、7479、7480、7481、7482、7483、7484、7485、7486、7487、7488、7489、7490、7491、7492、7493、7494、7495、7496、7497、7498、7499、7500、7501、7502、7503、7504、7505、7506、7507、7508、7509、7510、7511、7512、7513、7514、7515、7516、7517、7518、7519、7520、7521、7522、7523、7524、7525、7526、7527、7528、7529、7530、7531、7532、7533、7534、7535、7536、7537、7538、7539、7540、7541、7542、7543、7544、7545、7546、7547、7548、7549、7550、7551、7552、7553、7554、7555、7556、7557、7558、7559、7560、7561、7562、7563、7564、7565、7566、7567、7568、7569、7570、7571、7572、7573、7574、7575、7576、7577、7578、7579、7580、7581、7582、7583、7584、7585、7586、7587、7588、7589、7590、7591、7592、7593、7594、7595、7596、7597、7598、7599、7600、7601、7602、7603、7604、7605、7606、7607、7608、7609、7610、7611、7612、7613、7614、7615、7616、7617、7618、7619、7620、7621、7622、7623、7624、7625、7626、7627、7628、7629、7630、7631、7632、7633、7634、7635、7636、7637、7638、7639、7640、7641、7642、7643、7644、7645、7646、7647、7648、7649、7650、7651、7652、7653、7654、7655、7656、7657、7658、7659、7660、7661、7662、7663、7664、7665、7666、7667、7668、7669、7670、7671、7672、7673、7674、7675、7676、7677、7678、7679、7680、7681、7682、7683、7684、7685、7686、7687、7688、7689、7690、7691、7692、7693、7694、7695、7696、7697、7698、7699、7700、7701、7702、7703、7704、7705、7706、7707、7708、7709、7710、7711、7712、7713、7714、7715、7716、7717、7718、7719、7720、7721、7722、7723、7724、7725、7726、7727、7728、7729、773、 0、7731、7732、7733、7734、7735、7736、7737、7738、7739、7740、7741、7742、7743、7744、7745、7746、7747、7748、7749、7750、7751、7752、7753、7754、7755、7756、7757、7758、7759、7760、7761、7762、7763、7764、7765、7766、7767、7768、7769、7770、7771、7772、7773、7774、7775、7776、7777、7778、7779、7780、7781、7782、7783、7784、7785、7786、7787、7788、7789、7790、7791、7792、7793、7794、7795、7796、7797、7798、7799、7800、7801、7802、7803、7804、7805、7806、7807、7808、7809、7810、7811、7812、7813、7814、7815、7816、7817、7818、7819、7820、7821、7822、7823、7824、7825、7826、7827、7828、7829、7830、7831、7832、7833、7834、7835、7836、7837、7838、7839、7840、7841、7842、7843、7844、7845、7846、7847、7848、7849、7850、7851、7852、7853、7854、7855、7856、7857、7858、7859、7860、7861、7862、7863、7864、7865、7866、7867、7868、7869、7870、7871、7872、7873、7874、7875、7876、7877、7878、7879、7880、7881、7882、7883、7884、7885、7886、7887、7888、7889、7890、7891、7892、7893、7894、7895、7896、7897、7898、7899、7900、7901、7902、7903、7904、7905、7906、7907、7908、7909、7910、7911、7912、7913、7914、7915、7916、7917、7918、7919、7920、7921、7922、7923、7924、7925、7926、7927、7928、7929、7930、7931、7932、7933、7934、7935、7936、7937、7938、7939、7940、7941、7942、7943、7944、7945、7946、7947、7948、7949、7950、7951、7952、7953、7954、7955、7956、7957、7958、7959、7960、7961、7962、7963、7964、7965、7966、7967、7968、7969、7970、7971、7972、7973、7974、7975、7976、7977、7978、7979、7980、7981、7982、7983、7984、7985、7986、7987、7988、7989、7990、7991、7992、7993、7994、7995、7996、7997、7998、7999、8000、8001、8002、8003、8004、8005、8006、8007、8008、8009、8010、8011、8012、8013、8014、8015、8016、8017、8018、8019、8020、8021、8022、8023、8024、8025、8026、8027、8028、8029、8030、8031、8032、8033、8034、8035、8036、8037、8038、8039、8040、8041、8042、8043、8044、8045、8046、8047、8048、8049、8050、8051、8052、8053、8054、8055、8056、8057、8058、8059、8060、8061、8062、8063、8064、8065、8066、8067、8068、8069、8070、8071、8072、8073、8074、8075、8076、8077、8078、8079、8080、8081、8082、8083、8084、8085、8086、8087、8088、8089、8090、8091、8092、8093、8094、8095、8096、8097、8098、8099、8100、8101、8102、8103、8104、8105、8106、8107、8108、8109、8110、8111、8112、8113、8114、8115、8116、8117、8118、8119、8120、8121、8122、8123、8124、8125、8126、8127、8128、8129、8130、8131、8132、8133、8134、8135、8136、8137、8138、8139、8140、8141、8142、8143、8144、8145、8146、8147、8148、8149、8150、8151、8152、8153、8154、8155、8156、8157、8158、8159、8160、8161、8162、8163、8164、8165、8166、8167、8168、8169、8170、8171、8172、8173、8174、8175、8176、8177、8178、8179、8180、8181、8182、8183、8184、8185、8186、8187、8188、8189、8190、8191、8192、8193、8194、8195、8196、8197、8198、8199、8200、8201、8202、8203、8204、8205、8206、8207、8208、8209、8210、8211、8212、8213、8214、8215、8216、8217、8218、8219、8220、8221、8222、8223、8224、8225、8226、8227、8228、8229、8230、8231、8232、8233、8234、8235、8236、8237、8238、8239、8240、8241、8242、8243、8244、8245、8246、8247、8248、8249、8250、8251、8252、8253、8254、8255、8256、8257、8258、8259、8260、8261、8262、8263、8264、8265、8266、8267、8268、8269、8270、8271、8272、8273、8274、8275、8276、8277、8278、8279、8280、8281、8282、8283、8284、8285、8286、8287、8288、8289、8290、8291、8292、8293、8294、8295、8296、8297、8298、8299、8300、8301、8302、8303、8304、8305、8306、8307、8308、8309、8310、8311、8312、8313、8314、8315、8316、8317、8318、8319、8320、8321、8322、8323、8324、8325、8326、8327、8328、8329、8330、8331、8332、8333、8334、8335、8336、8337、8338、8339、8340、8341、8342、8343、8344、8345、8346、8347、8348、8349、8350、8351、8352、8353、8354、8355、8356、8357、8358、8359、8360、8361、8362、8363、8364、8365、8366、8367、8368、8369、8370、8371、8372、8373、8374、8375、8376、8377、8378、8379、8380、8381、8382、8383、8384、8385、8386、8387、8388、8389、8390、8391、8392、8393、8394、8395、8396、8397、8398、8399、8400、8401、8402、8403、8404、8405、8406、8407、8408、8409、8410、8411、8412、8413、8414、8415、8416、8417、8418、8419、8420、8421、8422、8423、8424、8425、8426、8427、8428、8429、8430、8431、8432、8433、8434、8435、8436、8437、8438、8439、8440、8441、8442、8443、8444、8445、8446、8447、8448、8449、8450、8451、8452、8453、8454、8455、8456、8457、8458、8459、8460、8461、8462、8463、8464、8465、8466、8467、8468、8469、8470、8471、8472、8473、8474、8475、8476、8477、8478、8479、8480、8481、8482、8483、8484、8485、8486、8487、8488、8489、8490、8491、8492、8493、8494、8495、8496、8497、8498、8499、8500、8501、8502、8503、8504、8505、8506、8507、8508、8509、8510、8511、8512、8513、8514、8515、8516、8517、8518、8519、8520、8521、8522、8523、8524、8525、8526、8527、8528、8529、8530、8531、8532、8533、8534、8535、8536、8537、8538、8539、8540、8541、8542、8543、8544、8545、8546、8547、8548、8549、8550、8551、8552、8553、8554、8555、8556、8557、8558、8559、8560、8561、8562、8563、8564、8565、8566、8567、8568、8569、8570、8571、8572、8573、8574、8575、8576、8577、8578、8579、8580、8581、8582、8583、8584、8585、8586、8587、8588、8589、8590、8591、8592、8593、8594、8595、8596、8597、8598、8599、8600、8601、8602、8603、8604、8605、8606、8607、8608、8609、8610、8611、8612、8613、8614、8615、8616、8617、8618、8619、8620、8621、8622、8623、8624、8625、8626、8627、8628、8629、8630、8631、8632、8633、8634、8635、8636、8637、8638、8639、8640、8641、8642、8643、8644、8645、8646、8647、8648、8649、8650、8651、8652、8653、8654、8655、8656、8657、8658、8659、8660、8661、8662、8663、8664、8665、8666、8667、8668、8669、8670、8671、8672、8673、8674、8675、8676、8677、8678、8679、8680、8681、8682、8683、8684、8685、8686、8687、8688、8689、8690、8691、8692、8693、8694、8695、8696、8697、8698、8699、8700、8701、8702、8703、8704、8705、8706、8707、8708、8709、8710、8711、8712、8713、8714、8715、8716、8717、8718、8719、8720、8721、8722、8723、8724、8725、8726、8727、8728、8729、8730、8731、8732、8733、8734、8735、8736、8737、8738、8739、8740、8741、8742、8743、8744、8745、8746、8747、8748、8749、8750、8751、8752、8753、8754、 、8755、8756、8757、8758、8759、8760、8761、8762、8763、8764、8765、8766、8767、8768、8769、8770、8771、8772、8773、8774、8775、8776、8777、8778、8779、8780、8781、8782、8783、8784、8785、8786、8787、8788、8789、8790、8791、8792、8793、8794、8795、8796、8797、8798、8799、8800、8801、8802、8803、8804、8805、8806、8807、8808、8809、8810、8811、8812、8813、8814、8815、8816、8817、8818、8819、8820、8821、8822、8823、8824、8825、8826、8827、8828、8829、8830、8831、8832、8833、8834、8835、8836、8837、8838、8839、8840、8841、8842、8843、8844、8845、8846、8847、8848、8849、8850、8851、8852、8853、8854、8855、8856、8857、8858、8859、8860、8861、8862、8863、8864、8865、8866、8867、8868、8869、8870、8871、8872、8873、8874、8875、8876、8877、8878、8879、8880、8881、8882、8883、8884、8885、8886、8887、8888、8889、8890、8891、8892、8893、8894、8895、8896、8897、8898、8899、8900、8901、8902、8903、8904、8905、8906、8907、8908、8909、8910、8911、8912、8913、8914、8915、8916、8917、8918、8919、8920、8921、8922、8923、8924、8925、8926、8927、8928、8929、8930、8931、8932、8933、8934、8935、8936、8937、8938、8939、8940、8941、8942、8943、8944、8945、8946、8947、8948、8949、8950、8951、8952、8953、8954、8955、8956、8957、8958、8959、8960、8961、8962、8963、8964、8965、8966、8967、8968、8969、8970、8971、8972、8973、8974、8975、8976、8977、8978、8979、8980、8981、8982、8983、8984、8985、8986、8987、8988、8989、8990、8991、8992、8993、8994、8995、8996、8997、8998、8999、9000、9001、9002、9003、9004、9005、9006、9007、9008、9009、9010、9011、9012、9013、9014、9015、9016、9017、9018、9019、9020、9021、9022、9023、9024、9025、9026、9027、9028、9029、9030、9031、9032、9033、9034、9035、9036、9037、9038、9039、9040、9041、9042、9043、9044、9045、9046、9047、9048、9049、9050、9051、9052、9053、9054、9055、9056、9057、9058、9059、9060、9061、9062、9063、9064、9065、9066、9067、9068、9069、9070、9071、9072、9073、9074、9075、9076、9077、9078、9079、9080、9081、9082、9083、9084、9085、9086、9087、9088、9089、9090、9091、9092、9093、9094、9095、9096、9097、9098、9099、9100、9101、9102、9103、9104、9105、9106、9107、9108、9109、9110、9111、9112、9113、9114、9115、9116、9117、9118、9119、9120、9121、9122、9123、9124、9125、9126、9127、9128、9129、9130、9131、9132、9133、9134、9135、9136、9137、9138、9139、9140、9141、9142、9143、9144、9145、9146、9147、9148、9149、9150、9151、9152、9153、9154、9155, 9156, 9157, 9158, 9159, 9160, 9161, 9162, 9163, 9164, 9165, 9166, 9167, 9168, 9169, 9170, 9171, 9172, 9173, 9174, 9175, 9176, 9177, 9178, 9179, 9180 , 9181, 9182, 9183, 9184, 9185, 9186, 9187, 9188, 9189, 9190, 9191, 9192, 9193, 9194, 9195, 9196, 9197, 9198, 9199, 9200, 9201, 9202, 9203.

[0087] The term "identity," as known in the art, refers to the relationship between the sequences of two or more peptides, as determined by comparing the sequences. In the art, identity also refers to the degree of sequence relatedness between peptides, as determined by the number of matches between strings of two or more amino acid residues. Identity measures the percentage of identical matches between the smaller of two or more sequences, with gap alignment (if any), as processed by a specific mathematical model or computer program (i.e., "algorithm"). The identity of related peptides can be easily calculated by known methods. Such methods include "Computational Molecular Biology," Lesk, AM, ed., Oxford University Press, New York, 1988; "Biocomputing: Informatics and Genome Projects," Smith, DW, ed., Academic Press, New York, 1993; "Computer Analysis of Sequence Data," Part 1, Griffin, AM, and Griffin, HG, eds., Humana Press, New Jersey, 1994; and "Sequence Analysis in Molecular Biology," von These include, but are not limited to, the methods described in Heinje, G., Academic Press, 1987, Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New York, 1991, and Carillo et al., SIAM J. Applied Math. 48, 1073 (1988).

[0088] In some embodiments, polypeptide variants may have the same or similar activity as the reference oncology-related polypeptide. Alternatively, variants may have altered (e.g., increased or decreased) activity compared to the reference oncology-related polypeptide. Generally, variants of particular oncology-related polynucleotides or oncology-related polypeptides of the present invention will have at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, but less than 100% sequence identity to a particular reference oncology-related polynucleotide or oncology-related polypeptide variant, as determined by sequence alignment programs and parameters described herein and known to those of skill in the art. Such alignment tools include the BLAST suite of programs (Stephen F. Altschul, Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," Nucleic Acids Res. 25:3389-3402. Other tools are described herein, specifically in the definition of "identity."

[0089] Default parameters for the BLAST algorithm include, for example, a prediction threshold of 10, a word size of 28, a match / mismatch score of 1, -2, and a linear gap cost. Optional filters can be applied, as well as selection of species-specific repeat sequences, e.g., human-specific repeat sequences.

[0090] In one embodiment, the oncology-related polynucleotides, oncology-related primary constructs and / or oncology-related mmRNA may be used to treat a disease, disorder, and / or condition in a subject.

[0091] In one embodiment, the oncology-related polynucleotides, oncology-related primary constructs and / or oncology-related mmRNA may be used to reduce, eliminate or prevent tumor growth in a subject.

[0092] In one embodiment, the oncology-related polynucleotides, oncology-related primary constructs and / or oncology-related mmRNA may be used to reduce and / or ameliorate at least one symptom of cancer in a subject. Symptoms of cancer may include, but are not limited to, weakness, aches and pains, fever, fatigue, weight loss, blood clots, elevated blood calcium levels, low white blood cell count, shortness of breath, dizziness, headache, hyperpigmentation, jaundice, erythema, pruritus, hirsutism, changes in bowel habits, changes in bladder function, persistent sores, white spots in the mouth, white spots on the tongue, abnormal bleeding or discharge, thickening or lumps in body areas, indigestion, difficulty swallowing, changes in warts or moles, new skin and persistent changes in the skin or hoarseness. Additionally, oncology-associated polynucleotides, oncology-associated primary constructs and / or oncology-associated mmRNA may reduce cancer-related side effects such as, but not limited to, chemobrain, peripheral neuropathy, fatigue, depression, nausea, vomiting, pain, anemia, lymphedema, infections, sexual side effects, reduced infertility or fertility, ostomy, infertility, and hair loss.

[0093] Oncology-related proteins or peptides The oncology-related primary constructs or oncology-related mmRNA disclosed herein may encode one or more validated or "investigational" oncology-related proteins or oncology-related peptides.

[0094] In accordance with the present invention, one or more oncology-related proteins or peptides currently on the market or in development may be encoded by the oncology-related polynucleotides, oncology-related primary constructs or oncology-related mmRNA of the present invention. Without wishing to be bound by theory, it is believed that incorporation into the oncology-related primary constructs or oncology-related mmRNA of the present invention results in improved therapeutic efficacy, at least in part due to the specificity, purity, and selectivity of the construct design.

[0095] Oncology-related polynucleotides, oncology-related primary constructs and / or oncology-related mmRNAs may be used to identify proteins involved in cell cycle, DNA damage response (e.g., DNA damage repair), apoptosis, angiogenesis, cell motility, epithelial-mesenchymal transition of epithelial cells, phosphatidylinositol 3 (PI3) kinase / Akt cell signaling pathways, telomerase activity and / or expression, tumor metastasis, tumorigenesis, cathepsins, cellular senescence, receptor tyrosine kinase signaling, metabolism and drug metabolism, G protein signaling, growth factors and receptors, heat shock proteins, histone deacetylases, hormone receptors, hypoxia, poly (ADP-ribose) polymerase, The biological and / or physiological processes and / or compounds may be altered, such as, but not limited to, protein kinases, RAS signaling, topoisomerases, transcription factors and anti-tumor activity of cancerous, pre-cancerous, and / or other cells.

[0096] In one embodiment, the polynucleotides, oncology-related primary constructs and / or oncology-related mmRNA may be used to express a polypeptide in a cell or tissue for the purpose of replacing a protein produced from a deleted or mutated gene.

[0097] Furthermore, the oncology-related polynucleotides, oncology-related primary constructs or oncology-related mmRNA of the present invention may be used to treat cancers caused by carcinogens of natural and / or synthetic origin. In another embodiment, the oncology-related polynucleotides, oncology-related primary constructs and / or oncology-related mmRNA may be used to treat cancers caused by other organisms and / or caused by viral infections.

[0098] Flanking region: untranslated region (UTR) The untranslated region (UTR) of a gene is transcribed but not translated. The 5'UTR begins at the transcription initiation site and follows but does not include the start codon, while the 3'UTR begins immediately after the stop codon and continues until the transcription termination signal. There have been increasing reports of the regulatory role that UTRs play in the stability of nucleic acid molecules and translation. Regulatory features of UTRs can be incorporated into the oncology-related polynucleotides, oncology-related primary constructs, and / or oncology-related mmRNA of the present invention to enhance the stability of the molecules. Specific features can also be incorporated to ensure controlled downregulation of transcripts in the event that they are misdirected to undesirable organ sites.

[0099] 5'UTR and translation start Natural 5'UTRs have features involved in translation initiation. They contain features such as the Kozak sequence, which is commonly known to be involved in the process by which ribosomes initiate the translation of many genes. The Kozak sequence has the consensus CCR(A / G)CCAUGG, where R is a purine (adenine or guanine) three bases upstream of the start codon (AUG), followed by another "G." 5'UTRs are also known to form secondary structures involved in elongation factor binding.

[0100] By manipulating features typically found in highly expressed genes in specific target organs, the stability of the oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNA of the present invention and oncology-related protein production can be increased. For example, introduction of the 5'UTR of liver-expressed mRNAs such as albumin, serum amyloid A, apolipoprotein A / B / E, transferrin, alpha-fetoprotein, erythropoietin, or factor VIII can be used to increase expression of nucleic acid molecules such as mmRNA in hepatic cell lines or the liver. Similarly, 5'UTRs from other tissue-specific mRNAs can be used to enhance expression in that tissue in muscle (MyoD, myosin, myoglobin, myogenin, herculin), endothelial cells (Tie-1, CD36), bone marrow cells (C / EBP, AML1, G-CSF, GM-CSF, CD11b, MSR, Fr-1, i-NOS), leukocytes (CD45, CD18), adipose tissue (CD36, GLUT4, ACRP30, adiponectin), and lung epithelial cells (SP-A / B / C / D).

[0101] Other non-UTR sequences can be incorporated into 5'UTR (or 3'UTR).For example, introns or parts of intron sequences can be incorporated into the adjacent regions of the oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNA of the present invention.The incorporation of intron sequences can increase protein production and mRNA levels.

[0102] 3'UTR and AU-rich elements 3'UTRs are known to have stretches of adenosine and uridine embedded within them. These AU-rich features are particularly common in genes with high turnover rates. Based on their sequence characteristics and functional properties, AU-rich elements (AREs) can be classified into three classes (Chen et al., 1995): Class I AREs contain several dispersed copies of the AUUUA motif within the U-rich region. C-Myc and MyoD contain class I AREs. Class II AREs have two or more overlapping UUAUUUA(U / A)(U / A) nonamers. Molecules containing this type of ARE include GM-CSF and TNF-α. Class III AREs are less well defined. These U-rich regions do not contain the AUUUA motif. C-Jun and myogenin are two well-studied examples of this class. While most proteins that bind to AREs are known to destabilize messengers, members of the ELAV family, most notably HuR, have been demonstrated to enhance mRNA stability. HuR binds to these three classes of AREs. Engineering a HuR-specific binding site into the 3'UTR of a nucleic acid molecule leads to HuR binding and, therefore, to message stabilization in vivo.

[0103] The introduction, removal, or modification of AU-rich elements (AREs) in the 3'UTR can be used to regulate the stability of oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNA of the present invention. When manipulating certain oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNA, one or more copies of AREs can be introduced to reduce the stability of the oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNA of the present invention, thereby suppressing the translation and reducing the production of the resulting protein. Similarly, AREs can be identified and removed or mutated to improve intracellular stability, thereby increasing the translation and production of the resulting protein. Transfection experiments using oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNA of the present invention can be performed in relevant cell lines, and protein production can be assayed at various time points after transfection. For example, cells can be transfected with different ARE-engineered molecules and the proteins produced can be assayed at 6 hours, 12 hours, 24 hours, 48 ​​hours, and 7 days post-transfection using an ELISA kit for the relevant protein.

[0104] Incorporation of microRNA binding sites MicroRNAs (or miRNAs) are 19-25 nucleotide-long non-coding RNAs that bind to the 3'UTR of nucleic acid molecules and downregulate gene expression by either reducing nucleic acid molecule stability or inhibiting translation. The oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNAs of the present invention may contain one or more microRNA target sequences, microRNA sequences, or microRNA species. Such sequences may correspond to any known microRNA, such as those taught in U.S. Patent Publication Nos. US2005 / 0261218 and US2005 / 0059005, the contents of which are incorporated herein by reference in their entireties.

[0105] A microRNA sequence comprises a "seed" region, i.e., a region from positions 2 to 8 of the mature microRNA, which has perfect Watson-Crick complementarity to the miRNA target sequence. A microRNA seed may comprise positions 2 to 8 or positions 2 to 7 of the mature microRNA. In some embodiments, a microRNA seed may comprise seven nucleotides (e.g., nucleotides 2 to 8 of the mature microRNA), and the seed-complementary site in the corresponding miRNA target is adjacent to an adenine (A) opposite microRNA position 1. In some embodiments, a microRNA seed may comprise six nucleotides (e.g., nucleotides 2 to 7 of the mature microRNA), and the seed-complementary site in the corresponding miRNA target is adjacent to an adenine (A) opposite microRNA position 1. See, for example, Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP; Mol Cell. 2007 Jul 6;27(1):91-105, each of which is incorporated herein by reference in its entirety. The bases of the microRNA species have perfect complementarity with the target sequence. By engineering a microRNA target sequence into the 3'UTR of an oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA of the present invention, the molecule can be targeted for degradation or reduced translation, provided that the microRNA in question is available. This process reduces the risk of off-target effects during nucleic acid molecule delivery. The identification of microRNAs, microRNA target regions, and their expression patterns, as well as their roles in biology, have been reported (Bonauer et al., Curr Drug Targets 2010 11:943-949; Anand and Cheresh Curr Opin Hematol 2011 18:171-176, Contreras and Rao Leukemia 2012 26:404-413(2011 Dec 20.doi:10.1038 / leu.2011.356), Bartel Cell 2009 136:215-233, Landgraf et al. al, Cell, 2007 129:1401-1414).

[0106] For example, if the nucleic acid molecule is an mRNA that is not intended to be delivered to the liver but settles there, miR-122, a microRNA abundant in the liver, can inhibit expression of a gene of interest if one or more target sites for miR-122 are engineered into the 3'UTR of an oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA. The introduction of one or more binding sites for a different microRNA can be engineered to further reduce the longevity, stability, and protein translation of the oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA. As used herein, the term "microRNA site" refers to a microRNA target site or microRNA recognition site, or any nucleotide sequence to which a microRNA binds or associates. It should be understood that "binding" may follow conventional Watson-Crick hybridization rules or may refer to any stable association of a microRNA with a target sequence at or adjacent to the microRNA site.

[0107] Conversely, for the purpose of the oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA of the present invention, naturally occurring microRNA binding sites can be engineered out of the sequence (i.e., removed from the sequence) to increase protein expression in specific tissues. For example, the miR-122 binding site can be removed to improve protein expression in the liver. Control of expression in multiple tissues can be achieved by introducing or removing one or several microRNA binding sites.

[0108] Examples of tissues in which microRNAs are known to regulate mRNA and therefore protein expression include, but are not limited to, liver (miR-122), muscle (miR-133, miR-206, miR-208), endothelial cells (miR-17-92, miR-126), bone marrow cells (miR-142-3p, miR-142-5p, miR-16, miR-21, miR-223, miR-24, miR-27), adipose tissue (let-7, miR-30c), heart (miR-ld, miR-149), kidney (miR-192, miR-194, miR-204), and lung epithelial cells (let-7, miR-133, miR-126). MicroRNAs may also regulate complex biological processes such as angiogenesis (miR-132) (Anand and Cheresh Curr Opin Hematol 2011 18:171-176, incorporated herein by reference in its entirety). In the oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNA of the present invention, binding sites for microRNAs involved in such processes may be removed or introduced to modulate expression of the oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNA to biologically relevant cell types or in relation to relevant biological processes. Lists of microRNAs, miR sequences, and miR binding sites are listed in Table 9 of U.S. Provisional Patent Application No. 61 / 753,661, filed January 17, 2013, Table 9 of U.S. Provisional Patent Application No. 61 / 754,159, filed January 18, 2013, and Table 7 of U.S. Provisional Patent Application No. 61 / 758,921, filed January 31, 2013, each of which is incorporated by reference in its entirety.

[0109] Finally, through understanding the expression patterns of microRNAs in different oncology-related cell types, oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNAs can be engineered for more targeted expression in specific cell types or only under specific biological conditions. By introducing tissue-specific microRNA binding sites, oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNAs can be designed to optimize oncology-related protein expression in tissues or in relation to biological conditions. Examples of the use of microRNAs to drive tissue- or disease-specific gene expression have been listed (Getner and Naldini, Tissue Antigens. 2012, 80:393-403, incorporated herein by reference in its entirety). In addition, microRNA seed sites can be incorporated into mRNAs to reduce expression in certain cells, resulting in biological improvements. An example of this is the incorporation of miR-142 sites into UGT1A1-expressing lentiviral vectors. The presence of miR-142 seeding sites reduced expression in hematopoietic cells, resulting in reduced expression in antigen-presenting cells and the absence of an immune response to virally expressed UGT1A1 (Schmitt et al., Gastroenterology 2010;139:999-1007; Gonzalez-Asequinolaza et al. Gastroenterology 2010,139:726-729, each of which is incorporated herein by reference in its entirety). Incorporation of miR-142 sites into modified mRNA not only reduced the expression of the encoded protein in hematopoietic cells, but also reduced or abolished the immune response to the protein encoded by the mRNA. Incorporation of miR-142 seeding sites (one or more) into mRNA is important when treating patients with complete protein deficiencies, including, but not limited to, UGT1A1 type I, LDLR-deficient patients, and CRIM-negative Pompe patients.

[0110] Transfection experiments can be carried out in relevant cell lines using engineered oncology-related polynucleotides, oncology-related primary constructs or oncology-related mmRNA, and protein production can be measured at various times after transfection.For example, cells can be transfected with different microRNA binding site engineered oncology-related polynucleotides, oncology-related primary constructs or oncology-related mmRNA, and the protein produced can be measured at 6 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours and 7 days after transfection using ELISA kits for relevant proteins.In vivo experiments can also be carried out using microRNA binding site engineered molecules to test the tissue-specific expression changes of formulated oncology-related polynucleotides, oncology-related primary constructs or oncology-related mmRNA.

[0111] 5' Capping The 5' cap structure of mRNA is involved in nuclear export, improves mRNA stability, and binds to mRNA cap-binding protein (CBP), which is involved in mRNA stability and translation competence in cells through its association with poly(A)-binding protein to form mature circular mRNA species. This cap also assists in the removal of 5'-proximal introns during mRNA splicing.

[0112] Endogenous mRNA molecules can be 5'-end capped, resulting in a 5'-ppp-5'-triphosphate linkage between the terminal guanosine cap residue and the 5'-terminal transcribed sense nucleotide of the mRNA molecule. This 5'-guanylate cap can then be methylated to generate an N7-methyl-guanylate residue. The ribose sugars of the terminal and / or pre-terminal transcribed nucleotides at the 5' end of the mRNA can also optionally be 2'-O-methylated. 5' decapping, via hydrolysis and cleavage of the guanylate cap structure, can target nucleic acid molecules, such as mRNA molecules, for degradation.

[0113] The modification of the oncology-related polynucleotides, oncology-related primary constructs, and oncology-related mmRNA of the present invention can generate a non-hydrolyzable cap structure that prevents decapping, thereby increasing the half-life of mRNA. Because hydrolysis of the cap structure requires cleavage of the 5'-ppp-5' phosphorodiester bond, modified nucleotides can be used during the capping reaction. For example, New England Biolabs' (Ipswich, MA) vaccinia capping enzyme can be used with α-thio-guanosine nucleotides according to the manufacturer's instructions to create a phosphorothioate bond in the 5'-ppp-5' cap. Additional modified guanosine nucleotides, such as α-methyl-phosphonate and seleno-phosphate nucleotides, can be used.

[0114] Further modifications include, but are not limited to, 2'-O-methylation (as described above) of the ribose sugar of the 5'-terminal and / or pre-5' terminal nucleotide of an mRNA at the 2'-hydroxyl group of the sugar ring. Several distinct 5'-cap structures can be used to generate the 5' cap of a nucleic acid molecule, such as an mRNA molecule.

[0115] Cap analogs, also referred to herein as synthetic cap analogs, chemical caps, chemical cap analogs, or structural or functional cap analogs, differ from the natural (i.e., endogenous, wild-type, or physiological) 5' cap in their chemical structure but retain cap function. Cap analogs can be synthesized and / or attached to nucleic acid molecules chemically (i.e., non-enzymatically) or enzymatically.

[0116] For example, the anti-reverse cap analog (ARCA) cap contains two guanines joined by 5'-5'-triphosphate groups, one guanine having an N7 methyl group as well as a 3'-O-methyl group (i.e., N7,3'-O-dimethyl-guanosine-5'-triphosphate-5'-guanosine (m 7The capped nucleic acid molecule (e.g., mRNA or mmRNA) contains the N7- and 3'-O-methylated guanine (G-3'mppp-G, which may equivalently be designated 3'O-Me-m7G(5')ppp(5')G). The 3'-O atom of the other unmodified guanine is attached to the 5'-terminal nucleotide of the capped nucleic acid molecule (e.g., mRNA or mmRNA). The N7- and 3'-O-methylated guanine provide the terminal portion of the capped nucleic acid molecule (e.g., mRNA or mmRNA).

[0117] Another exemplary cap is mCAP, which is similar to ARCA but has a 2'-O-methyl group on the guanosine (i.e., N7,2'-O-dimethyl-guanosine-5'-triphosphate-5'-guanosine, m 7 Gm-ppp-G).

[0118] While cap analogs allow for the capping of nucleic acid molecules concomitantly in in vitro transcription reactions, up to 20% of the transcripts may remain uncapped. This, as well as structural differences between the cap analog and the endogenous 5'-cap structure of nucleic acids produced by the endogenous cellular transcription machinery, can result in reduced translational competence and reduced cellular stability.

[0119] The oncology-related polynucleotides, oncology-related primary constructs, and oncology-related mmRNA of the present invention can also be post-transcriptionally capped using enzymes to generate more authentic 5'-cap structures. As used herein, the term "more authentic" refers to features that closely resemble or mimic endogenous or wild-type features, either structurally or functionally. That is, a "more authentic" feature better represents endogenous, wild-type, natural, or physiological cellular function and / or structure compared to prior art synthetic features or analogs, or surpasses the corresponding endogenous, wild-type, natural, or physiological features in one or more respects. Non-limiting examples of more authentic 5'-cap structures of the present invention include those that have, among others, enhanced cap-binding protein binding, increased half-life, reduced susceptibility to 5' endonucleases, and / or reduced 5'-decapping compared to synthetic 5'-cap structures (or wild-type, natural, or physiological 5'-cap structures) known in the art. For example, recombinant vaccinia virus capping enzyme and recombinant 2'-O-methyltransferase enzyme can generate a standard 5'-5'-triphosphate bond between the 5'-terminal nucleotide of an mRNA and a guanine cap nucleotide, where the cap guanine contains an N7 methylation and the 5'-terminal nucleotide of the mRNA contains a 2'-O-methyl. Such a structure is referred to as the Cap 1 structure. This cap results in greater translation competence and cellular stability, as well as reduced activation of cellular proinflammatory cytokines, compared to, for example, other 5'-cap analog structures known in the art. Cap structures include, but are not limited to, 7mG(5')ppp(5')N,pN2p (Cap 0), 7mG(5')ppp(5')NlmpNp (Cap 1), and 7mG(5')-ppp(5')NlmpN2mp (Cap 2).

[0120] Because oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNA can be capped post-transcriptionally and this process is more efficient, nearly 100% of oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNA can be capped, which is in stark contrast to the approximately 80% that occurs when a cap analog is attached to the mRNA during an in vitro transcription reaction.

[0121] According to the present invention, the 5'-end cap can comprise an endogenous cap or a cap analog. According to the present invention, the 5'-end cap can comprise a guanine analog. Useful guanine analogs include, but are not limited to, inosine, N1-methyl-guanosine, 2'fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, and 2-azido-guanosine.

[0122] Viral sequence Additional viral sequences, such as, but not limited to, the translation enhancer sequence of Barley Yellow Dwarf Virus (BYDV-PAV), Jaagsiekte Sheep Retrovirus (JSRV), and / or Enzootic Nasal Tumor Virus (see, e.g., International Publication No. WO2012129648, incorporated herein by reference in its entirety), can be engineered and inserted into the 3'UTR of the oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNAs of the invention to stimulate translation of the constructs in vitro and in vivo. Transfection experiments can be performed in relevant cell lines, and protein production can be assayed by ELISA at 12 hours, 24 hours, 48 ​​hours, 72 hours, and 7 days post-transfection.

[0123] IRES sequence Additionally, oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNAs are provided that may contain an internal ribosome entry site (IRES). IRESs, first identified in characteristic picornavirus RNAs, play an important role in initiating protein synthesis in the absence of a 5' cap structure. An IRES may serve as the sole ribosome binding site for an mRNA, or may serve as one of multiple ribosome binding sites. Oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNAs containing two or more functional ribosome binding sites may encode several oncology-related peptides or polypeptides that are independently translated by ribosomes ("polycistronic nucleic acid molecules"). When an IRES is provided in an oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA, a second translatable region is optionally further provided. Examples of IRES sequences that may be used in accordance with the present invention include, without limitation, those derived from picornaviruses (e.g., FMDV), plague viruses (CFFV), polioviruses (PV), encephalomyocarditis viruses (ECMV), foot-and-mouth disease viruses (FMDV), hepatitis C viruses (HCV), classical swine fever viruses (CSFV), murine leukemia viruses (MLV), simian immunodeficiency viruses (SIV), or cricket paralysis viruses (CrPV).

[0124] Poly A tail During RNA processing, long chains of adenine nucleotides (poly-A tails) can be added to polynucleotides, such as mRNA molecules, to improve stability. Immediately after transcription, the 3' end of the transcript can be cleaved to free a 3' hydroxyl. Poly-A polymerase then adds chains of adenine nucleotides to the RNA. This process, called polyadenylation, adds a poly-A tail that can be approximately 100-250 residues long.

[0125] It has been found that particular polyA tail lengths provide certain advantages to the oncology-related polynucleotides, oncology-related primary constructs or oncology-related mmRNA of the present invention. Generally, the length of a polyA tail of the present invention is greater than 30 nucleotides in length, hi another embodiment, the polyA tail is greater than 35 nucleotides in length (e.g., at least or greater than about 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,500, and 3,000 nucleotides in length). In some embodiments, the oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA is from about 30 to about 3,000 nucleotides (e.g., 30-50, 30-100, 30-250, 30-500, 30-750, 30-1,000, 30-1,500, 30-2,000, 30-2,500, 50-100, 50-250, 50-500, 50-750, 50-1,000, 50-1,500, 50-2,000, 50-2,500, 50-3,000, 100-500, 100-750, Includes sizes 100-1,000, 100-1,500, 100-2,000, 100-2,500, 100-3,000, 500-750, 500-1,000, 500-1,500, 500-2,000, 500-2,500, 500-3,000, 1,000-1,500, 1,000-2,000, 1,000-2,500, 1,000-3,000, 1,500-2,000, 1,500-2,500, 1,500-3,000, 2,000-3,000, 2,000-2,500, and 2,500-3,000.

[0126] In one embodiment, the polyA tail is designed relative to the length of the entire oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA. This design may be based on the length of the coding region, the length of a particular feature or region (such as the first or adjacent region), or may be based on the length of the final product expressed from the oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA.

[0127] In this context, the polyA tail can be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% longer than the length of the oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA, or a feature thereof. The polyA tail can also be designated as a fraction of the oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA to which it belongs. In this context, the polyA tail can be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the full length of the construct or the full length of the construct minus the polyA tail. Furthermore, engineering binding sites and conjugating oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNA to polyA-binding proteins can enhance expression.

[0128] Additionally, multiple distinct oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNA can be linked to PABP (polyA binding protein) via their 3' ends using modified nucleotides at the 3' end of the polyA tail. Transfection experiments can be performed in relevant cell lines, and oncology-related protein production can be assayed by ELISA at 12 hours, 24 hours, 48 ​​hours, 72 hours, and 7 days post-transfection.

[0129] In one embodiment, the oncology-related polynucleotides and oncology-related primary constructs of the present invention are designed to contain a polyA-G quartet. A G quartet is a cyclic hydrogen-bonded array of four guanine nucleotides that can be formed by G-rich sequences in both DNA and RNA. In this embodiment, a G quartet is incorporated at the end of a polyA tail. The resulting oncology-related mmRNA constructs are assayed for stability, protein production, and half-life and other parameters at various time points. It has been found that a polyA-G quartet results in protein production that is at least 75% of the protein production that results from using a 120-nucleotide polyA tail alone.

[0130] Quantification In one embodiment, the oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNA of the present invention can be quantified in exosomes derived from one or more bodily fluids. As used herein, "bodily fluids" includes peripheral blood, serum, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, earwax, breast milk, bronchoalveolar lavage fluid, semen, prostatic fluid, Cooper's gland fluid or pre-ejaculatory fluid, sweat, feces, hair, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, leucorrhea, pus, sebum, vomit, vaginal secretions, mucosal secretions, stool water, pancreatic juice, nasal lavage fluid, bronchopulmonary aspirate, blastocyst cavity fluid, and umbilical cord blood. Alternatively, exosomes may be recovered from an organ selected from the group consisting of lung, heart, pancreas, stomach, intestine, bladder, kidney, ovary, testicle, skin, colon, breast, prostate, brain, esophagus, liver, and placenta.

[0131] In the quantification method, a sample of less than 2 mL is obtained from a subject, and exosomes are isolated by size-exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunosorbent capture, affinity purification, microfluidic separation, or a combination thereof. In the analysis, the level or concentration of oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNA can be the expression level, presence, absence, cleavage, or modification of the administered construct. It is advantageous to correlate this level with an assay for one or more clinical phenotypes or human disease biomarkers. While this assay can be performed using construct-specific probes, cytometry, qRT-PCR, real-time PCR, PCR, flow cytometry, electrophoresis, mass spectrometry, or a combination thereof, exosomes can also be isolated using immunohistochemistry, such as enzyme-linked immunosorbent assay (ELISA). Exosomes can also be isolated by size-exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunosorbent capture, affinity purification, microfluidic separation, or a combination thereof.

[0132] These methods provide researchers with the ability to monitor the levels of remaining or delivered oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNA in real time. This is possible because the oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNA of the present invention differ from endogenous forms due to structural and / or chemical modifications.

[0133] II. mmRNA Design and Synthesis Oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNA for use in accordance with the present invention may be prepared according to any available technique, including, but not limited to, chemical synthesis, enzymatic synthesis, commonly referred to as in vitro transcription (IVT), or enzymatic or chemical cleavage of longer precursors. Methods for synthesizing RNA are known in the art (see, for example, Gait, MJ (ed.) Oligonucleotide synthesis: a practical approach, Oxford [Oxfordshire], Washington, DC: IRL Press, 1984, and Herdewijn, P. (ed.) Oligonucleotide synthesis: methods and applications,Methods in Molecular Biology,v.288(Clifton,NJ)Totowa,NJ:Humana Press, 2005).

[0134] The process of designing and synthesizing the oncology-related primary constructs of the present invention generally includes a gene construction step, an mRNA production step (with or without modification), and a purification step. In the enzymatic synthesis method, a target oncology-related polynucleotide sequence encoding a desired oncology-related polypeptide is first selected for incorporation into a vector that is amplified to produce a cDNA template. Optionally, the target oncology-related polynucleotide sequence and / or any adjacent sequences can be codon-optimized. The cDNA template is then used to produce mRNA by in vitro transcription (IVT). After production, the mRNA can undergo a purification and cleanup process. These steps are provided in more detail below.

[0135] Gene construction Gene construction steps may include, but are not limited to, gene synthesis, vector amplification, plasmid purification, plasmid linearization and purification, and cDNA template synthesis and purification.

[0136] Gene synthesis Once the desired oncology-related polypeptide or target is selected for production, an oncology-related primary construct is designed. Within the oncology-related primary construct, the first region of linked nucleosides encoding the desired polypeptide can be constructed using the open reading frame (ORF) of a selected nucleic acid (DNA or RNA) transcript. The ORF can include a wild-type ORF, an isoform, a mutant, or a fragment thereof. As used herein, "open reading frame" or "ORF" is intended to refer to a nucleic acid sequence (DNA or RNA) capable of encoding the desired oncology-related polypeptide. The ORF often begins with an ATG start codon and ends with a nonsense or stop codon or signal.

[0137] Furthermore, the nucleotide sequence of the first region can be codon-optimized. Codon optimization methods are known in the art and can be useful in efforts to achieve one or more of several goals. These goals include: matching the codon frequency in the target and host organisms to ensure proper folding; biasing GC content to increase mRNA stability or reduce secondary structure; minimizing tandem repeat codons or base pairs that may interfere with gene assembly or expression; customizing transcriptional and translational control regions; inserting or removing protein transport sequences; removing / adding post-translational modification sites (e.g., glycosylation sites) in the encoded protein; adding, removing, or recombining protein domains; inserting or deleting restriction sites; modifying ribosome binding sites and mRNA degradation sites; adjusting the translation rate to allow the various domains of the protein to fold properly; or reducing or eliminating problematic secondary structures in mRNA. Codon optimization tools, algorithms, and services are known in the art, and non-limiting examples include GeneArt services (Life Technologies), DNA2.0 (Menlo Park, CA), and / or proprietary methods. In one embodiment, the ORF sequence is optimized using an optimization algorithm. Codon choices for each amino acid are provided in Table 1.

[0138] Table 1. Codon choices

[0139] [Table 0001]

[0140] Features that may be considered beneficial in some embodiments of the present invention may be encoded by the oncology-related primary construct and may flank the ORF as first or second flanking regions. These flanking regions may be incorporated into the oncology-related primary construct before and / or after ORF optimization. It is not necessary for the oncology-related primary construct to contain both 5' and 3' flanking regions. Examples of such features include, but are not limited to, untranslated regions (UTRs), Kozak sequences, oligo(dT) sequences, and detectable tags, and may also include multiple cloning sites that may have XbaI recognition.

[0141] In some embodiments, a 5'UTR and / or a 3'UTR can be provided as a flanking region. Multiple 5' or 3'UTRs can be included in a flanking region and can be the same or different sequences. Any portion of a flanking region (including none) can be codon-optimized, any of which can independently contain one or more different structural or chemical modifications before and / or after codon optimization. A combination of features can be included in the first and second flanking regions, and can be contained within other features. For example, an ORF can be flanked by a 5'UTR that can contain a strong Kozak translation initiation signal and / or a 3'UTR that can contain an oligo(dT) sequence for templated addition of a polyA tail. A 5'UTR, such as the 5'UTR described in U.S. Patent Application Publication No. 20100293625, incorporated herein by reference in its entirety, can comprise a first polynucleotide fragment and a second polynucleotide fragment from the same and / or different genes.

[0142] Tables 2 and 3 provide a list of exemplary UTRs that may be utilized in the oncology-related primary constructs of the present invention as flanking regions. A list of 5' untranslated regions of the present invention is shown in Table 2. Variants of the 5' UTR in which one or more nucleotides including A, T, C, or G are added to or removed from the end may be utilized.

[0143] Table 2. 5' untranslated region

[0144] [Table 0002]

[0145] A representative list of 3' untranslated regions of the present invention is shown in Table 3. Variants of the 3' UTR in which one or more nucleotides, including A, T, C, or G, are added to or removed from the end may be utilized.

[0146] Table 3. 3' untranslated region

[0147] [Table 0003-1]

[0148] [Table 0003-2]

[0149] [Table 0003-3]

[0150] [Table 0003-4]

[0151] [Table 0003-5]

[0152] [Table 0003-6]

[0153] [Table 0003-7]

[0154] [Table 0003-8]

[0155] It should be understood that the UTRs listed in the previous table are examples, and any UTR from any gene can be incorporated into the first or second flanking region of each primary construct. Furthermore, multiple wild-type UTRs from any known gene can be utilized. It is also within the scope of the present invention to provide artificial UTRs that are not mutants of wild-type genes. These UTRs or portions thereof can be positioned in the same orientation as the UTRs or portions thereof of the transcripts from which they can be selected, or their orientation or position can be changed. Thus, 5' or 3' UTRs can be inverted, shortened, extended, or chimerized with one or more other 5' or 3' UTRs. As used herein, the term "altered" when referring to a UTR sequence means that the UTR has changed in some respect relative to the reference sequence. For example, the 3' or 5' UTR can be altered relative to the wild-type or natural UTR by changing the orientation or position as taught above, or by including additional nucleotides, deleting nucleotides, exchanging or transposing nucleotides. Any of these changes that result in an "altered" UTR (whether 3' or 5') includes a mutant UTR.

[0156] In one embodiment, a double, triple, or quadruple UTR, such as a 5' or 3' UTR, can be used. As used herein, a "double" UTR is one in which two copies of the same UTR are encoded either contiguously or substantially contiguously. For example, the double β-globin 3' UTR described in U.S. Patent Publication No. 20100129877, the contents of which are incorporated herein by reference in its entirety, can be used.

[0157] It is also within the scope of the present invention to have patterned UTR.As used herein, " patterned UTR " refers to the UTR that shows a repeat or alternating pattern that repeats once, twice, or three or more times, such as ABABAB or AABBAABBAABB or ABCABCABC or its variants.In these patterns, each letter A, B or C represents different UTR at nucleotide level.

[0158] In one embodiment, the flanking region is selected from a family of transcripts whose proteins share common function, structure, or characteristic features.For example, the oncology-related polypeptide of interest may belong to a family of proteins that are expressed in a specific cell, tissue, or at a certain time during development.Any UTR of these genes can be exchanged with any other UTR of the same or different protein family to create a new chimeric primary transcript.As used herein, the term "protein family" is used in the broadest sense to refer to a group of two or more oncology-related polypeptides of interest that share at least one function, structure, characteristic, localization, origin, or expression pattern.

[0159] After optimization (if desired), the oncology-related primary construct components can be reconstructed and transformed into vectors, such as, but not limited to, plasmids, viruses, cosmids, and artificial chromosomes. For example, the optimized constructs can be reconstructed and transformed into chemically competent E. coli, yeast, Neurospora crassa, maize, Drosophila, etc., and high copy number, plasmid-like or chromosomal structures generated by the methods described herein.

[0160] The untranslated region may also include a translational enhancer element (TEE). By way of non-limiting example, the TEE may include those described in U.S. Patent Application No. 20090226470, which is incorporated herein by reference in its entirety, and TEEs known in the art.

[0161] stop codon In one embodiment, the oncology-related primary construct of the present invention may comprise at least two stop codons before the 3' untranslated region (UTR). The stop codons may be selected from TGA, TAA, and TAG. In one embodiment, the oncology-related primary construct of the present invention comprises the stop codon TGA and another stop codon. In a further embodiment, the other stop codon may be TAA. In another embodiment, the primary construct of the present invention comprises three stop codons.

[0162] Vector amplification The vector containing the oncology-related primary construct is then amplified and the plasmid isolated and purified using methods known in the art, such as, but not limited to, maxiprep using the Invitrogen PURELINK™ HiPure Maxiprep kit (Carlsbad, CA).

[0163] Plasmid linearization The plasmid can then be linearized using methods known in the art, such as, but not limited to, the use of restriction enzymes and buffers. The linearized reaction can be purified using, for example, Invitrogen's PURELINK™ PCR Micro Kit (Carlsbad, CA), as well as HPLC-based purification methods, such as, but not limited to, strong anion exchange HPLC, weak anion exchange HPLC, reverse-phase HPLC (RP-HPLC), and hydrophobic interaction HPLC (HIC-HPLC), as well as Invitrogen's standard PURELINK™ PCR Kit (Carlsbad, CA). Purification methods can be modified depending on the size of the resulting linearized reaction. The linearized plasmid is then used to generate cDNA for in vitro transcription (IVT) reactions.

[0164] cDNA template synthesis The cDNA template can be synthesized by subjecting the linearized plasmid to polymerase chain reaction (PCR). Table 4 lists primers and probes that may be useful in the PCR reactions of the present invention. It should be understood that this list is not exhaustive, and primer-probe design for any amplification is within the skill of the art. The probe may also contain chemically modified bases to enhance base-pairing fidelity and strength to the target molecule. Such modifications may include 5-methyl-cytidine, 2,6-diamino-purine, 2'-fluoro, phosphoro-thioate, or locked nucleic acid.

[0165] Table 4. Primers and probes

[0166] [Table 0004]

[0167] *UFP is a universal forward primer and URP is a universal reverse primer. In one embodiment, the cDNA may be submitted for sequencing analysis before undergoing transcription.

[0168] mRNA production The process of mRNA or mmRNA production may include, but is not limited to, in vitro transcription, cDNA template removal and RNA purification, and mRNA capping and / or tailing reactions.

[0169] In vitro transcription The cDNA produced in the previous step can be transcribed using an in vitro transcription (IVT) system. This system typically includes a transcription buffer, nucleotide triphosphates (NTPs), an RNase inhibitor, and a polymerase. The NTPs can be produced in-house, selected from a supplier, or synthesized as described herein. The NTPs can be selected from, but are not limited to, the NTPs described herein, including natural and non-natural (modified) NTPs. The polymerase can be selected from, but is not limited to, mutant polymerases, such as T7 RNA polymerase, T3 RNA polymerase, and polymerases that can incorporate modified nucleic acids.

[0170] RNA polymerase Any number of RNA polymerases or variants may be used in the design of the oncology-related primary constructs of the present invention.

[0171] RNA polymerase can be modified by inserting or deleting amino acids in the RNA polymerase sequence.As a non-limiting example, RNA polymerase can be modified to show improved ability to incorporate 2'-modified nucleotide triphosphates compared to unmodified RNA polymerase (see International Publication No. WO2008078180 and U.S. Patent No. 8,101,385, which are incorporated herein by reference in their entirety).

[0172] Variants can be obtained by evolving RNA polymerases, optimizing RNA polymerase amino acid and / or nucleic acid sequences, and / or using other methods known in the art. As a non-limiting example, T7 RNA polymerase variants can be evolved using the continuous directed evolution system designed by Esvelt et al. (Nature (2011) 472(7344):499-503, incorporated herein by reference in its entirety), to generate T7 The RNA polymerase clones contained mutations that resulted in a substitution of lysine at position 93 with threonine (K93T), I4M, A7T, E63V, V64D, A65E, D66Y, T76N, C125R, S128R, A136T, N165S, G175R, H176L, Y178H, F182L, L196F, G198V, D208Y, E222K, S228A, Q239R, T243N, G259D, M267I, G280C, H300R, D351A, A354S, and β161M. It may encode at least one mutation such as, but not limited to, E356D, L360P, A383V, Y385C, D388Y, S397R, M401T, N410S, K450R, P451T, G452V, E484A, H523L, H524N, G542V, E565K, K577E, K577M, N601S, S684Y, L699I, K713E, N748D, Q754R, E775K, A827V, D851N, or L864F. As another non-limiting example, a T7 RNA polymerase variant may encode at least one mutation described in U.S. Patent Publication Nos. 20100120024 and 20070117112, which are incorporated by reference in their entireties. Mutant forms of RNA polymerase can also include, but are not limited to, substitution mutants, conservative amino acid substitutions, insertion mutants, deletion mutants, and / or covalent derivatives.

[0173] In one embodiment, the primary construct may be designed to be recognized by a wild-type or mutant RNA polymerase, and in doing so, the primary construct may be modified to contain sites or regions of sequence variation from the wild-type or parent primary construct.

[0174] In one embodiment, an oncology-related primary construct may be designed to include at least one substitution and / or insertion within the 5'UTR, before the 5'UTR, and / or after the 5'UTR upstream of the RNA polymerase binding or recognition site of the oncology-related primary construct, downstream of the RNA polymerase binding or recognition site, upstream of the TATA box sequence, downstream of the TATA box sequence but upstream of the coding region of the oncology-related primary construct.

[0175] In one embodiment, the 5'UTR of an oncology-related primary construct may be replaced by the insertion of at least one region and / or string of nucleotides of identical bases. The region and / or string of nucleotides may include, but is not limited to, at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8 nucleotides, and the nucleotides may be natural and / or non-natural. As a non-limiting example, the nucleotide group may include a string of 5-8 adenines, cytosines, thymines, any of the other nucleotides disclosed herein, and / or combinations thereof.

[0176] In one embodiment, the 5'UTR of an oncology-related primary construct may be replaced by the insertion of at least two regions and / or strings of nucleotides of two different bases, such as, but not limited to, adenine, cytosine, thymine, any of the other nucleotides disclosed herein, and / or combinations thereof. For example, the 5'UTR may be replaced by inserting 5-8 adenine bases followed by 5-8 cytosine bases. In another example, the 5'UTR may be replaced by inserting 5-8 cytosine bases followed by 5-8 adenine bases.

[0177] In one embodiment, the oncology-related primary construct may contain at least one substitution and / or insertion downstream of the transcription start site that can be recognized by RNA polymerase. As a non-limiting example, the at least one substitution and / or insertion may occur downstream of the transcription start site by substituting at least one nucleic acid within the region immediately downstream of the transcription start site (such as, but not limited to, +1 to +6). Altering the nucleotide region immediately downstream of the transcription start site can affect the initiation rate, increase the apparent nucleotide triphosphate (NTP) reaction constant, and enhance the dissociation of short transcripts from the transcription complex by stiffening the nascent transcript (Brieba et al., Biochemistry (2002) 41:5144-5149, incorporated herein by reference in its entirety). The modification, substitution, and / or insertion of at least one nucleic acid may result in a silent mutation in the nucleic acid sequence or in a mutation in the amino acid sequence.

[0178] In one embodiment, the oncology-related primary construct may comprise substitutions of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, or at least 13 guanine bases downstream of the transcription start site.

[0179] In one embodiment, the oncology-related primary construct may contain substitutions of at least one, at least two, at least three, at least four, at least five, or at least six guanine bases in the region immediately downstream of the transcription start site. As a non-limiting example, when the nucleotides in that region are GGGAGA, the guanine bases may be substituted with at least one, at least two, at least three, or at least four adenine nucleotides. In another non-limiting example, when the nucleotides in that region are GGGAGA, the guanine bases may be substituted with at least one, at least two, at least three, or at least four cytosine bases. In another non-limiting example, when the nucleotides in that region are GGGAGA, the guanine bases may be substituted with at least one, at least two, at least three, or at least four thymines and / or any of the nucleotides described herein.

[0180] In one embodiment, the oncology-related primary construct may contain at least one substitution and / or insertion upstream of the start codon. For clarity, those skilled in the art will understand that the start codon is the first codon in a protein-coding region, while the transcription start site is the site where transcription begins. The oncology-related primary construct may contain, but is not limited to, at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or at least eight substitutions and / or insertions of nucleotide bases. Nucleotide bases may be inserted or substituted at one, at least one, at least two, at least three, at least four, or at least five positions upstream of the start codon. The inserted and / or substituted nucleotides may be the same base (e.g., all A or all C or all T or all G), two different bases (e.g., A and C, A and T, or C and T), three different bases (e.g., A, C, and T, or A, C, and T), or at least four different bases. As a non-limiting example, the guanine base upstream of the coding region in the oncology-related primary construct can be replaced with adenine, cytosine, thymine, or any of the nucleotides described herein. In another non-limiting example, the guanine base replacement in the oncology-related primary construct can be designed to leave one guanine base downstream of the transcription start site and in the region before the start codon (see Esvelt et al. Nature (2011) 472 (7344): 499-503, which is incorporated herein by reference in its entirety). As a non-limiting example, at least five nucleotides can be inserted into one position downstream of the transcription start site and upstream of the start codon, and at least five nucleotides can be of the same base type.

[0181] cDNA template removal and purification The cDNA template may be removed using methods known in the art, such as, but not limited to, treatment with deoxyribonuclease I (DNase I). RNA purification may also include purification methods such as, but not limited to, the AGENCOURT® CLEANSEQ® system from Beckman Coulter (Danvers, MA); HPLC-based purification methods such as, but not limited to, strong anion exchange HPLC, weak anion exchange HPLC, reverse phase HPLC (RP-HPLC), and hydrophobic interaction HPLC (HIC-HPLC).

[0182] Capping and / or tailing reactions Oncology-related primary constructs or oncology-related mmRNA can also undergo capping and / or tailing reaction. Capping reaction can be carried out using methods known in the art to add a 5' cap to the 5' end of oncology-related primary constructs. Methods for capping include, but are not limited to, the use of vaccinia capping enzyme (New England Biolabs, Ipswich, MA).

[0183] The polyA tailing reaction can be performed using methods known in the art, such as, but not limited to, 2'O-methyltransferase and the methods described herein. If the oncology-related primary construct generated from cDNA does not contain polyT, it may be beneficial to perform the polyA tailing reaction before the oncology-related primary construct is purified.

[0184] mRNA purification Primary construct or mmRNA purification can include, but is not limited to, mRNA or mmRNA purification, quality assurance, and quality control. mRNA or mmRNA purification can be performed using methods known in the art, such as, but not limited to, AGENCOURT® beads (Beckman Coulter Genomics, Danvers, MA); poly-T beads; LNA™ Oligo-T capture probes (EXIQON® Inc., Vedbaek, Denmark); or HPLC-based purification methods, such as, but not limited to, strong anion exchange HPLC, weak anion exchange HPLC, reverse-phase HPLC (RP-HPLC), and hydrophobic interaction HPLC (HIC-HPLC). The term "purified," as in "purified mRNA or mmRNA," when used in reference to a polynucleotide, refers to something that is separated from at least one contaminant. As used herein, a "contaminant" is any substance that renders another substance unsuitable, impure, or inferior. Thus, purified oncology-related polynucleotides (e.g., DNA and RNA) are present in a form or environment that is different from that in which they are found in nature or that is different from the form or environment in which they existed prior to being subjected to a treatment or purification method.

[0185] Quality assurance and / or quality control testing may be performed using methods such as, but not limited to, gel electrophoresis, ultraviolet absorbance, or analytical HPLC. In another embodiment, oncology-related mRNA or mmRNA may be sequenced using methods including, but not limited to, reverse transcription PCR.

[0186] In one embodiment, oncology-related mRNA or mmRNA can be quantified using methods such as, but not limited to, ultraviolet-visible spectroscopy (UV / Vis). A non-limiting example of a UV / Vis spectrometer is the NANODROP® spectrometer (ThermoFisher, Waltham, MA). The quantified oncology-related mRNA or mmRNA can be analyzed to determine whether the oncology-related mRNA or mmRNA may be of an appropriate size and to confirm that degradation of the oncology-related mRNA or mmRNA has not occurred. Degradation of oncology-related mRNA and / or mmRNA can be confirmed using methods such as, but not limited to, agarose gel electrophoresis; HPLC-based purification methods such as, but not limited to, strong anion exchange HPLC, weak anion exchange HPLC, reverse-phase HPLC (RP-HPLC), and hydrophobic interaction HPLC (HIC-HPLC); liquid chromatography-mass spectrometry (LCMS); capillary electrophoresis (CE); and capillary gel electrophoresis (CGE).

[0187] signal sequence An oncology-related primary construct or oncology-related mmRNA may also encode additional features that facilitate transport of the oncology-related polypeptide to a therapeutically relevant site. One such feature that aids in protein transport is a signal sequence. As used herein, a "signal sequence" or "signal peptide" is a polynucleotide or polypeptide, respectively, approximately 9 to 200 nucleotides in length (3 to 60 amino acids in length), that is incorporated into the 5' (or N-terminus) of a coding region or encoded polypeptide. The addition of these sequences results in transport of the encoded oncology-related polypeptide through one or more secretory pathways to the endoplasmic reticulum. Some signal peptides are cleaved from the protein by a signal peptidase after the protein has been transported.

[0188] Table 5 is a representative list of protein signal sequences that can be incorporated to encode an oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA of the present invention.

[0189] Table 5. Signal sequences

[0190] [Table 0005-1]

[0191] [Table 0005-2]

[0192] [Table 0005-3]

[0193] [Table 0005-4]

[0194] [Table 0005-5]

[0195] [Table 0005-6]

[0196] In this table, SS is a secretion signal and MLS is a mitochondrial leader signal. An oncology-related primary construct or oncology-related mmRNA of the present invention may be designed to encode any of the signal sequences of SEQ ID NOs: 94-155, or a fragment or variant thereof. These sequences may be included at the beginning, middle, or end of the oncology-related polypeptide coding region, or alternatively, in a flanking region. Additionally, any of the oncology-related polynucleotide primary constructs of the present invention may also include one or more of the sequences defined by SEQ ID NOs: 32-93. These may be present in the first region or in any of the flanking regions.

[0197] Additional signal sequences that can be utilized in the present invention include, for example, those taught in databases such as those found at http: / / www.signalpeptide.de / or http: / / proline.bic.nus.edu.sg / spdb / . Also within the scope of the present invention are those described in U.S. Patent Nos. 8,124,379, 7,413,875, and 7,385,034, the contents of each of which are incorporated herein by reference in their entirety.

[0198] Target Selection In accordance with the present invention, an oncology-related primary construct comprises at least one first region of linked nucleosides that encodes at least one oncology-related polypeptide of interest.

[0199] Oncology-related polypeptides or "targets" or oncology-related proteins and peptides of interest of the present invention are listed in Tables 6 and 7. In addition to the target number (Target No), name, and description (Target Description) of the gene encoding the oncology-related polypeptide of interest, Table 6 also lists the ENSEMBL transcript sequence number (ENST) and sequence number (TransSeq No), the ENSEMBL protein sequence number (ENSP) and sequence number (Peptide Seq No), and, where available, the optimized transcript and / or ORF sequence identifier (Optimized TransSeq No or Optimized ORF Seq No). Common cancer syndromes, tumor suppressor genes and sequence identifiers (e.g., ENST Seq No for sequence identifiers associated with ENSEMBL transcript sequences or ENSP Seq No for sequence identifiers associated with ENSEMBL protein sequences), tumor suppressor gene function, chromosomal location, and observed tumor types are listed in Table 7. For any particular gene, one or more variants or isoforms may exist. If present, these are also listed in the tables. Those skilled in the art will appreciate that the disclosed tables represent potential flanking regions. These are encoded either 5' (upstream) or 3' (downstream) of the ORF or coding region in each ENST transcript. The coding region is categorically and specifically disclosed by the ENSP sequence teaching. Consequently, the adjacent teaching sequences that encode proteins are considered flanking regions. The 5' and 3' flanking regions can also be further characterized by utilizing one or more available databases or algorithms. Databases annotating the features contained in the flanking regions of ENST transcripts are available in the art.

[0200] Table 6. Oncology-related targets

[0201] [Table 0006-1]

[0202] [Table 0006-2]

[0203]

Table 0006-3

[0204]

Table 0006-4

[0205]

Table 0006-5

[0206]

Table 0006-6

[0207]

Table 0006-7

[0208]

Table 0006-8

[0209]

Table 0006-9

[0210]

Table 0006-10

[0211]

Table 0006-11

[0212]

Table 0006-12

[0213]

Table 0006-13

[0214]

Table 0006-14

[0215]

Table 0006-15

[0216]

Table 0006-16

[0217]

Table 0006-17

[0218]

Table 0006-18

[0219]

Table 0006-19

[0220]

Table 0006-20

[0221]

Table 0006-21

[0222]

Table 0006-22

[0223]

Table 0006-23

[0224]

Table 0006-24

[0225]

Table 0006-25

[0226]

Table 0006-26

[0227]

Table 0006-27

[0228]

Table 0006-28

[0229]

Table 0006-29

[0230]

Table 0006-30

[0231]

Table 0006-31

[0232]

Table 0006-32

[0233]

Table 0006-33

[0234]

Table 0006-34

[0235]

Table 0006-35

[0236]

Table 0006-36

[0237]

Table 0006-37

[0238]

Table 0006-38

[0239]

Table 0006-39

[0240]

Table 0006-40

[0241]

Table 0006-41

[0242]

Table 0006-42

[0243]

Table 0006-43

[0244]

Table 0006-44

[0245]

Table 0006-45

[0246]

Table 0006-46

[0247]

Table 0006-47

[0248]

Table 0006-48

[0249]

Table 0006-49

[0250]

Table 0006-50

[0251]

Table 0006-51

[0252]

Table 0006-52

[0253]

Table 0006-53

[0254]

Table 0006-54

[0255]

Table 0006-55

[0256]

Table 0006-56

[0257]

Table 0006-57

[0258]

Table 0006-58

[0259]

Table 0006-59

[0260]

Table 0006-60

[0261]

Table 0006-61

[0262]

Table 0006-62

[0263]

Table 0006-63

[0264]

Table 0006-64

[0265]

Table 0006-65

[0266]

Table 0006-66

[0267]

Table 0006-67

[0268]

Table 0006-68

[0269]

Table 0006-69

[0270]

Table 0006-70

[0271]

Table 0006-71

[0272]

Table 0006-72

[0273]

Table 0006-73

[0274]

Table 0006-74

[0275]

Table 0006-75

[0276]

Table 0006-76

[0277]

Table 0006-77

[0278]

Table 0006-78

[0279]

Table 0006-79

[0280]

Table 0006-80

[0281]

Table 0006-81

[0282]

Table 0006-82

[0283]

Table 0006-83

[0284]

Table 0006-84

[0285]

Table 0006-85

[0286]

Table 0006-86

[0287]

Table 0006-87

[0288]

Table 0006-88

[0289]

Table 0006-89

[0290]

Table 0006-90

[0291]

Table 0006-91

[0292]

Table 0006-92

[0293]

Table 0006-93

[0294]

Table 0006-94

[0295]

Table 0006-95

[0296]

Table 0006-96

[0297]

Table 0006-97

[0298]

Table 0006-98

[0299]

Table 0006-99

[0300]

Table 0006-100

[0301]

Table 0006-101

[0302]

Table 0006-102

[0303]

Table 0006-103

[0304]

Table 0006-104

[0305]

Table 0006-105

[0306]

Table 0006-106

[0307]

Table 0006-107

[0308]

Table 0006-108

[0309]

Table 0006-109

[0310]

Table 0006-110

[0311]

Table 0006-111

[0312]

Table 0006-112

[0313]

Table 0006-113

[0314]

Table 0006-114

[0315]

Table 0006-115

[0316]

Table 0006-116

[0317]

Table 0006-117

[0318]

Table 0006-118

[0319]

Table 0006-119

[0320]

Table 0006-120

[0321]

Table 0006-121

[0322]

Table 0006-122

[0323]

Table 0006-123

[0324]

Table 0006-124

[0325]

Table 0006-125

[0326]

Table 0006-126

[0327]

Table 0006-127

[0328]

Table 0006-128

[0329]

Table 0006-129

[0330]

Table 0006-130

[0331]

Table 0006-131

[0332]

Table 0006-132

[0333]

Table 0006-133

[0334]

Table 0006-134

[0335]

Table 0006-135

[0336]

Table 0006-136

[0337]

Table 0006-137

[0338]

Table 0006-138

[0339]

Table 0006-139

[0340]

Table 0006-140

[0341]

Table 0006-141

[0342]

Table 0006-142

[0343]

Table 0006-143

[0344]

Table 0006-144

[0345]

Table 0006-145

[0346]

Table 0006-146

[0347]

Table 0006-147

[0348]

Table 0006-148

[0349]

Table 0006-149

[0350]

Table 0006-150

[0351]

Table 0006-151

[0352]

Table 0006-152

[0353]

Table 0006-153

[0354]

Table 0006-154

[0355]

Table 0006-155

[0356]

Table 0006-156

[0357]

Table 0006-157

[0358]

Table 0006-158

[0359]

Table 0006-159

[0360]

Table 0006-160

[0361]

Table 0006-161

[0362]

Table 0006-162

[0363]

Table 0006-163

[0364]

Table 0006-164

[0365]

Table 0006-165

[0366]

Table 0006-166

[0367]

Table 0006-167

[0368]

Table 0006-168

[0369]

Table 0006-169

[0370]

Table 0006-170

[0371]

Table 0006-171

[0372]

Table 0006-172

[0373]

Table 0006-173

[0374]

Table 0006-174

[0375]

Table 0006-175

[0376]

Table 0006-176

[0377]

Table 0006-177

[0378]

Table 0006-178

[0379]

Table 0006-179

[0380]

Table 0006-180

[0381]

Table 0006-181

[0382]

Table 0006-182

[0383]

Table 0006-183

[0384]

Table 0006-184

[0385]

Table 0006-185

[0386]

Table 0006-186

[0387]

Table 0006-187

[0388]

Table 0006-188

[0389]

Table 0006-189

[0390]

Table 0006-190

[0391]

Table 0006-191

[0392]

Table 0006-192

[0393]

Table 0006-193

[0394]

Table 0006-194

[0395]

Table 0006-195

[0396]

Table 0006-196

[0397]

Table 0006-197

[0398]

Table 0006-198

[0399]

Table 0006-199

[0400]

Table 0006-200

[0401]

Table 0006-201

[0402]

Table 0006-202

[0403]

Table 0006-203

[0404]

Table 0006-204

[0405]

Table 0006-205

[0406]

Table 0006-206

[0407]

Table 0006-207

[0408]

Table 0006-208

[0409]

Table 0006-209

[0410]

Table 0006-210

[0411]

Table 0006-211

[0412]

Table 0006-212

[0413]

Table 0006-213

[0414]

Table 0006-214

[0415]

Table 0006-215

[0416]

Table 0006-216

[0417]

Table 0006-217

[0418]

Table 0006-218

[0419]

Table 0006-219

[0420]

Table 0006-220

[0421]

Table 0006-221

[0422]

Table 0006-222

[0423]

Table 0006-223

[0424]

Table 0006-224

[0425]

Table 0006-225

[0426]

Table 0006-226

[0427]

Table 0006-227

[0428]

Table 0006-228

[0429]

Table 0006-229

[0430]

Table 0006-230

[0431]

Table 0006-231

[0432]

Table 0006-232

[0433]

Table 0006-233

[0434]

Table 0006-234

[0435]

Table 0006-235

[0436]

Table 0006-236

[0437]

Table 0006-237

[0438]

Table 0006-238

[0439]

Table 0006-239

[0440]

Table 0006-240

[0441]

Table 0006-241

[0442]

Table 0006-242

[0443]

Table 0006-243

[0444]

Table 0006-244

[0445]

Table 0006-245

[0446]

Table 0006-246

[0447]

Table 0006-247

[0448]

Table 0006-248

[0449]

Table 0006-249

[0450]

Table 0006-250

[0451]

Table 0006-251

[0452]

Table 0006-252

[0453]

Table 0006-253

[0454]

Table 0006-254

[0455]

Table 0006-255

[0456]

Table 0006-256

[0457]

Table 0006-257

[0458]

Table 0006-258

[0459]

Table 0006-259

[0460]

Table 0006-260

[0461]

Table 0006-261

[0462]

Table 0006-262

[0463]

Table 0006-263

[0464]

Table 0006-264

[0465]

Table 0006-265

[0466]

Table 0006-266

[0467]

Table 0006-267

[0468]

Table 0006-268

[0469]

Table 0006-269

[0470]

Table 0006-270

[0471]

Table 0006-271

[0472]

Table 0006-272

[0473]

Table 0006-273

[0474]

Table 0006-274

[0475]

Table 0006-275

[0476]

Table 0006-276

[0477]

Table 0006-277

[0478]

Table 0006-278

[0479]

Table 0006-279

[0480]

Table 0006-280

[0481]

Table 0006-281

[0482]

Table 0006-282

[0483]

Table 0006-283

[0484]

Table 0006-284

[0485]

Table 0006-285

[0486]

Table 0006-286

[0487]

Table 0006-287

[0488]

Table 0006-288

[0489]

Table 0006-289

[0490]

Table 0006-290

[0491]

Table 0006-291

[0492]

Table 0006-292

[0493]

Table 0006-293

[0494]

Table 0006-294

[0495]

Table 0006-295

[0496]

Table 0006-296

[0497]

Table 0006-297

[0498]

Table 0006-298

[0499]

Table 0006-299

[0500]

Table 0006-300

[0501]

Table 0006-301

[0502]

Table 0006-302

[0503]

Table 0006-303

[0504]

Table 0006-304

[0505]

Table 0006-305

[0506]

Table 0006-306

[0507]

Table 0006-307

[0508]

Table 0006-308

[0509]

Table 0006-309

[0510]

Table 0006-310

[0511]

Table 0006-311

[0512]

Table 0006-312

[0513]

Table 0006-313

[0514]

Table 0006-314

[0515]

Table 0006-315

[0516]

Table 0006-316

[0517]

Table 0006-317

[0518]

Table 0006-318

[0519]

Table 0006-319

[0520]

Table 0006-320

[0521]

Table 0006-321

[0522]

Table 0006-322

[0523]

Table 0006-323

[0524]

Table 0006-324

[0525]

Table 0006-325

[0526]

Table 0006-326

[0527]

Table 0006-327

[0528]

Table 0006-328

[0529]

Table 0006-329

[0530]

Table 0006-330

[0531]

Table 0006-331

[0532]

Table 0006-332

[0533]

Table 0006-333

[0534]

Table 0006-334

[0535]

Table 0006-335

[0536]

Table 0006-336

[0537]

Table 0006-337

[0538]

Table 0006-338

[0539]

Table 0006-339

[0540]

Table 0006-340

[0541]

Table 0006-341

[0542]

Table 0006-342

[0543]

Table 0006-343

[0544]

Table 0006-344

[0545]

Table 0006-345

[0546]

Table 0006-346

[0547]

Table 0006-347

[0548]

Table 0006-348

[0549]

Table 0006-349

[0550]

Table 0006-350

[0551]

Table 0006-351

[0552]

Table 0006-352

[0553]

Table 0006-353

[0554]

Table 0006-354

[0555]

Table 0006-355

[0556]

Table 0006-356

[0557]

Table 0006-357

[0558]

Table 0006-358

[0559]

Table 0006-359

[0560]

Table 0006-360

[0561]

Table 0006-361

[0562]

Table 0006-362

[0563]

Table 0006-363

[0564]

Table 0006-364

[0565]

Table 0006-365

[0566]

Table 0006-366

[0567]

Table 0006-367

[0568]

Table 0006-368

[0569]

Table 0006-369

[0570]

Table 0006-370

[0571]

Table 0006-371

[0572]

Table 0006-372

[0573]

Table 0006-373

[0574]

Table 0006-374

[0575]

Table 0006-375

[0576]

Table 0006-376

[0577]

Table 0006-377

[0578]

Table 0006-378

[0579]

Table 0006-379

[0580]

Table 0006-380

[0581]

Table 0006-381

[0582]

Table 0006-382

[0583]

Table 0006-383

[0584]

Table 0006-384

[0585]

Table 0006-385

[0586]

Table 0006-386

[0587]

Table 0006-387

[0588]

Table 0006-388

[0589]

Table 0006-389

[0590]

Table 0006-390

[0591]

Table 0006-391

[0592]

Table 0006-392

[0593]

Table 0006-393

[0594]

Table 0006-394

[0595]

Table 0006-395

[0596]

Table 0006-396

[0597]

Table 0006-397

[0598]

Table 0006-398

[0599]

Table 0006-399

[0600]

Table 0006-400

[0601]

Table 0006-401

[0602]

Table 0006-402

[0603]

Table 0006-403

[0604]

Table 0006-404

[0605]

Table 0006-405

[0606]

Table 0006-406

[0607]

Table 0006-407

[0608]

Table 0006-408

[0609]

Table 0006-409

[0610]

Table 0006-410

[0611]

Table 0006-411

[0612]

Table 0006-412

[0613]

Table 0006-413

[0614] [Table 0006-414]

[0615] Table 7. Familial Cancer Syndrome Targets

[0616] [Table 0007-1]

[0617] [Table 0007-2]

[0618] [Table 0007-3]

[0619] [Table 0007-4]

[0620] Protein cleavage signals and sites In one embodiment, the oncology-related polypeptides of the present invention may comprise at least one proteolytic cleavage signal containing at least one proteolytic cleavage site, which may be located at the N-terminus, the C-terminus, in any space between the N-terminus and the C-terminus, including, but not limited to, in the middle of the N-terminus and the C-terminus, between the N-terminus and the midpoint, between the midpoint and the C-terminus, and combinations thereof.

[0621] Oncology-related polypeptides of the present invention may include, but are not limited to, proprotein convertase (or prohormone convertase), thrombin, or factor Xa proteolytic cleavage signals. Proprotein convertases are a family of nine proteinases, including seven basic amino acid-specific subtilisin-like serine proteinases related to yeast kexin, known as prohormone convertase 1 / 3 (PC1 / 3), PC2, furin, PC4, PC5 / 6, paired basic amino acid cleaving enzyme 4 (PACE4), and PC7, and two other subtilases that cleave at non-basic residues, termed subtilisin kexin isozyme 1 (SKI-1) and proprotein convertase subtilisin kexin 9 (PCSK9). Non-limiting examples of proteolytic cleavage signal amino acid sequences are listed in Table 8. In Table 8, "X" refers to any amino acid, "n" can be 0, 2, 4, or 6 amino acids, and "*" refers to the proteolytic cleavage site. In Table 8, SEQ ID NO: 33885 refers to when n is 4, and SEQ ID NO: 33886 refers to when n is 6.

[0622] Table 8. Protein cleavage site sequences

[0623] [Table 0008]

[0624] In one embodiment, the oncology-related primary constructs and oncology-related mmRNA of the present invention can be engineered such that the oncology-related primary construct or oncology-related mmRNA contains at least one encoded protein cleavage signal. The encoded protein cleavage signal can be located before the start codon, after the start codon, before the coding region, within the coding region, for example, but not limited to, in the middle of the coding region, between the start codon and the midpoint, between the midpoint and the stop codon, after the coding region, after the stop codon, between two stop codons, after the stop codon, and combinations thereof.

[0625] In one embodiment, an oncology-related primary construct or oncology-related mmRNA of the present invention may contain at least one encoded protein cleavage signal containing at least one protein cleavage site. The encoded protein cleavage signal may include, but is not limited to, a proprotein convertase (or prohormone convertase), thrombin, and / or factor Xa protein cleavage signal. One of skill in the art can use Table 1 above or other known methods to determine an appropriate encoded protein cleavage signal to include in an oncology-related primary construct or mmRNA of the present invention. For example, starting with a signal in Table 8, one can design a signal in an oncology-related primary construct that can generate a protein signal in the resulting oncology-related polypeptide, taking into account the codons in Table 1.

[0626] In one embodiment, the oncology-related polypeptides of the invention comprise at least one proteolytic cleavage signal and / or site. As a non-limiting example, U.S. Patent No. 7,374,930 and U.S. Patent Publication No. 20090227660, which are incorporated by reference in their entireties, use a furin cleavage site to cleave the N-terminal methionine of GLP-1 in the expression product from the Golgi apparatus of the cell. In one embodiment, a polypeptide of the invention comprises at least one protein cleavage signal and / or site, provided that the polypeptide is not GLP-1.

[0627] In one embodiment, the oncology-related primary construct or oncology-related mmRNA of the present invention comprises at least one encoded protein cleavage signal and / or site. In one embodiment, the oncology-related primary construct or oncology-related mmRNA of the present invention comprises at least one encoded protein cleavage signal and / or site, provided that the oncology-related primary construct or oncology-related mmRNA does not encode GLP-1.

[0628] In one embodiment, the oncology-related primary constructs or oncology-related mmRNA of the present invention may contain two or more coding regions. When multiple coding regions are present in the oncology-related primary constructs or oncology-related mmRNA of the present invention, the multiple coding regions may be separated by encoded protein cleavage sites. As a non-limiting example, the oncology-related primary constructs or oncology-related mmRNA may be written in an ordered pattern. Such a pattern follows the format AXBY, where A and B are coding regions that may be the same or different and / or may encode the same or different oncology-related polypeptides, and X and Y are encoded protein cleavage signals that may encode the same or different protein cleavage signals. A second such pattern follows the format AXYBZ, where A and B are coding regions that may be the same or different and / or may encode the same or different oncology-related polypeptides, and X, Y, and Z are encoded protein cleavage signals that may encode the same or different protein cleavage signals. A third pattern follows the ABXCY format, where A, B, and C are coding regions that may be the same or different coding regions and / or may encode the same or different oncology-related polypeptides, and X and Y are encoded protein cleavage signals that may encode the same or different protein cleavage signals.

[0629] In one embodiment, the oncology-related polypeptides, oncology-related primary constructs and oncology-related mmRNA may also contain sequences encoding said protein cleavage sites, such that the oncology-related polypeptides, oncology-related primary constructs and oncology-related mmRNA can be released from the carrier region or fusion partner by treatment with a protease specific for the protein cleavage site.

[0630] In one embodiment, the oncology-related polypeptides, primary constructs, and mmRNA of the present invention may comprise a sequence encoding a 2A peptide. In one embodiment, this sequence can be used to separate the coding regions for two or more polypeptides of interest. As a non-limiting example, a sequence encoding a 2A peptide can be present between coding region A and coding region B (A-2Apep-B). The presence of the 2A peptide results in cleavage of a single long protein into protein A, protein B, and the 2A peptide. Protein A and protein B can be the same or different polypeptides of interest. In another embodiment, the 2A peptide can be used in the oncology-related polynucleotides, primary constructs, and / or mmRNA of the present invention to produce two, three, four, five, six, seven, eight, nine, ten, or more proteins.

[0631] Incorporation of post-transcriptional regulatory factors In one embodiment, the oncology-related polynucleotides, primary constructs, and / or mmRNA of the present invention may comprise at least one post-transcriptional regulatory factor. These post-transcriptional regulatory factors may be, but are not limited to, small molecules, chemical compounds, and regulatory sequences. As a non-limiting example, post-transcriptional regulation may be achieved using small molecules identified by PTC Therapeutics Inc. (South Plainfield, NJ) using GEMS™ (Gene Expression Modulation by Small-Molecules) screening technology.

[0632] The post-transcriptional regulatory factor may be a gene expression regulatory factor screened by or described in the method detailed in International Publication No. WO2006022712, which is incorporated herein by reference in its entirety. A method for identifying RNA regulatory sequences involved in translational control is described in International Publication No. WO2004067728, which is incorporated herein by reference in its entirety, and a method for identifying compounds that regulate the untranslated region-dependent expression of genes is described in International Publication No. WO2004065561, which is incorporated herein by reference in its entirety.

[0633] In one embodiment, the oncology-related polynucleotides, primary constructs, and / or mmRNA of the present invention may comprise at least one post-transcriptional regulatory element located in the 5' and / or 3' untranslated region of the polynucleotides, primary constructs, and / or mmRNA of the present invention.

[0634] In another embodiment, the oncology-related polynucleotides, primary constructs, and / or mmRNA of the present invention can comprise at least one post-transcriptional regulatory factor to regulate premature translation termination.The post-transcriptional regulatory factor can be a compound described in International Publication Nos. WO2004010106, WO2006044456, WO2006044682, WO2006044503, and WO2006044505, each of which is incorporated herein by reference in its entirety, or a compound found by the methods outlined therein.As a non-limiting example, this compound can bind to a region of 28S ribosomal RNA to regulate premature translation termination (see, for example, International Publication No. WO2004010106, which is incorporated herein by reference in its entirety).

[0635] In one embodiment, the oncology-related polynucleotides, primary constructs, and / or mmRNA of the present invention can comprise at least one post-transcriptional regulatory element to alter protein expression. As a non-limiting example, VEGF expression can be controlled using compounds described in International Publication Nos. WO2005118857, WO2006065480, WO2006065479, and WO2006058088, each of which is incorporated herein by reference in its entirety, or compounds that can be found by the methods described therein.

[0636] The oncology-related polynucleotide, primary construct, and / or mmRNA of the present invention can comprise at least one post-transcriptional regulatory element to control translation.In one embodiment, the post-transcriptional regulatory element can be an RNA regulatory sequence.As a non-limiting example, the RNA regulatory sequence can be identified by the method described in International Publication No. WO2006071903, the entirety of which is incorporated herein by reference.

[0637] III. Qualification In oncology-related polynucleotides (such as oncology-related primary constructs or oncology-related mRNA molecules) herein, the term "modification" or, where appropriate, "modified" refers to a modification to an A, G, U, or C ribonucleotide. Generally, as used herein, these terms are not intended to refer to ribonucleotide modifications in the naturally occurring 5'-terminal mRNA cap moiety. In polypeptides, the term "modification" refers to a modification compared to a reference set of 20 amino acids (moieties).

[0638] The modifications may be a variety of distinct modifications. In some embodiments, the coding region, the flanking region, and / or the terminal region may contain one, two, or more than one (optionally different) nucleoside or nucleotide modifications. In some embodiments, a modified oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA introduced into a cell may exhibit reduced degradation in the cell compared to an unmodified oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA.

[0639] Oncology-related polynucleotides, oncology-related primary constructs, and oncology-related mmRNA can include any useful modifications to the sugar, nucleobase, or internucleoside linkage (e.g., to the phosphate / phosphodiester linkage / phosphodiester backbone). One or more atoms of a pyrimidine nucleobase can be replaced with or substituted with an optionally substituted amino, an optionally substituted thiol, an optionally substituted alkyl (e.g., methyl or ethyl), or a halo (e.g., chloro or fluoro). In certain embodiments, a modification (e.g., one or more modifications) is present in each of the sugar and the internucleoside linkage. Modifications according to the present invention can be modifications of ribonucleic acid (RNA) relative to deoxyribonucleic acid (DNA), threose nucleic acid (TNA), glycol nucleic acid (GNA), peptide nucleic acid (PNA), locked nucleic acid (LNA), or hybrids thereof. Further modifications are described herein.

[0640] As described herein, the oncology-related polynucleotides, oncology-related primary constructs, and oncology-related mmRNA of the present invention do not substantially induce an innate immune response in cells into which the mRNA is introduced. Characteristics of an induced innate immune response include: 1) increased expression of proinflammatory cytokines, 2) activation of intracellular PRRs (e.g., RIG-I, MDA5), and / or 3) termination or reduction of protein translation.

[0641] In certain embodiments, it may be desirable to degrade modified nucleic acid molecules introduced into cells intracellularly. For example, degradation of modified oncology-related nucleic acid molecules may be preferable when precise timing of protein production is desired. Thus, in some embodiments, the present invention provides modified oncology-related nucleic acid molecules containing a degradation domain that can be acted on intracellularly in a directed manner. In another aspect, the present disclosure provides oncology-related polynucleotides that contain nucleosides or nucleotides that can disrupt the binding of major groove interaction (e.g., binding) partners with oncology-related polynucleotides (e.g., when the modified nucleotide has a reduced binding affinity for the major groove interaction partner compared to the unmodified nucleotide).

[0642] Oncology-related polynucleotides, oncology-related primary constructs, and oncology-related mmRNA may optionally include other agents (e.g., RNAi-inducing agents, RNAi agents, siRNA, shRNA, miRNA, antisense RNA, ribozymes, catalytic DNA, tRNA, RNA that induces triple helix formation, aptamers, vectors, etc.). In some embodiments, oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNA may include one or more messenger RNAs (mRNAs) and one or more modified nucleosides or nucleotides (e.g., mmRNA molecules). More details about these oncology-related polynucleotides, oncology-related primary constructs, and oncology-related mmRNAs follow below.

[0643] Oncology-related polynucleotides and oncology-related primary constructs The oncology-related polynucleotides, primary constructs, and mmRNA of the present invention comprise a first region of linked nucleosides encoding a polypeptide of interest, a first flanking region located at the 5' end of the first region, and a second flanking region located at the 3' end of the first region.

[0644] In some embodiments, the oncology-related polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) has the structure of Formula (Ia) or Formula (Ia-1):

[0645] [ka]

[0646] or a pharmaceutically acceptable salt or stereoisomer thereof, During the ceremony, U is O, S, N(R U ) nu , or C(R U ) nu wherein nu is an integer from 0 to 2, and each R U is independently H, halo, or optionally substituted alkyl; --- is a single bond or is absent, R 1’ , R 2’ , R 1” , R 2” , R 1 , R 2 , R 3 , R 4 , and R 5each, when present, is independently H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or absent; and R3 in combination with one or more of R1', R1", R2', R2", or R5 (e.g., a combination of R1' and R3, a combination of R1" and R3, a combination of R2' and R3, a combination of R2" and R3, or The combination of R and R) together can form an optionally substituted alkylene or an optionally substituted heteroalkylene and, together with the carbons to which they are attached, can provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl); the combination of R and one or more of R, R", R, or R (e.g., a combination of R and R, a combination of R and R, a combination of R and R, or a combination of R and R) can together form an optionally substituted alkylene or an optionally substituted heteroalkylene and, together with the carbons to which they are attached, can provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl); R 4 and R 1’ , R 1” , R 2’ , R 2” , R 3 , or R 5 may be combined together to form an optionally substituted alkylene or an optionally substituted heteroalkylene, and together with the carbons to which they are attached, provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl), wherein each of m' and m" is independently an integer from 0 to 3 (e.g., 0 to 2, 0 to 1, 1 to 3, or 1 to 2); Y 1 , Y2 , and Y 3 each independently represents O, S, Se, -NR N1 -, optionally substituted alkylene, or optionally substituted heteroalkylene, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or absent; Each Y 4 are independently H, hydroxy, thiol, boranyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino; Each Y 5 is independently O, S, Se, optionally substituted alkylene (e.g., methylene), or optionally substituted heteroalkylene; n is an integer from 1 to 100,000, B is a nucleobase (e.g., a purine, a pyrimidine, or a derivative thereof), and B and R 1’ Combination of B and R 2’ Combination of B and R 1” combination of B and R 2” together with the carbons to which they are attached can optionally form a bicyclic group (e.g., a bicyclic heterocyclyl), or B, R 1” , and R 3 A combination of B and R 2” , and R 3may optionally form a tricyclic or tetracyclic group (e.g., a tricyclic or tetracyclic heterocyclyl such as those of formula (IIo)-(IIp) herein). In some embodiments, an oncology-related polynucleotide, primary construct, or mmRNA comprises a modified ribose. In some embodiments, an oncology-related polynucleotide, primary construct, or mmRNA (e.g., a first region, a first flanking region, or a second flanking region) comprises n linked nucleosides having formula (Ia-2) through (Ia-5), or a pharmaceutically acceptable salt or stereoisomer thereof.

[0647] [ka]

[0648] In some embodiments, the oncology-related polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) has the structure of Formula (Ib) or Formula (Ib-1):

[0649] [ka]

[0650] or a pharmaceutically acceptable salt or stereoisomer thereof, During the ceremony, U is O, S, N(R U ) nu , or C(R U ) nu wherein nu is an integer from 0 to 2, and each R U is independently H, halo, or optionally substituted alkyl; --- is a single bond or is absent, R 1 , R 3’ , R 3” , and R 4each is independently H, halo, hydroxy, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or absent; and R 1 and R 3’ combination or R 1 and R 3” can be taken together to form an optionally substituted alkylene or an optionally substituted heteroalkylene (e.g., to produce a locked nucleic acid), Each R 5 is independently H, halo, hydroxy, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, or absent; Y 1 , Y 2 , and Y 3 each independently represents O, S, Se, -NR N1 -, optionally substituted alkylene, or optionally substituted heteroalkylene, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl; Each Y 4 are independently H, hydroxy, thiol, boranyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted alkoxyalkoxy, or optionally substituted amino; n is an integer from 1 to 100,000, B is a nucleobase.

[0651] In some embodiments, the oncology-related polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) has the formula (Ic):

[0652] [ka]

[0653] or a pharmaceutically acceptable salt or stereoisomer thereof, During the ceremony, U is O, S, N(R U ) nu , or C(R U ) nu wherein nu is an integer from 0 to 2, and each R U is independently H, halo, or optionally substituted alkyl; --- is a single bond or is absent, B 1 , B 2 , and B 3 each is independently a nucleobase (e.g., a purine, pyrimidine, or derivative thereof described herein), H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl; and B 1 , B 2 , and B 3 only one of the is a nucleobase, R b1 , R b2 , R b3 , R 3 , and R 5each is independently H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl; Y 1 , Y 2 , and Y 3 each independently represents O, S, Se, -NR N1 -, optionally substituted alkylene, or optionally substituted heteroalkylene, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl; Each Y 4 are independently H, hydroxy, thiol, boranyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino; Each Y 5 is independently O, S, Se, optionally substituted alkylene (e.g., methylene), or optionally substituted heteroalkylene; n is an integer from 1 to 100,000, The ring containing U may contain one or more double bonds.

[0654] In certain embodiments, the ring containing U is U-CB 3 R b3 Between or CB 3 R b3 -C B2 R b2 There is no double bond between them. In some embodiments, the oncology-related polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) has the formula (Id):

[0655] [ka]

[0656] or a pharmaceutically acceptable salt or stereoisomer thereof, During the ceremony, U is O, S, N(R U ) nu , or C(R U ) nu wherein nu is an integer from 0 to 2, and each R U is independently H, halo, or optionally substituted alkyl; Each R 3 are independently H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl; Y 1 , Y 2 , and Y 3 each independently represents O, S, Se, -NR N1 -, optionally substituted alkylene, or optionally substituted heteroalkylene, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl; Each Y 4are independently H, hydroxy, thiol, boranyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino; Each Y 5 is independently O, S, optionally substituted alkylene (e.g., methylene), or optionally substituted heteroalkylene; n is an integer from 1 to 100,000, B is a nucleobase (eg, a purine, pyrimidine, or derivative thereof).

[0657] In some embodiments, the oncology-related polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) has a structure represented by Formula (Ie):

[0658] [ka]

[0659] or a pharmaceutically acceptable salt or stereoisomer thereof, During the ceremony, Each of U' and U" is independently O, S, N(R U ) nu , or C(R U ) nu wherein nu is an integer from 0 to 2, and each R U is independently H, halo, or optionally substituted alkyl; Each R 6are independently H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl; Each Y 5’ is independently O, S, optionally substituted alkylene (e.g., methylene or ethylene), or optionally substituted heteroalkylene; n is an integer from 1 to 100,000, B is a nucleobase (eg, a purine, pyrimidine, or derivative thereof).

[0660] In some embodiments, the oncology-related polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) has a structure represented by formula (If) or (If-1):

[0661] [ka]

[0662] or a pharmaceutically acceptable salt or stereoisomer thereof, During the ceremony, Each of U' and U" is independently O, S, N, N(R U ) nu , or C(R U ) nu wherein nu is an integer from 0 to 2, and each R U are independently H, halo, or optionally substituted alkyl (e.g., U' is O and U" is N); --- is a single bond or is absent, R 1’ , R 2’ , R 1”, R 2” , R 3 , and R 4 each is independently H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or absent; and R 1’ and R 3 Combination of R 1” and R 3 Combination of R 2’ and R 3 combination, or R 2” and R 3 can be taken together to form an optionally substituted alkylene or an optionally substituted heteroalkylene (e.g., to produce a locked nucleic acid), and each of m' and m" is independently an integer from 0 to 3 (e.g., 0 to 2, 0 to 1, 1 to 3, or 1 to 2); Y 1 , Y 2 , and Y 3 each independently represents O, S, Se, -NR N1 -, optionally substituted alkylene, or optionally substituted heteroalkylene, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or absent; Each Y 4 are independently H, hydroxy, thiol, boranyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino; Each Y 5is independently O, S, Se, optionally substituted alkylene (e.g., methylene), or optionally substituted heteroalkylene; n is an integer from 1 to 100,000, B is a nucleobase (eg, a purine, pyrimidine, or derivative thereof).

[0663] In some embodiments of the oncology-related polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia), (Ia-1) through (Ia-3), (Ib) through (If), and (IIa) through (IIp)), the ring containing U has one or two double bonds.

[0664] In some embodiments of the oncology-related polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia) through (Ia-5), (Ib) through (If-1), (IIa) through (IIp), (IIb-1), (IIb-2), (IIc-1) through (IIc-2), (IIn-1), (IIn-2), (IVa) through (IVl), and (IXa) through (IXr)), R 1 , R 1’ , and R 1” Each of, when present, is H. In a further embodiment, R 2 , R 2’ , and R 2” Each of, when present, is independently H, halo (e.g., fluoro), hydroxy, optionally substituted alkoxy (e.g., methoxy or ethoxy), or optionally substituted alkoxyalkoxy. In certain embodiments, alkoxyalkoxy is —(CH) s2 (OCH2CH2) s1 (CH2) s3 OR', wherein s1 is an integer of 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer of 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6, or 1 to 10), and R' is H or C 1~20 In some embodiments, s2 is 0, s1 is 1 or 2, s3 is 0 or 1, and R' is C 1~6 It is alkyl.

[0665] In some embodiments of the oncology-related polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia) through (Ia-5), (Ib) through (If-1), (IIa) through (IIp), (IIb-1), (IIb-2), (IIc-1) through (IIc-2), (IIn-1), (IIn-2), (IVa) through (IVl), and (IXa) through (IXr)), R 2 , R 2’ , and R 2” Each of, when present, is H. In a further embodiment, R 1 , R 1’ , and R 1” Each of, when present, is independently H, halo (e.g., fluoro), hydroxy, optionally substituted alkoxy (e.g., methoxy or ethoxy), or optionally substituted alkoxyalkoxy. In certain embodiments, alkoxyalkoxy is —(CH) s2 (OCH2CH2) s1 (CH2) s3 OR', wherein s1 is an integer of 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer of 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6, or 1 to 10), and R' is H or C 1~20 In some embodiments, s2 is 0, s1 is 1 or 2, s3 is 0 or 1, and R' is C 1~6 It is alkyl.

[0666] In some embodiments of the oncology-related polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia) through (Ia-5), (Ib) through (If-1), (IIa) through (IIp), (IIb-1), (IIb-2), (IIc-1) through (IIc-2), (IIn-1), (IIn-2), (IVa) through (IVl), and (IXa) through (IXr)), R 3 , R 4 , and R 5Each of R is independently H, halo (e.g., fluoro), hydroxy, optionally substituted alkyl, optionally substituted alkoxy (e.g., methoxy or ethoxy), or optionally substituted alkoxyalkoxy. In certain embodiments, R 3 is H and R 4 is H and R 5 is H or R 3 , R 4 , and R 5 are all H. In certain embodiments, R 3 C 1~6 alkyl, and R 4 C 1~6 alkyl, and R 5 C 1~6 alkyl or R 3 , R 4 , and R 5 All of them are C 1~6 In certain embodiments, R 3 MoR 4 are both H, and R 5 is C 1~6 It is alkyl.

[0667] In some embodiments of the oncology-related polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia) through (Ia-5), (Ib) through (If-1), (IIa) through (IIp), (IIb-1), (IIb-2), (IIc-1) through (IIc-2), (IIn-1), (IIn-2), (IVa) through (IVl), and (IXa) through (IXr)), R 3 and R 5 taken together form an optionally substituted alkylene or an optionally substituted heteroalkylene, and together with the carbons to which they are attached provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl), such as the trans-3',4' analogs, and R 3 and R 5 together form a heteroalkylene (e.g., -(CH2) b1 O(CH2) b2 O(CH2) b3wherein each of b1, b2, and b3 is independently an integer of 0 to 3.

[0668] In some embodiments of the oncology-related polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia) through (Ia-5), (Ib) through (If-1), (IIa) through (IIp), (IIb-1), (IIb-2), (IIc-1) through (IIc-2), (IIn-1), (IIn-2), (IVa) through (IVl), and (IXa) through (IXr)), R 3 and R 1’ , R 1” , R 2’ , R 2” , or R 5 taken together form an optionally substituted alkylene or an optionally substituted heteroalkylene, and together with the carbons to which they are attached provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl), and R 3 and R 1’ , R 1” , R 2’ , R 2” , or R 5 taken together form a heteroalkylene (e.g., -(CH2) b1 O(CH2) b2 O(CH2) b3 wherein each of b1, b2, and b3 is independently an integer of 0 to 3.

[0669] In some embodiments of the oncology-related polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia) through (Ia-5), (Ib) through (If-1), (IIa) through (IIp), (IIb-1), (IIb-2), (IIc-1) through (IIc-2), (IIn-1), (IIn-2), (IVa) through (IVl), and (IXa) through (IXr)), R 5 and R 1’ , R 1” , R 2’ , or R 2”taken together form an optionally substituted alkylene or an optionally substituted heteroalkylene, and together with the carbons to which they are attached provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl), and R 5 and R 1’ , R 1” , R 2’ , or R 2” taken together form a heteroalkylene (e.g., -(CH2) b1 O(CH2) b2 O(CH2) b3 wherein each of b1, b2, and b3 is independently an integer of 0 to 3.

[0670] In some embodiments of the oncology-related polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia) through (Ia-5), (Ib) through (If-1), (IIa) through (IIp), (IIb-1), (IIb-2), (IIc-1) through (IIc-2), (IIn-1), (IIn-2), (IVa) through (IVl), and (IXa) through (IXr)), each Y 2 are independently O, S, or -NR N1 -, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl. In certain embodiments, Y 2 is NR N1 -, wherein R N1 is H or optionally substituted alkyl (e.g., C 1~6 alkyl, for example, methyl, ethyl, isopropyl, or n-propyl).

[0671] In some embodiments of the oncology-related polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia) through (Ia-5), (Ib) through (If-1), (IIa) through (IIp), (IIb-1), (IIb-2), (IIc-1) through (IIc-2), (IIn-1), (IIn-2), (IVa) through (IVl), and (IXa) through (IXr)), each Y3 are independently O or S.

[0672] In some embodiments of the oncology-related polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia) through (Ia-5), (Ib) through (If-1), (IIa) through (IIp), (IIb-1), (IIb-2), (IIc-1) through (IIc-2), (IIn-1), (IIn-2), (IVa) through (IVl), and (IXa) through (IXr)), R 1 is H, and each R 2 are independently H, halo (e.g., fluoro), hydroxy, optionally substituted alkoxy (e.g., methoxy or ethoxy), or optionally substituted alkoxyalkoxy (e.g., —(CH) s2 (OCH2CH2) s1 (CH2) s3 OR', wherein s1 is an integer of 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer of 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6, or 1 to 10), and R' is H or C 1~20 alkyl, for example, in which s2 is 0, s1 is 1 or 2, and s3 is 0 or 1 (e.g., R' is C 1~6 alkyl), and each Y 2 are independently -O or -NR N1 -, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl (e.g., in formula R N1 is H or optionally substituted alkyl (e.g., C 1~6 alkyl, for example, methyl, ethyl, isopropyl, or n-propyl), and each Y 3 is independently O or S (e.g., S). In a further embodiment, R 3is H, halo (e.g., fluoro), hydroxy, optionally substituted alkyl, optionally substituted alkoxy (e.g., methoxy or ethoxy), or optionally substituted alkoxyalkoxy. In still further embodiments, each Y 1 are independently -O or -NR N1 -, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl (e.g., in formula R N1 is H or optionally substituted alkyl (e.g., C 1~6 alkyl, for example, methyl, ethyl, isopropyl, or n-propyl), and each Y 4 are independently H, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino.

[0673] In some embodiments of the oncology-related polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia) through (Ia-5), (Ib) through (If-1), (IIa) through (IIp), (IIb-1), (IIb-2), (IIc-1) through (IIc-2), (IIn-1), (IIn-2), (IVa) through (IVl), and (IXa) through (IXr)), each R 1 are independently H, halo (e.g., fluoro), hydroxy, optionally substituted alkoxy (e.g., methoxy or ethoxy), or optionally substituted alkoxyalkoxy (e.g., —(CH) s2 (OCH2CH2) s1 (CH2) s3 OR', wherein s1 is an integer of 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer of 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6, or 1 to 10), and R' is H or C 1~20 alkyl (e.g., where s2 is 0, s1 is 1 or 2, s3 is 0 or 1, and R' is C 1~6alkyl), R 2 is H, and each Y 2 are independently -O or -NR N1 -, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl (e.g., in formula R N1 is H or optionally substituted alkyl (e.g., C 1~6 alkyl, for example, methyl, ethyl, isopropyl, or n-propyl), and each Y 3 is independently O or S (e.g., S). In a further embodiment, R 3 is H, halo (e.g., fluoro), hydroxy, optionally substituted alkyl, optionally substituted alkoxy (e.g., methoxy or ethoxy), or optionally substituted alkoxyalkoxy. In still further embodiments, each Y 1 are independently -O or -NR N1 -, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl (e.g., in formula R N1 is H or optionally substituted alkyl (e.g., C 1~6 alkyl, for example, methyl, ethyl, isopropyl, or n-propyl), and each Y 4 are independently H, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino.

[0674] In some embodiments of the oncology-related polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-1), (IIa)-(IIp), (IIb-1), (IIb-2), (IIc-1)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IVl), and (IXa)-(IXr)), the ring containing the U is in the β-D (e.g., β-D-ribo) configuration.

[0675] In some embodiments of the oncology-related polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-1), (IIa)-(IIp), (IIb-1), (IIb-2), (IIc-1)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IVl), and (IXa)-(IXr)), the ring containing the U is in the α-L (e.g., α-L-ribo) configuration.

[0676] In some embodiments of the oncology-related polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-1), (IIa)-(IIp), (IIb-1), (IIb-2), (IIc-1)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IVl), and (IXa)-(IXr)), one or more B is pseudouridine (ψ) or 5-methyl-cytidine (m 5 In some embodiments, about 10% to about 100% of the n B nucleobases are neither ψ nor m 5 Neither C (for example, 10% to 20%, 10% to 35%, 10% to 50%, 10% to 60%, 10% to 75%, 10% to 90%, 10% to 95%, 10% to 98%, 10% to 99%, 20% to 35%, 20% to 50%, 20% to 60%, 20% to 75%, 20% to 90%, 20% to 95% of n Bs) %, 20%~98%, 20%~99%, 20%~100%, 50%~60%, 50%~75%, 50%~90%, 50%~95%, 50%~98%, 50%~99%, 50%~100%, 75%~90%, 75%~95%, 75%~98%, 75%~99%, and 75%~100% are also m 5 C). In some embodiments, B is neither ψ nor m 5 It's not C either.

[0677] In some embodiments of the oncology-related polynucleotides, primary constructs, or mmRNA (e.g., Formulas (Ia)-(Ia-5), (Ib)-(If-1), (IIa)-(IIp), (IIb-1), (IIb-2), (IIc-1)-(IIc-2), (IIn-1), (IIn-2), (IVa)-(IVl), and (IXa)-(IXr)), when B is an unmodified nucleobase selected from cytosine, guanine, uracil, and adenine, then Y 1 , Y 2 , or Y 3 At least one of them is not O.

[0678] In some embodiments, the oncology-related polynucleotide, primary construct, or mmRNA comprises a modified ribose. In some embodiments, the oncology-related polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) has a structure represented by Formula (IIa)-(IIc):

[0679] [ka]

[0680] or a pharmaceutically acceptable salt or stereoisomer thereof. In certain embodiments, U is O or C(R U ) nu wherein nu is an integer from 0 to 2, and each R U is independently H, halo, or optionally substituted alkyl (e.g., U is -CH- or -CH-). In other embodiments, R 1 , R 2 , R 3 , R 4 , and R 5each is independently H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or absent (e.g., each R 1 and R 2 are independently H, halo, hydroxy, optionally substituted alkyl, or optionally substituted alkoxy, and each R 3 and R 4 are independently H or optionally substituted alkyl, and R 5 is H or hydroxy), and --- is a single or double bond.

[0681] In certain embodiments, the polynucleotide or mRNA has the formula (IIb-1) to (IIb-2):

[0682] [ka]

[0683] or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, U is O or C(R U ) nu wherein nu is an integer from 0 to 2, and each R U is independently H, halo, or optionally substituted alkyl (e.g., U is -CH- or -CH-). In other embodiments, R 1 and R 2is independently H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or absent (e.g., each R 1 and R 2 are independently H, halo, hydroxy, optionally substituted alkyl, or optionally substituted alkoxy, e.g., H, halo, hydroxy, alkyl, or alkoxy). In certain embodiments, R 2 is hydroxy or optionally substituted alkoxy (e.g., methoxy, ethoxy, or any described herein).

[0684] In certain embodiments, the oncology-related polynucleotide, primary construct, or mmRNA has the formula (IIc-1) to (IIc-4):

[0685] [ka]

[0686] or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, U is O or C(R U ) nu wherein nu is an integer from 0 to 2, and each R U is independently H, halo, or optionally substituted alkyl (e.g., U is -CH- or -CH-). In some embodiments, R 1 , R 2 , and R 3is independently H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or absent (e.g., each R 1 and R 2 is independently H, halo, hydroxy, optionally substituted alkyl, or optionally substituted alkoxy, e.g., H, halo, hydroxy, alkyl, or alkoxy, and each R 3 are independently H or optionally substituted alkyl). In certain embodiments, R 2 is an optionally substituted alkoxy (e.g., methoxy or ethoxy, or any described herein). In certain embodiments, R 1 is optionally substituted alkyl, and R 2 is hydroxy. In other embodiments, R 1 is hydroxy and R 2 is optionally substituted alkyl. In a further embodiment, R 3 is optionally substituted alkyl.

[0687] In some embodiments, the oncology-related polynucleotide, primary construct, or mmRNA comprises an acyclic modified ribose. In some embodiments, the oncology-related polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) has a structure represented by Formula (IId)-(IIf):

[0688] [ka]

[0689] or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, the oncology-related polynucleotide, primary construct, or mmRNA comprises an acyclic modified hexitol. In some embodiments, the oncology-related polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) has a structure represented by Formula (IIg)-(IIj):

[0690] [ka]

[0691] or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, the oncology-related polynucleotide, primary construct, or mmRNA comprises a sugar moiety having a shortened or extended ribose ring. In some embodiments, the oncology-related polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) has a structure represented by Formula (IIk)-(IIm):

[0692] [ka]

[0693] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1’ , R 1” , R 2’ , and R 2” each is independently H, halo, hydroxy, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, or absent; and R 2’ and R 3 combination or R 2” and R 3may be taken together to form an optionally substituted alkylene or an optionally substituted heteroalkylene.

[0694] In some embodiments, the oncology-related polynucleotide, primary construct, or mmRNA comprises a locked modified ribose. In some embodiments, the oncology-related polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) has a structure represented by Formula (IIn):

[0695] [ka]

[0696] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3’ is O, S, or -NR N1 -, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl, and R 3” is an optionally substituted alkylene (e.g., -CH2-, -CH2CH2-, or -CH2CH2CH2-) or an optionally substituted heteroalkylene (e.g., -CH2NH-, -CH2CH2NH-, -CH2OCH2-, or -CH2CH2OCH2-) (e.g., R 3’ is O and R 3” is optionally substituted alkylene (e.g., -CH2-, -CH2CH2-, or -CH2CH2CH2-).

[0697] In some embodiments, the oncology-related polynucleotide, primary construct, or mmRNA has the formula (IIn-1) to (II-n2):

[0698] [ka]

[0699] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3’ is O, S, or -NR N1 -, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl, and R 3” is an optionally substituted alkylene (e.g., -CH2-, -CH2CH2-, or -CH2CH2CH2-) or an optionally substituted heteroalkylene (e.g., -CH2NH-, -CH2CH2NH-, -CH2OCH2-, or -CH2CH2OCH2-) (e.g., R 3’ is O and R 3” is optionally substituted alkylene (e.g., -CH2-, -CH2CH2-, or -CH2CH2CH2-).

[0700] In some embodiments, the oncology-related polynucleotide, primary construct, or mmRNA comprises a locked modified ribose that forms a tetracyclic heterocyclyl. In some embodiments, the oncology-related polynucleotide, primary construct, or mmRNA (e.g., the first region, the first flanking region, or the second flanking region) has the formula (IIo):

[0701] [ka]

[0702] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 12a , R 12c , T 1’ , T 1” , T 2’ , T 2” , V 1 , and V 3 is as described herein.

[0703] Any of the oncology-related polynucleotide, primary construct, or mmRNA formulas may comprise one or more nucleobases described herein (eg, formulas (b1)-(b43)).

[0704] In one embodiment, the present invention provides a method for preparing a polynucleotide, primary construct, or mmRNA, wherein the polynucleotide has formula (Ia) as defined herein:

[0705] [ka]

[0706] and the method comprises n nucleosides having formula (IIIa) as defined herein:

[0707] [ka]

[0708] with an RNA polymerase and a cDNA template. In a further embodiment, the present invention provides a method for amplifying a polynucleotide, primary construct, or mmRNA comprising at least one nucleotide (e.g., an mmRNA molecule), the method comprising reacting a compound of formula (IIIa) as defined herein with a primer, a cDNA template, and an RNA polymerase.

[0709] In one embodiment, the present invention provides a method for preparing a polynucleotide, primary construct, or mmRNA comprising at least one nucleotide (e.g., an mmRNA molecule), the polynucleotide having a structure represented by formula (Ia), as defined herein:

[0710] [ka]

[0711] and the method comprises n nucleosides having formula (IIIa-1) as defined herein:

[0712] [ka]

[0713] with an RNA polymerase and a cDNA template. In a further embodiment, the present invention provides a method for amplifying a polynucleotide, primary construct, or mmRNA comprising at least one nucleotide (e.g., an mmRNA molecule), the method comprising: It involves reacting a compound of formula (IIIa-1) as defined herein with a primer, a cDNA template, and an RNA polymerase.

[0714] In one embodiment, the present invention provides a method for preparing a modified mRNA (e.g., an mmRNA molecule) comprising at least one nucleotide, the polynucleotide having the formula (Ia-2) as defined herein:

[0715] [ka]

[0716] and the method comprises n nucleosides having formula (IIIa-2):

[0717] [ka]

[0718] with an RNA polymerase and a cDNA template. In a further embodiment, the present invention provides a method for amplifying modified mRNA comprising at least one nucleotide (e.g., an mRNA molecule), the method comprising: It involves reacting a compound of formula (IIIa-2) as defined herein with a primer, a cDNA template, and an RNA polymerase.

[0719] In some embodiments, the reaction can be repeated from 1 to about 7,000 times.In any of the embodiments herein, B can be a nucleobase of formula (b1)-(b43).

[0720] The oncology-related polynucleotides, primary constructs and mmRNA may optionally include 5' and / or 3' flanking regions as described herein. Modified RNA (mRNA) molecules The present invention also includes building blocks of modified RNA (mmRNA) molecules, such as modified ribonucleosides, modified ribonucleotides, etc. For example, these building blocks may be useful in preparing the oncology-related polynucleotides, primary constructs, or mmRNA of the present invention.

[0721] In some embodiments, the building block molecule has formula (IIIa) or (IIIa-1):

[0722] [ka]

[0723] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the substituents are as described herein (e.g., Formulas (Ia) and (Ia-1)), and when B is an unmodified nucleobase selected from cytosine, guanine, uracil, and adenine, then Y 1 , Y 2 , or Y 3 At least one of them is not O.

[0724] In some embodiments, the building block molecule that can be incorporated into a polynucleotide, primary construct, or mmRNA has the formula (IVa)-(IVb):

[0725] [ka]

[0726] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein B is as described herein (e.g., any one of (b1)-(b43)). In certain embodiments, Formula (IVa) or (IVb) is combined with a modified uracil (e.g., any one of Formulas (b1)-(b9), (b21)-(b23), and (b28)-(b31), e.g., Formula (b1), (b8), (b28), (b29), or (b30)). In certain embodiments, Formula (IVa) or (IVb) is combined with a modified cytosine (e.g., any one of Formulas (b10)-(b14), (b24), (b25), and (b32)-(b36), e.g., Formula (b10) or (b32)). In certain embodiments, Formula (IVa) or (IVb) is combined with a modified guanine (e.g., any one of Formulas (b15)-(b17) and (b37)-(b40)). In certain embodiments, Formula (IVa) or (IVb) is combined with a modified adenine (e.g., any one of Formulas (b18)-(b20) and (b41)-(b43)).

[0727] In some embodiments, the building block molecules that can be incorporated into polynucleotides, primary constructs, or mmRNA are represented by formulas (IVc)-(IVk):

[0728] [ka]

[0729] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein B is as described herein (e.g., any one of (b1)-(b43)). In certain embodiments, one of Formulas (IVc)-(IVk) is combined with a modified uracil (e.g., any one of Formulas (b1)-(b9), (b21)-(b23), and (b28)-(b31), e.g., Formula (b1), (b8), (b28), (b29), or (b30)). In certain embodiments, one of Formulas (IVc)-(IVk) is combined with a modified cytosine (e.g., any one of Formulas (b10)-(b14), (b24), (b25), and (b32)-(b36), e.g., Formula (b10) or (b32)). In certain embodiments, one of Formulas (IVc)-(IVk) is combined with a modified guanine (e.g., any one of Formulas (b15)-(b17) and (b37)-(b40)). In certain embodiments, one of Formulas (IVc)-(IVk) is combined with a modified adenine (e.g., any one of Formulas (b18)-(b20) and (b41)-(b43)).

[0730] In other embodiments, the building block molecule that can be incorporated into a polynucleotide, primary construct, or mmRNA has the formula (Va) or (Vb):

[0731] [ka]

[0732] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein B is as described herein (e.g., any one of (b1) to (b43)). In other embodiments, the building block molecule that can be incorporated into a polynucleotide, primary construct, or mmRNA has the formula (IXa)-(IXd):

[0733] [ka]

[0734] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein B is as described herein (e.g., any one of (b1)-(b43)). In certain embodiments, one of Formulas (IXa)-(IXd) is combined with a modified uracil (e.g., any one of Formulas (b1)-(b9), (b21)-(b23), and (b28)-(b31), e.g., Formula (b1), (b8), (b28), (b29), or (b30)). In certain embodiments, one of Formulas (IXa)-(IXd) is combined with a modified cytosine (e.g., any one of Formulas (b10)-(b14), (b24), (b25), and (b32)-(b36), e.g., Formula (b10) or (b32)). In certain embodiments, one of formulas (IXa)-(IXd) is combined with a modified guanine (e.g., any one of formulas (b15)-(b17) and (b37)-(b40)). In certain embodiments, one of formulas (IXa)-(IXd) is combined with a modified adenine (e.g., any one of formulas (b18)-(b20) and (b41)-(b43)).

[0735] In other embodiments, the building block molecule that can be incorporated into a polynucleotide, primary construct, or mmRNA has the formula (IXe)-(IXg):

[0736] [ka]

[0737] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein B is as described herein (e.g., any one of (b1)-(b43)). In certain embodiments, one of Formulas (IXe)-(IXg) is combined with a modified uracil (e.g., any one of Formulas (b1)-(b9), (b21)-(b23), and (b28)-(b31), e.g., Formula (b1), (b8), (b28), (b29), or (b30)). In certain embodiments, one of Formulas (IXe)-(IXg) is combined with a modified cytosine (e.g., any one of Formulas (b10)-(b14), (b24), (b25), and (b32)-(b36), e.g., Formula (b10) or (b32)). In certain embodiments, one of Formulas (IXe)-(IXg) is combined with a modified guanine (e.g., any one of Formulas (b15)-(b17) and (b37)-(b40)). In certain embodiments, one of Formulas (IXe)-(IXg) is combined with a modified adenine (e.g., any one of Formulas (b18)-(b20) and (b41)-(b43)).

[0738] In other embodiments, the building block molecules that can be incorporated into polynucleotides, primary constructs, or mmRNA are represented by formulas (IXh)-(IXk):

[0739] [ka]

[0740] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein B is as described herein (e.g., any one of (b1)-(b43)). In certain embodiments, one of Formulas (IXh)-(IXk) is combined with a modified uracil (e.g., any one of Formulas (b1)-(b9), (b21)-(b23), and (b28)-(b31), e.g., Formula (b1), (b8), (b28), (b29), or (b30)). In certain embodiments, one of Formulas (IXh)-(IXk) is combined with a modified cytosine (e.g., any one of Formulas (b10)-(b14), (b24), (b25), and (b32)-(b36), e.g., Formula (b10) or (b32)). In certain embodiments, one of formulas (IXh)-(IXk) is combined with a modified guanine (e.g., any one of formulas (b15)-(b17) and (b37)-(b40)). In certain embodiments, one of formulas (IXh)-(IXk) is combined with a modified adenine (e.g., any one of formulas (b18)-(b20) and (b41)-(b43)).

[0741] In other embodiments, the building block molecules that can be incorporated into polynucleotides, primary constructs, or mmRNA have the formula (IXl)-(IXr):

[0742] [ka]

[0743] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each r1 and r2 is independently an integer from 0 to 5 (e.g., 0 to 3, 1 to 3, or 1 to 5), and B is as described herein (e.g., any one of (b1) to (b43)). In certain embodiments, one of Formulas (IXl) to (IXr) is combined with a modified uracil (e.g., any one of Formulas (b1) to (b9), (b21) to (b23), and (b28) to (b31), e.g., Formula (b1), (b8), (b28), (b29), or (b30)). In certain embodiments, one of Formulas (IXl)-(IXr) is combined with a modified cytosine (e.g., any one of Formulas (b10)-(b14), (b24), (b25), and (b32)-(b36), e.g., Formula (b10) or (b32)). In certain embodiments, one of Formulas (IXl)-(IXr) is combined with a modified guanine (e.g., any one of Formulas (b15)-(b17) and (b37)-(b40)). In certain embodiments, one of Formulas (IXl)-(IXr) is combined with a modified adenine (e.g., any one of Formulas (b18)-(b20) and (b41)-(b43)).

[0744] In some embodiments, the building block molecules that can be incorporated into the polynucleotide, primary construct, or mmRNA are:

[0745] [ka]

[0746] [ka]

[0747] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each r is independently an integer from 0 to 5 (e.g., 0 to 3, 1 to 3, or 1 to 5). In some embodiments, the building block molecules that can be incorporated into the polynucleotide, primary construct, or mmRNA are:

[0748] [ka]

[0749] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each r is independently an integer from 0 to 5 (e.g., from 0 to 3, from 1 to 3, or from 1 to 5), and s1 is as described herein.

[0750] In some embodiments, a building block molecule that can be incorporated into a nucleic acid (e.g., an RNA, mRNA, polynucleotide, primary construct, or mmRNA) is a modified uridine (e.g., selected from the group consisting of: or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Y 1 , Y 3 , Y 4 , Y 6 and r is as described herein (e.g., each r is independently an integer from 0 to 5, e.g., from 0 to 3, from 1 to 3, or from 1 to 5):

[0751] [ka]

[0752] [ka]

[0753] [ka]

[0754] [ka]

[0755]

change

[0756]

change

[0757]

change

[0758]

change

[0759]

change

[0760]

change

[0761]

change

[0762]

change

[0763]

change

[0764]

change

[0765]

change

[0766] [ka]

[0767] In some embodiments, a building block molecule that can be incorporated into a polynucleotide, primary construct, or mmRNA is a modified cytidine (e.g., selected from the group consisting of: or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Y 1 , Y 3 , Y 4 , Y 6 and r is as described herein (e.g., each r is independently an integer from 0 to 5, e.g., from 0 to 3, from 1 to 3, or from 1 to 5):

[0768] [ka]

[0769] [ka]

[0770] [ka]

[0771] [ka]

[0772] [ka]

[0773] For example, building block molecules that can be incorporated into polynucleotides, primary constructs, or mmRNA include:

[0774] [ka]

[0775] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each r is independently an integer from 0 to 5 (e.g., 0 to 3, 1 to 3, or 1 to 5). In some embodiments, a building block molecule that can be incorporated into a polynucleotide, primary construct, or mmRNA is a modified adenosine (e.g., selected from the group consisting of: or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Y 1 , Y 3 , Y 4 , Y 6 and r is as described herein (e.g., each r is independently an integer from 0 to 5, e.g., from 0 to 3, from 1 to 3, or from 1 to 5):

[0776] [ka]

[0777] [ka]

[0778] [ka]

[0779] [ka]

[0780] [ka]

[0781] In some embodiments, a building block molecule that can be incorporated into a polynucleotide, primary construct, or mmRNA is a modified guanosine (e.g., selected from the group consisting of: or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Y 1 , Y 3 , Y 4 , Y 6 and r is as described herein (e.g., each r is independently an integer from 0 to 5, e.g., from 0 to 3, from 1 to 3, or from 1 to 5):

[0782] [ka]

[0783] [ka]

[0784] [ka]

[0785] [ka]

[0786] In some embodiments, the chemical modification is a substitution of a C group at C-5 of the ring (e.g., of a pyrimidine nucleoside, e.g., cytosine or uracil) with an N (e.g., a >CH group at C-5 with an >NR N1 Substitution with a group (wherein R N 1 is H or optionally substituted alkyl). For example, a building block molecule that can be incorporated into a polynucleotide, primary construct, or mmRNA can include:

[0787] [ka]

[0788] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each r is independently an integer from 0 to 5 (e.g., 0 to 3, 1 to 3, or 1 to 5). In another embodiment, the chemical modification can include replacing the hydrogen at C-5 of cytosine with halo (e.g., Br, Cl, F, or I) or optionally substituted alkyl (e.g., methyl). For example, building block molecules that can be incorporated into polynucleotides, primary constructs, or mmRNA include:

[0789] [ka]

[0790] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each r is independently an integer from 0 to 5 (e.g., 0 to 3, 1 to 3, or 1 to 5). In yet further embodiments, the chemical modification may include a fused ring formed by NH2 at the C-4 position and a carbon atom at the C-5 position. For example, a building block molecule that may be incorporated into a polynucleotide, primary construct, or mmRNA may be:

[0791] [ka]

[0792] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each r is independently an integer from 0 to 5 (e.g., 0 to 3, 1 to 3, or 1 to 5). Sugar modifications Modified nucleosides and nucleotides (e.g., building block molecules) that can be incorporated into polynucleotides, primary constructs, or mmRNA (e.g., RNA or mRNA described herein) can be modified in the sugar of the ribonucleic acid. For example, the 2' hydroxyl group (OH) can be modified or replaced with several different substituents. Exemplary substitutions at the 2' position include H, halo, optionally substituted C, hydroxyl ... 1~6 Alkyl, optionally substituted C 1~6Alkoxy, optionally substituted C 6~10 Aryloxy, optionally substituted C 3~8 Cycloalkyl, optionally substituted C 3~8 Cycloalkoxy, optionally substituted C 6~10 Aryloxy, optionally substituted C 6~10 Aryl-C 1~6 Alkoxy, optionally substituted C 1~12 (heterocyclyl)oxy, sugar (e.g., ribose, pentose, or any described herein), polyethylene glycol (PEG), -O(CH2CHO) n CH2CH2OR, where R is H or optionally substituted alkyl and n is an integer from 0 to 20 (e.g., 0 to 4, 0 to 8, 0 to 10, 0 to 16, 1 to 4, 1 to 8, 1 to 10, 1 to 16, 1 to 20, 2 to 4, 2 to 8, 2 to 10, 2 to 16, 2 to 20, 4 to 8, 4 to 10, 4 to 16, and 4 to 20), and the 2'-hydroxyl is C 1~6 Alkylene or C 1~6 "Locked" nucleic acids (LNAs) linked to the 4'-carbon of the same ribose sugar by a heteroalkylene bridge (exemplary bridges include methylene, propylene, ether, or amino bridges), include, but are not limited to, aminoalkyl as defined herein, aminoalkoxy as defined herein, amino as defined herein, and amino acid as defined herein.

[0793] Generally, RNA comprises the sugar ribose, a five-membered ring containing oxygen. Non-limiting exemplary modified nucleotides include substitution of the ribose oxygen (e.g., with S, Se, or alkylene, e.g., methylene or ethylene), addition of a double bond (e.g., to replace ribose with cyclopentenyl or cyclohexenyl), ring contraction of ribose (e.g., to form a four-membered ring of cyclobutane or oxetane), ring expansion of ribose (e.g., to form a six- or seven-membered ring with additional carbon or heteroatoms, such as anhydrohexitol, altritol, mannitol, cyclohexanyl, cyclohexenyl, and morpholino, which also have a phosphoramidate backbone), polycyclic forms (e.g., tricyclic, and "unlocked" forms, e.g., Examples include glycol nucleic acids (GNAs) (e.g., R-GNA or S-GNA, where the ribose is replaced with a glycol unit linked to a phosphodiester bond), threose nucleic acids (TNA, where the ribose is replaced with α-L-threofuranosyl-(3'→2')), and peptide nucleic acids (PNA, where a 2-amino-ethyl-glycine bond replaces the ribose and phosphodiester backbone). The sugar group may also contain one or more carbons with the opposite stereochemical configuration to that of the corresponding carbon in ribose. Thus, a polynucleotide, primary construct, or mmRNA molecule may include nucleotides containing, for example, arabinose as the sugar.

[0794] Modifications in Nucleobases The present disclosure provides modified nucleosides and nucleotides. As described herein, a "nucleoside" is defined as a compound containing a sugar molecule (e.g., pentose or ribose) or a derivative thereof in combination with an organic base (e.g., purine or pyrimidine) or a derivative thereof (also referred to herein as a "nucleobase"). As described herein, a "nucleotide" is defined as a nucleoside containing a phosphate group. Modified nucleotides can be synthesized by any useful method described herein (e.g., chemically, enzymatically, or recombinantly to include one or more modified or non-natural nucleosides).

[0795] Modified nucleotide base pairing encompasses not only standard adenosine-thymine, adenosine-uracil, or guanosine-cytosine base pairs, but also base pairs formed between nucleotides containing and / or modified bases, where the arrangement of hydrogen bond donors and hydrogen bond acceptors allows hydrogen bonding between the non-standard and standard bases or between two complementary non-standard base structures. One example of such non-standard base pairing is base pairing between the modified nucleotide inosine and adenine, cytosine, or uracil.

[0796] Modified nucleosides and nucleotides can contain modified nucleobases. Examples of nucleobases found in RNA include, but are not limited to, adenine, guanine, cytosine, and uracil. Examples of nucleobases found in DNA include, but are not limited to, adenine, guanine, cytosine, and thymine. These nucleobases can be modified or completely replaced to provide oncology-related polynucleotides, primary constructs, or mmRNA molecules with enhanced properties, such as resistance to nucleases by disrupting the binding of major groove binding partners. Table 9 below identifies the chemical appearance of each standard nucleotide. Circles identify the atoms that comprise each chemical region.

[0797] Table 9

[0798] [Table 0009]

[0799] In some embodiments, B is a modified uracil. Exemplary modified uracils have the formulas (b1)-(b5):

[0800] [ka]

[0801] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

[0802] [ka]

[0803] is a single or double bond, T 1’ , T 1” , T 2’ , and T 2” each is independently H, optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted thioalkoxy, or T 1’ and T 1” combination or T 2’ and T 2” The combination of these together (e.g., T 2 (as in Figure 1), O (oxo), S (thio), or Se (seleno), V 1 and V 2 each independently represents O, S, N(R Vb ) nv , or C(R Vb ) nv wherein nv is an integer of 0 to 2, and each R Vbare independently H, halo, an optionally substituted amino acid, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted aminoalkyl (e.g., substituted with an N-protecting group, e.g., any of those described herein, e.g., trifluoroacetyl), optionally a substituted aminoalkenyl, an optionally substituted aminoalkynyl, an optionally substituted acylaminoalkyl (e.g., substituted with an N-protecting group, e.g., any described herein, e.g., trifluoroacetyl), an optionally substituted alkoxycarbonylalkyl, an optionally substituted alkoxycarbonylalkenyl, an optionally substituted alkoxycarbonylalkynyl, or an optionally substituted alkynyloxy (e.g., optionally substituted with any of the substituents described herein, e.g., alkyl selected from (1) to (21)); R 10 is H, halo, optionally substituted amino, hydroxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aminoalkyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted alkoxy, optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkenyl, optionally substituted alkoxycarbonylalkynyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkoxy, optionally substituted carboxyalkyl, or optionally substituted carbamoylalkyl; R 11 is H or optionally substituted alkyl; R 12ais H, optionally substituted alkyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl, optionally substituted carboxyalkyl (e.g., optionally substituted with hydroxy), optionally substituted carboxyalkoxy, optionally substituted carboxyaminoalkyl, or optionally substituted carbamoylalkyl; R 12c is H, halo, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted thioalkoxy, optionally substituted amino, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl.

[0804] Other exemplary modified uracils are represented by formulas (b6)-(b9):

[0805] [ka]

[0806] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

[0807] [ka]

[0808] is a single or double bond, T 1’ , T 1” , T 2’ , and T 2” each is independently H, optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted thioalkoxy, or T 1’ and T 1”The combination of these together (e.g., T 1 ), or T 2’ and T 2” The combination of these together (e.g., T 2 (as in 1 and T 2 are independently O (oxo), S (thio), or Se (seleno); W 1 and W 2 each independently represents N(R Wa ) nw or C(R Wa ) nw wherein nw is an integer of 0 to 2, and each R Wa is independently H, optionally substituted alkyl, or optionally substituted alkoxy; Each V 3 However, independently, O, S, N(R Va ) nv , or C(R Va ) nv wherein nv is an integer of 0 to 2, and each R Vaare independently H, halo, optionally substituted amino acid, optionally substituted alkyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heterocyclyl, optionally substituted alkylheterocyclyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy, optionally substituted aminoalkyl (e.g., substituted with an N-protecting group, e.g., any of those described herein, e.g., trifluoroacetyl, or sulfoalkyl), optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted acylaminoalkyl (e.g., and optionally substituted with an N-protecting group, e.g., any of those described herein, e.g., trifluoroacetyl), optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkenyl, optionally substituted alkoxycarbonylalkynyl, optionally substituted alkoxycarbonylacyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkyl (e.g., optionally substituted with a hydroxy and / or O-protecting group), optionally substituted carboxyalkoxy, optionally substituted carboxyaminoalkyl, or optionally substituted carbamoylalkyl (e.g., optionally substituted with any of the substituents described herein, e.g., alkyl (1) to (21)), and R Va and R 12c may be taken together with the carbon atom to which they are attached to form an optionally substituted cycloalkyl, an optionally substituted aryl, or an optionally substituted heterocyclyl (e.g., a 5- or 6-membered ring); R 12ais H, optionally substituted alkyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted carboxyalkyl (e.g., optionally substituted with hydroxy and / or O-protecting groups), optionally substituted carboxyalkoxy, optionally substituted carboxyaminoalkyl, optionally substituted carbamoylalkyl, or absent; R 12b is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted alkylaryl, optionally substituted heterocyclyl, optionally substituted alkylheterocyclyl, optionally substituted amino acid, optionally substituted alkoxycarbonylacyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkenyl, optionally substituted alkoxycarbonylalkynyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkyl (e.g., optionally substituted with hydroxy and / or O-protecting groups), optionally substituted carboxyalkoxy, optionally substituted carboxyaminoalkyl, or optionally substituted carbamoylalkyl; R 12b and T 1’ combination or R 12b and R 12c can be combined to form an optionally substituted heterocyclyl, R 12cis H, halo, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted thioalkoxy, optionally substituted amino, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl.

[0809] Further exemplary modified uracils are represented by formulae (b28)-(b31):

[0810] [ka]

[0811] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: T 1 and T 2 each is independently O (oxo), S (thio), or Se (seleno); Each R Vb’ and R Vb”are independently H, halo, optionally substituted amino acid, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkyl (e.g., substituted with an N-protecting group, e.g., any of those described herein, e.g., trifluoroacetyl, or sulfoalkyl), optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted acylaminoalkyl (e.g., substituted with an N-protecting group, e.g., any of those described herein, e.g., any of those described herein, e.g., substituted with trifluoroacetyl), optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkenyl, optionally substituted alkoxycarbonylalkynyl, optionally substituted alkoxycarbonylacyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkyl (e.g., optionally substituted with hydroxy and / or O-protecting groups), optionally substituted carboxyalkoxy, optionally substituted carboxyaminoalkyl, or optionally substituted carbamoylalkyl (e.g., optionally substituted with any of the substituents described herein, e.g., alkyl (1) to (21)) (e.g., R Vb’ is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted aminoalkyl, e.g., substituted with an N-protecting group, e.g., any of those described herein, e.g., trifluoroacetyl, or sulfoalkyl; R 12a is H, optionally substituted alkyl, optionally substituted carboxyaminoalkyl, optionally substituted aminoalkyl (e.g., substituted with an N-protecting group, e.g., any of those described herein, e.g., trifluoroacetyl, or sulfoalkyl), optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl; R12b is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl (e.g., substituted with an N-protecting group, e.g., any of those described herein, e.g., trifluoroacetyl, or sulfoalkyl); optionally substituted alkoxycarbonylacyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkenyl, optionally substituted alkoxycarbonylalkynyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkoxy, optionally substituted carboxyalkyl, or optionally substituted carbamoylalkyl.

[0812] In certain embodiments, T 1 is O (oxo) and T 2 is S (thio) or Se (seleno). 1 is S(thio) and T 2 is O (oxo) or Se (seleno). In some embodiments, R Vb’ is H, optionally substituted alkyl, or optionally substituted alkoxy.

[0813] In other embodiments, each R 12a and R 12b are independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted hydroxyalkyl. In certain embodiments, R 12a is H. In other embodiments, R 12a MoR 12b Both are H.

[0814] In some embodiments, R 12b Each RVb’ are independently an optionally substituted aminoalkyl (e.g., substituted with an N-protecting group, e.g., any described herein, e.g., trifluoroacetyl, or sulfoalkyl), an optionally substituted aminoalkenyl, an optionally substituted aminoalkynyl, or an optionally substituted acylaminoalkyl (e.g., substituted with an N-protecting group, e.g., any described herein, e.g., trifluoroacetyl). In some embodiments, the amino and / or alkyl of the optionally substituted aminoalkyl are substituted with one or more of an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted sulfoalkyl, an optionally substituted carboxy (e.g., substituted with an O-protecting group), an optionally substituted hydroxy (e.g., substituted with an O-protecting group), an optionally substituted carboxyalkyl (e.g., substituted with an O-protecting group), an optionally substituted alkoxycarbonylalkyl (e.g., substituted with an O-protecting group), or an N-protecting group. In some embodiments, the optionally substituted aminoalkyl is substituted with an optionally substituted sulfoalkyl or an optionally substituted alkenyl. In certain embodiments, R 12a MoR Vb” are both H. In certain embodiments, T 1 is O (oxo) and T 2 is S (thio) or Se (seleno).

[0815] In some embodiments, R Vb’ is an optionally substituted alkoxycarbonylalkyl or an optionally substituted carbamoylalkyl. In certain embodiments, R 12a , R 12b , R 12c , or R Va The optional substituents may be polyethylene glycol groups (e.g., -(CH2) s2 (OCH2CH2) s1 (CH2) s3OR', wherein s1 is an integer of 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer of 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6, or 1 to 10), and R' is H or C 1~20 alkyl), or an amino-polyethylene glycol group (e.g., —NR N1 (CH2) s2 (CH2CH2O) s1 (CH2) s3 NR N1 wherein s1 is an integer of 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer of 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6, or 1 to 10), and each R N1 are independently hydrogen or optionally substituted C 1~6 alkyl).

[0816] In some embodiments, B is a modified cytosine. Exemplary modified cytosines are represented by formulas (b10)-(b14):

[0817] [ka]

[0818] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: T 3’ and T 3” each is independently H, optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted thioalkoxy, or T 3’ and T 3” The combination of these together (e.g., T 3 (as in Figure 1), O (oxo), S (thio), or Se (seleno), Each V 4 However, independently, O, S, N(R Vc ) nv , or C(R Vc ) nv wherein nv is an integer of 0 to 2, and each RVc are independently H, halo, an optionally substituted amino acid, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted alkoxy, an optionally substituted alkenyloxy, an optionally substituted heterocyclyl, an optionally substituted alkylheterocyclyl, or an optionally substituted alkynyloxy (e.g., optionally substituted with any substituent described herein, e.g., a substituent selected from alkyl (1)-(21)), and R 13b and R Vc can be combined to form an optionally substituted heterocyclyl, Each V 5 However, independently, N(R Vd ) nv , or C(R Vd ) nv wherein nv is an integer of 0 to 2, and each R Vd are independently H, halo, an optionally substituted amino acid, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted alkoxy, an optionally substituted alkenyloxy, an optionally substituted heterocyclyl, an optionally substituted alkylheterocyclyl, or an optionally substituted alkynyloxy (e.g., optionally substituted with any substituent described herein, e.g., alkyl, selected from (1)-(21)) (e.g., V 5 is -CH or N), R 13a and R 13b is independently H, optionally substituted acyl, optionally substituted acyloxyalkyl, optionally substituted alkyl, or optionally substituted alkoxy; and R 13b and R 14 can be combined to form an optionally substituted heterocyclyl, Each R 14are independently H, halo, hydroxy, thiol, optionally substituted acyl, optionally substituted amino acid, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl (e.g., substituted with an O-protecting group), optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted acyloxyalkyl, optionally substituted amino (e.g., —NHR where R is H, alkyl, aryl, or phosphoryl), azido, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted alkylheterocyclyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkyl; R 15 and R 16 is independently H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl.

[0819] Further exemplary modified cytosines are represented by formulas (b32)-(b35):

[0820] [ka]

[0821] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: T 1 and T 3 each is independently O (oxo), S (thio), or Se (seleno); R 13a and R 13b is independently H, optionally substituted acyl, optionally substituted acyloxyalkyl, optionally substituted alkyl, or optionally substituted alkoxy; and R 13band R 14 can be combined to form an optionally substituted heterocyclyl, Each R 14 are independently H, halo, hydroxy, thiol, optionally substituted acyl, optionally substituted amino acid, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl (e.g., substituted with an O-protecting group), optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted acyloxyalkyl, optionally substituted amino (e.g., —NHR where R is H, alkyl, aryl, or phosphoryl), azido, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted alkylheterocyclyl, optionally substituted aminoalkyl (e.g., hydroxyalkyl, alkyl, alkenyl, or alkynyl), optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl; R 15 and R 16 is independently H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl (e.g., R 15 is H and R 16 is H or optionally substituted alkyl).

[0822] In some embodiments, R 15 is H and R 16 is H or optionally substituted alkyl. In certain embodiments, R 14 is H, acyl, or hydroxyalkyl. In some embodiments, R 14 is halo. In some embodiments, R 14 MoR 15 and R are both H. In some embodiments, R 15MoR 16 and R are both H. In some embodiments, R 14 and R 15 and R 16 Each of is H. In a further embodiment, R 13a and R 13b Each of is independently H or optionally substituted alkyl.

[0823] Further non-limiting examples of modified cytosines include those of formula (b36):

[0824] [ka]

[0825] or a pharmaceutically acceptable salt or stereoisomer thereof, During the ceremony, Each R 13b are independently H, optionally substituted acyl, optionally substituted acyloxyalkyl, optionally substituted alkyl, or optionally substituted alkoxy; R 13b and R 14b can be combined to form an optionally substituted heterocyclyl, Each R 14a and R 14bare independently H, halo, hydroxy, thiol, optionally substituted acyl, optionally substituted amino acid, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl (e.g., substituted with an O-protecting group), optionally substituted hydroxyalkenyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted acyloxyalkyl, optionally substituted amino (e.g., —NHR where R is H, alkyl, aryl, phosphoryl, optionally substituted aminoalkyl, or optionally substituted carboxyaminoalkyl), azido, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted alkylheterocyclyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, or optionally substituted aminoalkynyl; R 15 is independently H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl.

[0826] In certain embodiments, R 14b is an optionally substituted amino acid (e.g., an optionally substituted lysine). In some embodiments, R 14a is H. In some embodiments, B is a modified guanine. Exemplary modified guanines are represented by formulas (b15)-(b17):

[0827] [ka]

[0828] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: T 4’ , T 4” , T 5’ , T 5” , T6’ , and T 6” is independently H, optionally substituted alkyl, or optionally substituted alkoxy; 4’ and T 4” combinations (e.g., T 4 (as in) or T 5’ and T 5” combinations (e.g., T 5 (as in) or T 6’ and T 6” combinations (e.g., T 6 ) together to form O (oxo), S (thio), or Se (seleno), V 5 and V 6 each independently represents O, S, N(R Vd ) nv , or C(R Vd ) nv wherein nv is an integer of 0 to 2, and each R Vd are independently H, halo, thiol, an optionally substituted amino acid, cyano, amidine, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy (e.g., optionally substituted with any substituent described herein, e.g., alkyl, selected from (1) to (21)), optionally substituted thioalkoxy, or optionally substituted amino; R 17 , R 18 , R 19a , R 19b , R 21 , R 22 , R 23 , and R 24 is independently H, halo, thiol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted thioalkoxy, optionally substituted amino, or an optionally substituted amino acid.

[0829] Exemplary modified guanosines are represented by formulas (b37)-(b40):

[0830] [ka]

[0831] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: T 4’ is independently H, optionally substituted alkyl, or optionally substituted alkoxy; and each T 4 are independently O (oxo), S (thio), or Se (seleno); R 18 , R 19a , R 19b , and R 21 is independently H, halo, thiol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted thioalkoxy, optionally substituted amino, or an optionally substituted amino acid.

[0832] In some embodiments, R 18 is H or optionally substituted alkyl. In a further embodiment, T 4 is oxo. In some embodiments, R 19a and R 19b Each of is independently H or optionally substituted alkyl.

[0833] In some embodiments, B is a modified adenine. Exemplary modified adenines are represented by formulas (b18)-(b20):

[0834] [ka]

[0835] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each V 7 However, independently, O, S, N(RVe ) nv , or C(R Ve ) nv wherein nv is an integer of 0 to 2, and each R Ve are independently H, halo, an optionally substituted amino acid, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted alkoxy, an optionally substituted alkenyloxy, or an optionally substituted alkynyloxy (e.g., optionally substituted with any substituent described herein, e.g., an alkyl substituent selected from (1)-(21)); Each R 25 are independently H, halo, thiol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted thioalkoxy, or optionally substituted amino; R 26a and R 26b each independently is H, optionally substituted acyl, optionally substituted amino acid, optionally substituted carbamoylalkyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted alkoxy, or a polyethylene glycol group (e.g., —(CH) s2 (OCH2CH2) s1 (CH2) s3 OR' (wherein s1 is an integer of 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer of 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6, or 1 to 10), and R' is H or C 1~20 alkyl)), or an amino polyethylene glycol group (e.g., —NR N1 (CH2) s2 (CH2CH2O) s1 (CH2) s3 NR N1(wherein s1 is an integer of 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer of 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6, or 1 to 10), and each R N1 are independently hydrogen or optionally substituted C 1~6 alkyl) Each R 27 are independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted thioalkoxy, or optionally substituted amino; Each R 28 are independently H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl; Each R 29 are independently H, optionally substituted acyl, optionally substituted amino acid, optionally substituted carbamoylalkyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted alkoxy, or optionally substituted amino.

[0836] Exemplary modified adenines are represented by formulas (b41)-(b43):

[0837] [ka]

[0838] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: Each R 25 are independently H, halo, thiol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted thioalkoxy, or optionally substituted amino; R 26a and R 26beach independently is H, optionally substituted acyl, optionally substituted amino acid, optionally substituted carbamoylalkyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted hydroxyalkyl, optionally substituted hydroxyalkenyl, optionally substituted hydroxyalkynyl, optionally substituted alkoxy, or a polyethylene glycol group (e.g., —(CH) s2 (OCH2CH2) s1 (CH2) s3 OR' (wherein s1 is an integer of 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer of 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6, or 1 to 10), and R' is H or C 1~20 alkyl), or an amino polyethylene glycol group (e.g., —NR N1 (CH2) s2 (CH2CH2O) s1 (CH2) s3 NR N1 (wherein s1 is an integer of 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer of 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6, or 1 to 10), and each R N1 are independently hydrogen or optionally substituted C 1~6 alkyl) Each R 27 are independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted thioalkoxy, or optionally substituted amino.

[0839] In some embodiments, R 26a is H and R 26b is optionally substituted alkyl. In some embodiments, R 26a and R 26b Each of R is independently an optionally substituted alkyl. In certain embodiments, R 27is optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted thioalkoxy. In other embodiments, R 25 is optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted thioalkoxy.

[0840] In certain embodiments, R 26a , R 26b , or R 29 The optional substituents may be polyethylene glycol groups (e.g., -(CH2) s2 (OCH2CH2) s1 (CH2) s3 OR' (wherein s1 is an integer of 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer of 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6, or 1 to 10), and R' is H or C 1~20 alkyl), or an amino polyethylene glycol group (e.g., —NR N1 (CH2) s2 (CH2CH2O) s1 (CH2) s3 NR N1 (wherein s1 is an integer of 1 to 10 (e.g., 1 to 6 or 1 to 4), s2 and s3 are each independently an integer of 0 to 10 (e.g., 0 to 4, 0 to 6, 1 to 4, 1 to 6, or 1 to 10), and each R N1 are independently hydrogen or optionally substituted C 1~6 It is alkyl).

[0841] In some embodiments, B is a group represented by formula (b21):

[0842] [ka]

[0843] wherein X 12 are independently O, S, optionally substituted alkylene (e.g., methylene), or optionally substituted heteroalkylene; xa is an integer from 0 to 3; R 12aand T 2 is as described herein.

[0844] In some embodiments, B is a group represented by formula (b22):

[0845] [ka]

[0846] wherein R 10’ are independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted alkoxy, optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkenyl, optionally substituted alkoxycarbonylalkynyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkoxy, optionally substituted carboxyalkyl, or optionally substituted carbamoylalkyl; R 11 , R 12a , T 1 , and T 2 is as described herein.

[0847] In some embodiments, B is a group represented by formula (b23):

[0848] [ka]

[0849] wherein R 10 is an optionally substituted heterocyclyl (e.g., optionally substituted furyl, optionally substituted thienyl, or optionally substituted pyrrolyl), an optionally substituted aryl (e.g., optionally substituted phenyl or optionally substituted naphthyl), or any substituent described herein (e.g., R 10(those of R 11 (e.g., H or any substituent described herein), R 12a (e.g., H or any substituent described herein), T 1 (e.g., oxo or any substituent described herein), and T 2 (eg, oxo or any substituent described herein) is as defined herein.

[0850] In some embodiments, B is a group represented by formula (b24):

[0851] [ka]

[0852] wherein R 14’ are independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted alkylaryl, optionally substituted alkylheterocyclyl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, optionally substituted alkoxy, optionally substituted alkoxycarbonylalkenyl, optionally substituted alkoxycarbonylalkynyl, optionally substituted alkoxycarbonylalkyl, optionally substituted alkoxycarbonylalkoxy, optionally substituted carboxyalkoxy, optionally substituted carboxyalkyl, or optionally substituted carbamoylalkyl; R 13a , R 13b , R 15 , and T 3 is as described herein.

[0853] In some embodiments, B is a group represented by formula (b25):

[0854] [ka]

[0855] wherein R 14’ is an optionally substituted heterocyclyl (e.g., optionally substituted furyl, optionally substituted thienyl, or optionally substituted pyrrolyl), an optionally substituted aryl (e.g., optionally substituted phenyl or optionally substituted naphthyl), or any substituent described herein (e.g., R 14 or R 14’ (those of R 13a (e.g., H or any substituent described herein), R 13b (e.g., H or any substituent described herein), R 15 (e.g., H or any substituent described herein), and T 3 (eg, oxo or any substituent described herein) is as defined herein.

[0856] In some embodiments, B is a nucleobase selected from the group consisting of cytosine, guanine, adenine, and uracil.

[0857] [ka]

[0858] It could be. In some embodiments, the modified nucleobase is a modified uracil. Exemplary nucleobases and nucleosides having modified uracil include pseudouridine (ψ), pyridin-4-one ribonucleoside, 5-aza-uridine, 6-aza-uridine, 2-thio-5-aza-uridine, 2-thio-uridine (s 2 U), 4-thio-uridine (s 4 U), 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy-uridine (ho 5 U), 5-aminoallyl-uridine, 5-halo-uridine (e.g., 5-iodo-uridine or 5-bromo-uridine), 3-methyl-uridine (m 3 U), 5-methoxy-uridine (mo 5U), uridine 5-hydroxyacetic acid (cmo 5 U), uridine 5-hydroxyacetic acid methyl ester (mcmo 5 U), 5-carboxymethyl-uridine (cm 5 U), 1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uridine (chm 5 U), 5-carboxyhydroxymethyl-uridine methyl ester (mchm 5 U), 5-methoxycarbonylmethyl-uridine (mcm 5 U), 5-methoxycarbonylmethyl-2-thiouridine (mcm 5 s 2 U), 5-aminomethyl-2-thio-uridine (nm 5 s 2 U), 5-methylaminomethyl-uridine (mnm 5 U), 5-methylaminomethyl-2-thiouridine (mnm 5 s 2 U), 5-methylaminomethyl-2-seleno-uridine (mnm 5 se 2 U), 5-carbamoylmethyl-uridine (ncm 5 U), 5-carboxymethylaminomethyl-uridine (cmnm 5 U), 5-carboxymethylaminomethyl-2-thiouridine (cmnm 5 s 2 U), 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyl-uridine (τm 5 U), 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thiouridine (τm 5 s 2 U), 1-taurinomethyl-4-thio-pseudouridine, 5-methyl-uridine (m 5 U, i.e., those with the nucleobase deoxythymine), 1-methylpseudouridine (m 1 ψ), 5-methyl-2-thiouridine (m 5 s 2 U), 1-methyl-4-thio-pseudouridine (m 1 s 4ψ), 4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m 3 ψ), 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine (D), dihydropseudouridine, 5,6-dihydrouridine, 5-methyl-dihydrouridine (m 5 D), 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxy-uridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, N1-methyl-pseudouridine (1-methylpseudouridine (m 1 ψ), 3-(3-amino-3-carboxypropyl)uridine (acp 3 U), 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp 3 ψ), 5-(isopentenylaminomethyl)uridine (inm 5 U), 5-(isopentenylaminomethyl)-2-thiouridine (inm 5 s 2 U), α-thio-uridine, 2'-O-methyl-uridine (Um), 5,2'-O-dimethyl-uridine (m 5 Um), 2'-O-methyl-pseudouridine (ψm), 2-thio-2'-O-methyl-uridine (s 2 Um), 5-methoxycarbonylmethyl-2'-O-methyl-uridine (mcm 5 Um), 5-carbamoylmethyl-2'-O-methyl-uridine (ncm 5 Um), 5-carboxymethylaminomethyl-2'-O-methyl-uridine (cmnm 5 Um), 3,2'-O-dimethyl-uridine (m 3 Um), 5-(isopentenylaminomethyl)-2'-O-methyl-uridine (inm 5Um), 1-thio-uridine, deoxythymidine, 2'-F-ara-uridine, 2'-F-uridine, 2'-OH-ara-uridine, 5-(2-carbomethoxyvinyl)uridine, and 5-[3-(1-E-propenylamino)uridine].

[0859] In some embodiments, the modified nucleobase is a modified cytosine. Exemplary nucleobases and nucleosides having modified cytosines include 5-aza-cytidine, 6-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine (m 3 C), N4-acetyl-cytidine (ac 4 C), 5-formyl-cytidine (f 5 C), N4-methyl-cytidine (m 4 C), 5-methyl-cytidine (m 5 C), 5-halo-cytidine (e.g., 5-iodo-cytidine), 5-hydroxymethyl-cytidine (hm 5 C), 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine (s 2 C), 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine, lysidine (k2C), α-thio-cytidine, 2'-O-methyl-cytidine (Cm), 5,2'-O-dimethyl-cytidine (m 5 Cm), N4-acetyl-2'-O-methyl-cytidine (ac 4 Cm), N4,2'-O-dimethyl-cytidine (m 4 Cm), 5-formyl-2'-O-methyl-cytidine (f 5 Cm), N4,N4,2'-O-trimethyl-cytidine (m 42Cm), 1-thio-cytidine, 2'-F-ara-cytidine, 2'-F-cytidine, and 2'-OH-ara-cytidine.

[0860] In some embodiments, the modified nucleobase is a modified adenine. Exemplary nucleobases and nucleosides having modified adenines include 2-amino-purine, 2,6-diaminopurine, 2-amino-6-halo-purine (e.g., 2-amino-6-chloro-purine), 6-halo-purine (e.g., 6-chloro-purine), 2-amino-6-methyl-purine, 8-azido-adenosine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-amino-purine, 7-deaza-8-aza-2-amino-purine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyl-adenosine (m 1 A), 2-methyl-adenine (m 2 A), N6-methyl-adenosine (m 6 A), 2-methylthio-N6-methyl-adenosine (ms 2 m 6 A), N6-isopentenyl-adenosine (i 6 A), 2-methylthio-N6-isopentenyl-adenosine (ms 2 i 6 A), N6-(cis-hydroxyisopentenyl)adenosine (io 6 A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine (ms 2 io 6 A), N6-glycinylcarbamoyl-adenosine (g 6 A), N6-threonylcarbamoyl-adenosine (t 6 A), N6-methyl-N6-threonylcarbamoyl-adenosine (m 6 t 6 A), 2-methylthio-N6-threonylcarbamoyl-adenosine (ms 2 g 6 A), N6,N6-dimethyl-adenosine (m 6 2A), N6-hydroxynorvalylcarbamoyl-adenosine (hn 6A), 2-methylthio-N6-hydroxynorvalylcarbamoyl-adenosine (ms 2 hn 6 A), N6-acetyl-adenosine (ac 6 A), 7-methyl-adenine, 2-methylthio-adenine, 2-methoxy-adenine, α-thio-adenosine, 2'-O-methyl-adenosine (Am), N6,2'-O-dimethyl-adenosine (m 6 Am), N6,N6,2'-O-trimethyl-adenosine (m 6 2Am), 1,2'-O-dimethyl-adenosine (m 1 Am), 2'-O-ribosyladenosine (phosphate) (Ar(p)), 2-amino-N6-methyl-purine, 1-thio-adenosine, 8-azido-adenosine, 2'-F-ara-adenosine, 2'-F-adenosine, 2'-OH-ara-adenosine, and N6-(19-amino-pentaoxanonadecyl)-adenosine.

[0861] In some embodiments, the modified nucleobase is a modified guanine. Exemplary nucleobases and nucleosides having a modified guanine include inosine (I), 1-methyl-inosine (m), and 1-methyl-inosine (m). 1 I), wyosine (imG), methylwyosine (mimG), 4-demethyl-wyosine (imG-14), isowyosine (imG2), wyobutosine (yW), peroxywyobutosine (o2yW), hydroxywyobutosine (OHyW), unmodified hydroxywyobutosine (OHyW*), 7-deaza-guanosine, queosine (Q), epoxyqueosine (oQ), galactosyl-queosine (galQ), mannosyl-queosine (manQ), 7-cyano-7-deaza-guanosine (preQ0), 7-aminomethyl-7-deaza-guanosine (preQ1), and archaeosine (G + ), 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine (m 7 G), 6-thio-7-methyl-guanosine, 7-methyl-inosine, 6-methoxy-guanosine, 1-methyl-guanosine (m1 G), N2-methyl-guanosine (m 2 G), N2,N2-dimethyl-guanosine (m 2 2G), N2,7-dimethyl-guanosine (m 2,7 G), N2, N2, 7-dimethyl-guanosine (m 2,2,7 G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, N2,N2-dimethyl-6-thio-guanosine, α-thio-guanosine, 2'-O-methyl-guanosine (Gm), N2-methyl-2'-O-methyl-guanosine (m 2 Gm), N2,N2-dimethyl-2'-O-methyl-guanosine (m 2 2Gm), 1-methyl-2'-O-methyl-guanosine (m 1 Gm), N2,7-dimethyl-2'-O-methyl-guanosine (m 2,7 Gm), 2'-O-methyl-inosine (Im), 1,2'-O-dimethyl-inosine (m 1 Im), and 2'-O-ribosylguanosine(phosphate) (Gr(p)).

[0862] The nucleobases of the nucleotides can be independently selected from purines, pyrimidines, purine, or pyrimidine analogs. For example, each nucleobase can be independently selected from adenine, cytosine, guanine, uracil, or hypoxanthine. In another embodiment, nucleobases include, for example, pyrazolo[3,4-d]pyrimidine, 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-propynyluracil and cytosine, 6-azouracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo (e.g., 8-bromo), 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, and other 8-substituted nucleobases. Naturally occurring and synthetic derivatives of bases may also be included, including substituted adenine and guanine, 5-halo, particularly 5-bromo, 5-trifluoromethyl, and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, deazaguanine, 7-deazaguanine, 3-deazaguanine, deazaadenine, 7-deazaadenine, 3-deazaadenine, pyrazolo[3,4-d]pyrimidine, imidazo[1,5-a]1,3,5 triazinone, 9-deazapurine, imidazo[4,5-d]pyrazine, thiazolo[4,5-d]pyrimidine, pyrazin-2-one, 1,2,4-triazine, pyridazine, and 1,3,5 triazine. When nucleotides are designated using the abbreviations A, G, C, T, or U, each letter refers to a representative base and / or its derivatives, e.g., A includes adenine or an adenine analog such as, e.g., 7-deazaadenine.

[0863] Modifications in internucleoside linkages Modified nucleotides that can be incorporated into polynucleotides, primary constructs, or mmRNA molecules can be modified in the internucleoside linkage (e.g., phosphate backbone). Herein, the terms "phosphate" and "phosphodiester" are used interchangeably in the context of polynucleotide backbones. The backbone phosphate group can be modified by replacing one or more of the oxygen atoms with different substituents. Furthermore, modified nucleosides and nucleotides can contain large-scale replacement of unmodified phosphate moieties with other internucleoside linkages described herein. Examples of modified phosphate groups include, but are not limited to, phosphorothioates, phosphoroselenates, boranophosphates, boranophosphate esters, hydrogen phosphonates, phosphororamidates, phosphorodiamidates, alkyl or aryl phosphonates, and phosphotriesters. Phosphorodithioates have both non-linked oxygens replaced with sulfur. Phosphate linkers can also be modified by substitution of the linking oxygen at nitrogen (bridging phosphoramidates), sulfur (bridging phosphorothioates), and carbon (bridging methylene phosphonates).

[0864] The α-thio-substituted phosphate moiety is provided to give stability to RNA and DNA polymers through non-natural phosphorothioate backbone bonds.Phosphorothioate DNA and RNA have increased nuclease resistance, and subsequently have a longer half-life in cellular environments.Phosphorothioate-linked oncology-related polynucleotides, primary constructs, or mmRNA molecules are also expected to reduce innate immune response by weaker binding / activation of cellular innate immune molecules.

[0865] In certain embodiments, the modified nucleoside comprises an α-thio-nucleoside (e.g., 5'-O-(1-thiophosphate)-adenosine, 5'-O-(1-thiophosphate)-cytidine (α-thio-cytidine), 5'-O-(1-thiophosphate)-guanosine, 5'-O-(1-thiophosphate)-uridine, or 5'-O-(1-thiophosphate)-pseudouridine).

[0866] Other internucleoside linkages that can be used in accordance with the present invention, including internucleoside linkages that do not contain a phosphorus atom, are described herein below. Combinations of modified sugars, nucleobases, and internucleoside linkages The oncology-related polynucleotides, primary constructs, and mmRNA of the present invention may contain combinations of modifications to the sugar, nucleobase, and / or internucleoside linkage. These combinations may include any one or more of the modifications described herein. For example, any of the nucleotides described herein in formulas (Ia), (Ia-1) through (Ia-3), (Ib) through (If), (IIa) through (IIp), (IIb-1), (IIb-2), (IIc-1) through (IIc-2), (IIn-1), (IIn-2), (IVa) through (IVl), and (IXa) through (IXr) may be combined with any of the nucleobases described herein (e.g., formulas (b1) through (b43) or any others described herein).

[0867] Synthesis of oncology-related polypeptides, primary constructs, and mmRNA molecules The oncology-related polypeptides, oncology-related primary constructs, and oncology-related mmRNA molecules used in accordance with the present invention can be prepared according to any useful technique described herein. The modified nucleosides and nucleotides used in the synthesis of the oncology-related polynucleotides, oncology-related primary constructs, and oncology-related mmRNA molecules disclosed herein can be prepared from readily available starting materials using the following general methods and procedures. Given the typical or preferred process conditions (e.g., reaction temperature, time, molar ratio of reactants, solvent, pressure, etc.), those skilled in the art will be able to optimize and develop further process conditions. Optimal reaction conditions may vary depending on the specific reactants or solvents used, but such conditions can be determined by those skilled in the art using routine optimization procedures.

[0868] The processes described herein can be monitored according to any suitable method known in the art. For example, product formation can be monitored by nuclear magnetic resonance spectroscopy (e.g.,1 H or 13 C), can be monitored by spectroscopic means such as infrared spectroscopy, spectrophotometry (e.g., ultraviolet-visible), or mass spectrometry, or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography.

[0869] The preparation of the oncology-related polypeptides, oncology-related primary constructs, and oncology-related mmRNA molecules of the present invention may involve the protection and deprotection of various chemical groups.The need for protection and deprotection, and the selection of appropriate protecting groups, can be easily determined by those skilled in the art.The chemistry of protecting groups can be found, for example, in Greene, et al., Protective Groups in Organic Synthesis, 2d.Ed., Wiley & Sons, 1991, which is incorporated herein by reference in its entirety.

[0870] The reactions of the processes described herein can be carried out in a suitable solvent that can be easily selected by one skilled in the art of organic synthesis. A suitable solvent can be substantially non-reactive with the starting materials (reactants), intermediates, or products at the temperature at which the reaction is carried out, i.e., a temperature that can range from the freezing temperature of the solvent to the boiling point of the solvent. A given reaction can be carried out in one solvent or a mixture of two or more solvents. A suitable solvent for a particular reaction step can be selected depending on the particular reaction step.

[0871] Resolution of racemic mixtures of modified nucleosides and nucleotides (e.g., mmRNA molecules) can be carried out by any of a number of methods known in the art. Exemplary methods include fractional recrystallization using a "chiral resolving acid," which is an optically active, salt-forming organic acid. Suitable resolving acids for fractional recrystallization include optically active acids such as tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, or the D and L forms of various optically active camphorsulfonic acids. Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent compositions can be determined by those skilled in the art.

[0872] Modified nucleosides and nucleotides (e.g., building block molecules) can be prepared according to the synthetic methods described in Ogata et al., J. Org. Chem. 74:2585-2588 (2009), Purmal et al., Nucl. Acids Res. 22(1):72-78, (1994), Fukuhara et al., Biochemistry, 1(4):563-568 (1962), and Xu et al., Tetrahedron, 48(9):1729-1740 (1992), each of which is incorporated by reference in its entirety.

[0873] The oncology-related polypeptides, oncology-related primary constructs, and oncology-related mmRNA of the present invention may or may not be uniformly modified along the entire length of the molecule. For example, one or more or all types of nucleotides (e.g., purines or pyrimidines, or any one or more or all of A, G, U, C) may or may not be uniformly modified in the oncology-related polynucleotides of the present invention or in a given, predetermined sequence region thereof (e.g., one or more of the sequence regions depicted in Figure 1). In some embodiments, all nucleotides X in the oncology-related polynucleotides of the present invention (or in a given sequence region thereof) are modified, where X can be any one of the nucleotides A, G, U, C, or any one of the combinations A+G, A+U, A+C, G+U, G+C, U+C, A+G+U, A+G+C, G+U, or A+G+C.

[0874] Different sugar modifications, nucleotide modifications, and / or internucleoside linkages (e.g., backbone structures) can be present at various positions in an oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA. Those skilled in the art will recognize that nucleotide analogs or other modification(s) can be placed at any position(s) in an oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA such that the function of the oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA is substantially reduced. Modifications can also be 5'- or 3'-terminal modifications. An oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA may contain from about 1% to about 100% modified nucleotides (either the total nucleotide content or associated with any one or more types of nucleotides, i.e., A, G, U, or C), or any intermediate percentage (e.g., 1%-20%, 1%-25%, 1%-50%, 1%-60%, 1%-70%, 1%-80%, 1%-90%, 1%-95%, 10%-20%, 10%-25%, 10%-50%, 10%-60%, 10%-70%, 10 ...0%-90%, 10%-95%, 10%-100%, 10%-100%, 10%-100%, 10%-100%, 10%-100%, 10%-100%, % to 80%, 10% to 90%, 10% to 95%, 10% to 100%, 20% to 25%, 20% to 50%, 20% to 60%, 20% to 70%, 20% to 80%, 20% to 90%, 20% to 95%, 20% to 100%, 50% to 60%, 50% to 70%, 50% to 80%, 50% to 90%, 50% to 95%, 50% to 100%, 70% to 80%, 70% to 90%, 70% to 95%, 70% to 100%, 80% to 90%, 80% to 95%, 80% to 100%, 90% to 95%, 90% to 100%, and 95% to 100%).

[0875] In some embodiments, the oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA comprises modified pyrimidines (e.g., modified uracil / uridine / U or modified cytosine / cytidine / C). In some embodiments, the uracil or uridine (generally, U) in the oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA molecule is from about 1% to about 100% modified uracil or uridine (e.g., 1% to 20%, 1% to 25%, 1% to 50%, 1% to 60%, 1% to 70%, 1% to 80%, 1% to 90%, 1% to 95%, 10% to 20%, 10% to 25%, 10% to 50%, 10% to 60%, 10% to 70%, 10% to 80%, 10% to 90%, 10% to 95%, 10% to It may be substituted with 100%, 20%-25%, 20%-50%, 20%-60%, 20%-70%, 20%-80%, 20%-90%, 20%-95%, 20%-100%, 50%-60%, 50%-70%, 50%-80%, 50%-90%, 50%-95%, 50%-100%, 70%-80%, 70%-90%, 70%-95%, 70%-100%, 80%-90%, 80%-95%, 80%-100%, 90%-95%, 90%-100%, and 95%-100% modified uracil or modified uridine). The modified uracil or uridine can be substituted with a compound having a single unique structure or with multiple compounds having different structures (eg, two, three, four or more unique structures as described herein).In some embodiments, the cytosines or cytidines (generally, C) in the oncology-related polynucleotides, oncology-related primary constructs, or oncology-related mmRNA molecules are from about 1% to about 100% modified cytosines or modified cytidines (e.g., 1% to 20%, 1% to 25%, 1% to 50%, 1% to 60%, 1% to 70%, 1% to 80%, 1% to 90%, 1% to 95%, 10% to 20%, 10% to 25%, 10% to 50%, 10% to 60%, 10% to 70%, 10% to 80%, 10% to 90%, 10% to 95%, 10% to 100%, 20% to 25%, 20% to 50%, 20% to 60%, 20% to 70%, 20% to 80%, 20% to 90%, 20% to 95%, 20% to 100%, 50% to 60%, 50% to 70%, 50% to 80%, 50% to 90%, 50% to 95%, 50% to 100%, 70% to 80%, 70% to 90%, 70% to 95%, 70% to 100%, 80% to 90%, 80% to 95%, 80% to 100%, 90% to 95%, 90% to 100%, and 95% to 100% modified cytosine or modified cytidine). The modified cytosine or cytidine can be substituted with a compound having a single unique structure or with multiple compounds having different structures (eg, two, three, four or more unique structures described herein).

[0876] In some embodiments, the present disclosure provides a compound of formula (Ia-1):

[0877] [ka]

[0878] The present invention provides a method for synthesizing an oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA (e.g., a first region, a first flanking region, or a second flanking region) comprising n linked nucleosides having a) Formula (IV-1):

[0879] [ka]

[0880] A nucleotide of formula (V-1):

[0881] [ka]

[0882] (wherein Y 9 is H, hydroxy, phosphoryl, pyrophosphate, sulfate, amino, thiol, an optionally substituted amino acid, or a peptide (e.g., containing 2 to 12 amino acids), and each P 1 , P 2 , and P 3 are independently suitable protecting groups;

[0883] [ka]

[0884] indicates a solid support), providing an oncology-related polynucleotide, an oncology-related primary construct, or an oncology-related mmRNA of formula (VI-1);

[0885] [ka]

[0886] b) oxidizing or sulfurizing an oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA of formula (V) to produce an oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA of formula (VII-1);

[0887] [ka]

[0888] c) removing the protecting group to yield an oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA of formula (Ia). In some embodiments, steps a) and b) are repeated 1 to about 10,000 times. In some embodiments, the method further comprises a nucleotide (e.g., an mmRNA molecule) selected from the group consisting of A, C, G, and U (adenosine, cytosine, guanosine, and uracil). In some embodiments, the nucleobase may be a pyrimidine or a derivative thereof. In some embodiments, the oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA may be translatable.

[0889] Other components of oncology-related polynucleotides, oncology-related primary constructs, and oncology-related mmRNA are optional and beneficial in some embodiments.For example, a 5' untranslated region (UTR) and / or a 3' UTR can be provided, and either or both of these can independently contain one or more different nucleotide modifications.In such embodiments, nucleotide modifications can also be present in translatable regions.Oncology-related polynucleotides, oncology-related primary constructs, and oncology-related mmRNA containing Kozak sequences are also provided.

[0890] Exemplary syntheses of oncology-relevant modified nucleotides incorporated into modified nucleic acids or mRNA, e.g., RNA or mRNA, are provided below in Schemes 1 through 11. Scheme 1 provides a general method for the phosphorylation of nucleosides, including modified nucleosides.

[0891] Scheme 1

[0892] [ka]

[0893] Various protecting groups can be used to control the reaction. For example, Scheme 2 provides the use of multiple protection and deprotection steps to facilitate phosphorylation of the 5' position of the sugar, rather than the 2' and 3' hydroxyl groups.

[0894] Scheme 2

[0895] [ka]

[0896] Modified nucleotide can be synthesized by any useful method.Schemes 3, 4 and 7 provide exemplary methods for synthesizing modified nucleotides having modified purine nucleobases, and schemes 5 and 6 provide exemplary methods for synthesizing modified nucleotides having modified pseudouridine or pseudoisocytidine, respectively.

[0897] Scheme 3

[0898] [ka]

[0899] Scheme 4

[0900] [ka]

[0901] Scheme 5

[0902] [ka]

[0903] Scheme 6

[0904] [ka]

[0905] Scheme 7

[0906] [ka]

[0907] Schemes 8 and 9 provide exemplary syntheses of modified nucleotides. Scheme 10 provides a non-limiting biocatalytic method for producing nucleotides. Scheme 8

[0908] [ka]

[0909] Scheme 9

[0910] [ka]

[0911] Scheme 10

[0912] [ka]

[0913] Scheme 11 provides an exemplary synthesis of modified uracils, in which the N1 position is substituted with R 12b The 5' position of the ribose is phosphorylated. 1 , T 2 , R 12a , R 12b , and r are as provided herein. This synthesis, as well as optimized versions thereof, can be used to modify other pyrimidine and purine nucleobases (see, e.g., formulas (b1)-(b43)) and / or introduce one or more phosphate groups (e.g., at the 5' position of the sugar). This alkylation reaction can also be used to include one or more optionally substituted alkyl groups at any reactive group (e.g., amino group) in any nucleobase described herein (e.g., amino groups at the Watson-Crick base pairing interface of cytosine, uracil, adenine, and guanine).

[0914] Scheme 11

[0915] [ka]

[0916] Nucleotide combinations in mmRNA Further examples of modified nucleotides and combinations of modified nucleotides are provided below in Table 10. These combinations of modified nucleotides can be used to form the oncology-related polypeptides, oncology-related primary constructs, or oncology-related mmRNA of the present invention.

[0917] Unless otherwise stated, modified nucleotides can be completely substituted for the natural nucleotides of the modified nucleic acids or mRNA of the present invention.As a non-limiting example, the natural nucleotide uridine can be substituted with the modified nucleosides described herein.In another non-limiting example, the natural nucleotide uridine can be partially substituted with at least one of the modified nucleosides disclosed herein (for example, about 0.1%, 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99.9%).

[0918] Table 10

[0919] [Table 0010-1]

[0920] [Table 0010-2]

[0921] Further examples of combinations of modified nucleotides are provided below in Table 11. These combinations of modified nucleotides can be used to form the polypeptides, primary constructs, or mRNA of the present invention.

[0922] Table 11

[0923] [Table 0011]

[0924] In some embodiments, at least 25% of the cytosines are substituted with compounds of formulas (b10)-(b14) (e.g., at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100%).

[0925] In some embodiments, at least 25% of the uracils are substituted with a compound of Formula (b1)-(b9) (e.g., at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100%).

[0926] In some embodiments, at least 25% of the cytosines are substituted with compounds of Formulae (b10)-(b14) and at least 25% of the uracils are substituted with compounds of Formulae (b1)-(b9) (e.g., at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100%).

[0927] IV. Pharmaceutical Compositions Formulation, Administration, Delivery, and Dosing The present invention provides compositions and complexes of oncology-related polynucleotides, oncology-related primary constructs, and oncology-related mmRNA in combination with one or more pharmaceutically acceptable excipients. Pharmaceutical compositions may optiona...

Claims

1. A method for treating a disease, disorder, and / or condition in a subject in need of such treatment by increasing the level of a desired oncology-related polypeptide, comprising administering to the subject an isolated polynucleotide encoding the oncology-related polypeptide.

2. A method for reducing and / or ameliorating at least one symptom of cancer in a subject in need thereof by increasing the level of an oncology-related polypeptide of interest, comprising administering to said subject an isolated polynucleotide encoding said oncology-related polypeptide.

3. 3. The method of claim 2, wherein the at least one cancer symptom is tumor growth.

4. The diseases, disorders, and / or conditions include adrenocortical carcinoma, advanced cancer, anal cancer, aplastic anemia, bile duct cancer, bladder cancer, bone cancer, bone metastasis, brain tumor, brain cancer, breast cancer, childhood cancer, cancer of unknown primary site, Castleman's disease, cervical cancer, colon / rectal cancer, endometrial cancer, esophageal cancer, Ewing's tumor, eye cancer, gallbladder cancer, gastrointestinal carcinoid, gastrointestinal stromal tumor, gestational trophoblastic disease, Hodgkin's disease, Kaposi's sarcoma, renal cell carcinoma, laryngeal and hypopharyngeal cancer, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, lung carcinoid 2. The method of claim 1, wherein the cancer is selected from the group consisting of tumors, cutaneous lymphoma, malignant mesothelioma, multiple myeloma, myelodysplastic syndromes, cancer of the nasal cavity and paranasal sinuses, nasopharyngeal carcinoma, neuroblastoma, non-Hodgkin's lymphoma, cancer of the oral cavity and oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, penile cancer, pituitary tumors, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, adult soft tissue sarcoma, basal cell carcinoma and squamous cell carcinoma, melanoma, small intestine cancer, gastric cancer, testicular cancer, pharyngeal cancer, thymic cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom's macroglobulinemia, Wilms' tumor, and secondary cancers resulting from cancer treatment.

5. The tumor growths include, but are not limited to, adrenal cortical carcinoma, advanced cancer, anal cancer, aplastic anemia, bile duct cancer, bladder cancer, bone cancer, bone metastasis, brain tumor, brain cancer, breast cancer, childhood cancer, cancer of unknown primary site, Castleman's disease, cervical cancer, colon / rectal cancer, endometrial cancer, esophageal cancer, Ewing's tumor, eye cancer, gallbladder cancer, gastrointestinal carcinoid, gastrointestinal stromal tumor, gestational trophoblastic disease, Hodgkin's disease, Kaposi's sarcoma, renal cell carcinoma, laryngeal and hypopharyngeal cancer, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, pulmonary carcinoid tumor, cutaneous lymphoma, malignant mesothelioma.

4. The method of claim 3, wherein the cancer is caused by a disease, disorder, and / or condition selected from the group consisting of: multiple myeloma, myelodysplastic syndromes, cancer of the nasal cavity and paranasal sinuses, nasopharyngeal cancer, neuroblastoma, non-Hodgkin's lymphoma, cancer of the oral cavity and oropharynx, osteosarcoma, ovarian cancer, pancreatic cancer, penile cancer, pituitary tumors, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, adult soft tissue sarcoma, basal and squamous cell carcinoma, melanoma, small intestine cancer, gastric cancer, testicular cancer, pharyngeal cancer, thymic cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom's macroglobulinemia, Wilms' tumor, and secondary cancers resulting from cancer treatment.

6. 3. The method of claim 1 or 2, wherein administration of the isolated polynucleotide reduces cancer cells, eliminates cancer cells, prevents the growth of cancer cells, and / or alleviates symptoms of cancer in the subject.

7. 3. The method of claim 2, wherein the at least one symptom of cancer is selected from the group consisting of weakness, aches and pains, fever, fatigue, weight loss, blood clots, elevated calcium levels in the blood, low white blood cell count, shortness of breath, dizziness, headache, hyperpigmentation, jaundice, erythema, pruritus, hirsutism, changes in bowel habits, changes in bladder function, persistent sores, white spots in the mouth, white spots on the tongue, abnormal bleeding or discharge, thickening or lumps in body parts, indigestion, difficulty swallowing, changes in warts or moles, new skin changes and persistent cough, or hoarseness.

8. The method of claim 1 or 2, wherein the isolated polynucleotide is formulated.

9. 9. The method of claim 8, wherein the formulation comprises a lipid selected from one of DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, 98N12-5, C12-200, DLin-MC3-DMA, PLGA, PEG, PEG-DMG, pegylated lipids, and mixtures thereof.

10. 10. The method of claim 9, wherein the isolated polynucleotide is administered in a dose of 0.001 ug to 150 ug total per day.

11. 11. The method of claim 10, wherein administration is by injection, topical administration, ocular administration and intranasal administration.

12. 12. The method of claim 11, wherein administration is by injection, said injection being selected from the group consisting of intradermal, subcutaneous, and intramuscular.

13. 13. The method of claim 12, wherein the administration is topical, said topical administration being selected from the group consisting of a cream, a lotion, an ointment, a gel, a spray, a solution, and the like.

14. The method of claim 13 , wherein the topical administration further comprises a penetration enhancer.

15. 15. The method of claim 14, wherein the penetration enhancer is selected from the group consisting of surfactants, fatty acids, bile salts, chelating agents, non-chelating non-surfactants, polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether, fatty acids and / or salts containing bile acids and / or salts, sodium salts containing lauric acid, capric acid and UDCA, and the like.

16. (a) a first region of linked nucleosides, said first region encoding an oncology-related polypeptide of interest selected from the group consisting of SEQ ID NOs: 4704-9203; (b) a first flanking region located at the 5′ end of the first region, (i) a first flanking region comprising a sequence of linked nucleosides selected from the group consisting of the naturally occurring 5' untranslated region (UTR) of any of the nucleic acids encoding any of SEQ ID NOs: 4704-9203, 1-4, and functional variants thereof; (c) a second flanking region located at the 3' end of the first region, (i') a sequence of linked nucleosides selected from the group consisting of the naturally occurring 3'UTR of any of the nucleic acids encoding any of SEQ ID NOs: 4704-9203, SEQ ID NOs: 5-21, and functional variants thereof; (ii') a 3' tail sequence of the linked nucleoside; and 2. An isolated polynucleotide comprising:

17. 17. The isolated polynucleotide of claim 16, wherein the first region of linked nucleosides comprises at least one open reading frame of a nucleic acid sequence, the nucleic acid sequence being selected from the group consisting of SEQ ID NOs: 4667-4703 and 9204-33882.

18. 17. The isolated polynucleotide of claim 16, wherein the first region further comprises two stop codons.

19. 17. The isolated polynucleotide of claim 16, wherein the first region further comprises a first stop codon "TGA" and a second stop codon selected from the group consisting of "TAA", "TGA" and "TAG".

20. 17. The isolated polynucleotide of claim 16, wherein the 3' tail sequence of the linked nucleoside is selected from the group consisting of a poly A tail of about 160 nucleotides and a poly A-G quartet.

21. 17. The isolated polynucleotide of claim 16, wherein the first flanking region further comprises at least one 5' terminal cap.

22. 22. The isolated polynucleotide of claim 21, wherein the at least one 5' end cap is selected from the group consisting of cap 0, cap 1, ARCA, inosine, N1-methyl-guanosine, 2'fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, and 2-azido-guanosine.

23. The isolated polynucleotide of any one of claims 16 to 22, wherein the isolated polynucleotide is substantially purified.

24. 23. The isolated polynucleotide of any one of claims 16 to 22, wherein the nucleotide comprises at least two modifications and a translatable region.

25. 25. The isolated polynucleotide of claim 24, wherein the modification is located on one or more nucleosides and / or the backbone of the nucleotide.

26. 26. The isolated polynucleotide of claim 25, wherein the modifications are located on both the nucleoside and backbone linkages.

27. 26. The isolated polynucleotide of claim 25, wherein the modification is located on a backbone bond.

28. 28. The isolated polynucleotide of claim 27, wherein the backbone bonds are modified by substitution of one or more oxygen atoms.

29. 28. The isolated polynucleotide of claim 27, wherein the modification comprises replacing at least one phosphodiester bond with a phosphorothioate bond.

30. 26. The isolated polynucleotide of claim 25, wherein the modification is located on a nucleoside.

31. 28. The isolated polynucleotide of claim 27, wherein the modification is present in the sugar of the nucleoside.

32. The modifications include pyridin-4-one ribonucleosides, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyluridine, 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thiouridine, 1-taurinomethyl-4- Thio-uridine, 5-methyl-uridine, 1-methylpseudouridine, 4-thio-1-methylpseudouridine, 2-thio-1-methylpseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, 5- Aza-cytidine, pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebra phosphorus, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine, 2-aminopurine, 2,6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-Diaminopurine, 1-methyladenosine, N6-methyladenosine, N6-isopentenyladenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine, N6-glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonylcarbamoyladenosine, N6,N6-dimethyladenosine, 7-methyladenine, 2-methylthio-adenine, 2-methoxy-adenine, inosine, 1-methyl-inosine, wyosine, wybutosine, 7-deaza-guanosine, 7-deaza-guanosine, 31. The isolated polynucleotide of claim 30, wherein the polynucleotide is selected from the group consisting of N-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, and N2,N2-dimethyl-6-thio-guanosine.

33. 26. The isolated polynucleotide of claim 25, wherein the modification is located on the nucleobase.

34. 34. The isolated polynucleotide of claim 33, wherein said modification on said nucleobase is selected from the group consisting of cytosine, guanine, adenine, thymine and uracil.

35. The isolated polynucleotide of claim 16, wherein the isolated polynucleotide is formulated.

36. 36. The isolated polynucleotide of claim 35, wherein the formulation comprises a lipid selected from one of DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, 98N12-5, C12-200, DLin-MC3-DMA, PLGA, PEG, PEG-DMG, pegylated lipids, and mixtures thereof.

37. 37. The isolated polynucleotide of claim 36, wherein the isolated polynucleotide is administered in a dose of 0.001 ug to 150 ug total per day.

38. 38. The isolated polynucleotide of claim 37, wherein administration is by injection, topical administration, ocular administration, and intranasal administration.

39. 39. The isolated polynucleotide of claim 38, wherein administration is by injection, said injection being selected from the group consisting of intradermal, subcutaneous, and intramuscular.

40. 40. The isolated polynucleotide of claim 39, wherein the administration is topical, said topical administration being selected from the group consisting of a cream, a lotion, an ointment, a gel, a spray, a solution, and the like.

41. 41. The isolated polynucleotide of claim 40, wherein the topical administration further comprises a penetration enhancer.

42. 42. The isolated polynucleotide of claim 41, wherein the penetration enhancer is selected from the group consisting of surfactants, fatty acids, bile salts, chelating agents, non-chelating non-surfactants, polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether, fatty acids and / or salts containing bile acids and / or salts, sodium salts containing lauric acid, capric acid and UDCA, and the like.

43. 17. The isolated polynucleotide of claim 16, further comprising a pharma- ceutically acceptable excipient.

44. 44. The isolated polynucleotide of claim 43, wherein the pharma- ceutically acceptable excipient is selected from the group consisting of a solvent, an aqueous solvent, a non-aqueous solvent, a dispersion medium, a diluent, a dispersant, a suspension aid, a surface active agent, an isotonic agent, a thickening agent or an emulsifier, a preservative, a lipid, a lipidoid liposome, a lipid nanoparticle, a core-shell nanoparticle, a polymer, a lipoplex, a peptide, a protein, a cell, a hyaluronidase, and mixtures thereof.

45. 45. The isolated polynucleotide of claim 44, wherein the oncology related composition further comprises a lipid, said lipid being selected from the group consisting of DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, 98N12-5, C12-200, DLin-MC3-DMA, PLGA, PEG, PEG-DMG, pegylated lipids, and mixtures thereof.